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Abstract 
 
There has been considerable progress in the clinical, pathological and genetic fractionation of 
frontotemporal lobar degeneration syndromes in recent years, driving the development of novel 
diagnostic criteria. However, phenotypic boundaries are not always distinct and syndromes 
converge with disease progression, limiting the insights available from traditional diagnostic 
classification. Alternative transdiagnostic approaches may provide novel insights into the 
neurobiological underpinnings of symptom commonalities across the frontotemporal lobar 
degeneration spectrum.  
      In this thesis, I illustrate the use of transdiagnostic methods to investigate apathy and 
impulsivity. These two multifaceted constructs are observed across all frontotemporal lobar 
degeneration syndromes, including frontotemporal dementia, progressive supranuclear palsy 
and corticobasal syndrome. They cause substantial patient morbidity and carer distress, often 
coexist and are undertreated. Using data from the Pick’s disease and Progressive supranuclear 
palsy Prevalence and INcidence (PiPPIN) Study, I examine the frequency, characteristics and 
components of apathy and impulsivity across the frontotemporal lobar degeneration spectrum.  
      A principal component analysis of the neuropsychological data identified eight distinct 
components of apathy and impulsivity, separating patient ratings, carer ratings and behavioural 
tasks. Apathy and impulsivity measures were positively correlated, frequently loading onto the 
same components and providing evidence of their overlap. The data confirmed that apathy and 
impulsivity are common across the spectrum of frontotemporal lobar degeneration syndromes. 
Voxel based morphometry revealed distinct neural correlates for the components of 
apathy and impulsivity. Patient ratings correlated with white matter changes in the corticospinal 
tracts, which may reflect retained insight into their physical impairments. Carer ratings 
correlated with grey and white matter changes in frontostriatal, frontotemporal and brainstem 
systems, which have previously been implicated in motivation, arousal and goal directed 
behaviour. Response inhibition deficits on behavioural tasks correlated with focal frontal 
cortical atrophy in areas implicated in goal-directed behaviour and cognitive control.  
Diffusion tensor imaging was highly sensitive to the white matter changes underlying 
apathy and impulsivity in frontotemporal lobar degeneration syndromes. Diffusion tensor 
imaging findings were largely consistent with voxel-based morphometry, with carer ratings 
reflecting widespread changes while objective measures showed changes in focal, task-specific 
brain regions. White matter abnormalities often extended beyond observed grey matter 
  x  
changes, providing supportive evidence that white matter dysfunction represents a core 
pathophysiology in frontotemporal lobar degeneration.  
      Apathy was a significant predictor of death within two and a half years from assessment, 
consistent with studies linking apathy to poor outcomes. The prognostic importance of apathy 
warrants more accurate measurement tools to facilitate clinical trials. Although causality 
remains unclear, the influence of apathy on survival suggests effective symptomatic treatments 
may also prove disease-modifying. 
These findings have several implications. First, clinical studies for apathy/impulsivity 
in frontotemporal lobar degeneration syndromes should target patients who present with these 
symptoms, irrespective of their diagnostic category. Second, data-driven approaches can inform 
the choice of assessment tools for clinical trials, and their link to neural drivers of apathy and 
impulsivity. Third, the components and their neural correlates provide a principled means to 
measure (and interpret) the effects of novel treatments in the context of frontotemporal lobar 
degeneration.  
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Chapter 1 | Introduction 
 
1.1 The Frontotemporal Lobar Degeneration Spectrum  
Frontotemporal lobar degeneration causes a range of clinically, genetically and pathologically 
heterogeneous clinical syndromes1–3. These include the behavioural and language variants of 
frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and the corticobasal 
syndrome (CBS, which is often but not exclusively associated with corticobasal degeneration 
pathology, CBD).  
 
In this chapter, I outline the clinical features, pathological underpinnings and genetic mutations 
associated with each of the FTLD spectrum syndromes. Despite recent progress in pathological 
and genetic fractionation of these disorders4–6, the soft boundaries between phenotypes and 
convergence of syndromes with disease progression calls for an alternative transdiagnostic 
approach, embracing symptom commonalities across the spectrum of disorders.  
 
The thesis focusses on apathy and impulsivity in FTLD; both are common, multifaceted 
constructs that cause substantial patient morbidity and carer distress across the spectrum of 
disorders. Apathy includes loss of interest, motivation, activity and ‘energisation’ of 
behaviours, and reduced spontaneous or voluntary behaviour. Impulsivity includes poor 
choices (risk-taking), impaired response inhibition (disinhibition), delay intolerance (delay 
discounting), and reflection impulsivity in humans and analogous animal models.  
 
I first discuss the evolving theoretical framework associated with apathy; including suggested 
definitions, diagnostic criteria and assessment tools. I then consider the proposed underlying 
mechanisms associated with apathy and the limitations to currently available symptomatic 
therapies. Subsequently, I discuss the proposed definitions, theoretical frameworks, available 
assessment tools, underlying neurobiology and available treatments associated with 
impulsivity. I then examine the relationship between apathy and impulsivity and the underlying 
mechanisms that may be responsible for their coexistence in neurodegenerative diseases. 
 
I will illustrate the advantages of trandiagnostic techniques to understand symptom 
commonalities across the FTLD spectrum and facilitate identification of novel treatment 
targets. Such approaches remain sensitive to the heterogeneity both within and across 
syndromes, and increase power to examine complex behavioural changes. 
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1.1.1 History 
The illness now known as frontotemporal dementia was described in 1892 by Arnold Pick, and 
was for many years known as Pick’s Disease7. Pick related the clinical features of aphasia, 
apraxia and behavioural change to atrophy of the frontal and temporal lobes. Neuronal inclusion 
bodies were identified by Alois Alzheimer in 19118. Later, a spectrum of related pathologies, 
known collectively as frontotemporal lobar degeneration9, came to be recognised, underlying a 
group of clinically and pathologically heterogeneous progressive syndromes that combined 
cognitive and motor disorders10. These include the behavioural and language variants of 
frontotemporal dementia9, and two related disorders; progressive supranuclear palsy and 
corticobasal syndrome11,12.  
 
1.1.2 Clinical Presentation  
The clinical syndromes associated with frontotemporal lobar degeneration include behavioural 
variant frontotemporal dementia (bvFTD)4, which can present with or without features of motor 
neuron disease (FTD-MND)13; the language variants of FTD, known as primary progressive 
aphasias (PPA), including semantic variant (svPPA), nonfluent variant (nvPPA) and logopenic 
variant (lvPPA)6; progressive supranuclear palsy (PSP)14,15 and the corticobasal syndrome 
(CBS)5.  
 
1.1.2.1 Behavioural Variant Frontotemporal Dementia  
Changes in personality, social conduct, emotion and cognition are characteristic of bvFTD2,4, 
reflecting the progressive disintegration of the neuronal circuits involved in emotion regulation, 
social cognition, decision making and motivation16. Approximately 10% of patients also 
develop clinical and neurophysiological evidence of motor neurone disease (FTD-MND)2,13,17. 
Recently proposed criteria for ‘possible bvFTD’ reflect the widespread behavioural changes 
associated with this syndrome; three of six clinically discriminating features are required to be 
present, including disinhibition (socially embarrassing behaviours, tactless or suggestive 
remarks, overspending), apathy (often paradoxically coexisiting with disinhibition), loss of 
empathy, perseverative/compulsive behaviours, hyperorality and dysexecutive 
neuropsychological profile4. Changes in eating behaviours, mental rigidity, irritability, 
agitation, loss of insight and blunting of affect are also common features of bvFTD17,18 and 
many cases may develop language impairments later in the disease course19. Psychosis is 
uncommon, except in cases caused by the C9orf72 mutation20. A diagnosis of ‘probable 
bvFTD’ requires additional functional decline and supportive neuroimaging4, while ‘definite 
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bvFTD’ requires pathological confirmation post mortem and/or underlying genetic mutations, 
despite advances in in vivo techniques providing evidence of the underlying cause of disease4.  
 
1.1.2.2 Primary Progressive Aphasias  
Pick and Serieux7,21 described a progressive language disorder reflecting atrophy of the frontal 
and temporal regions of the left hemisphere, which was later coined “progressive aphasia”22,23. 
For many years PPAs were subtyped as “fluent/semantic” variant (svPPA)24–26 and “non-fluent 
variant”(nvPPA)27. A third subtype was defined in 2004, termed logopenic variant aphasia 
(lvPPA)28. Current criteria classify these variants into 3 categories of diagnostic certainty; 
clinical, imaging-supported and pathologically confirmed6.  
 
Progressive semantic loss is a hallmark of svPPA, over and above the language changes, and 
the term Semantic Dementia is widely used24–26,29. Semantic dementia includes a ‘right-
dominant’ variant which is not captured fully by the criteria for svPPA6. Non-verbal domains 
include visual, tactile, olfactory and gustatory systems, and many patients develop behavioural 
changes similar to bvFTD19,24,30. 
 
The non-fluent variant, nvPPA, a speech output disorder, presents as apraxia of speech and/or 
agrammatism, with literacy deficits, effortful speech6,22,27 and in some cases mutism31. 
Progressively telegraphic speech/writing and deterioration of sentence comprehension reflects 
cortical dysfunction in the left hemisphere27. Gorno-Tempini criteria require one of the two 
core features to be present; agrammatism or effortful speech, and at least two of three additional 
features including impaired syntax comprehension, spared single-word comprehension and/or 
spared object knowledge. Many patients develop motor abnormalities consistent with CBS or 
PSP32, whereas memory and visual functioning are largely preserved.  
 
Logopenic aphasia is characterised by hesitant but grammatically correct speech28, with core 
deficits in word retrieval (spontaneous speech and confrontation naming) and sentence 
repetition. Common features include word finding pauses, anomia, and impaired phonological 
working memory, resulting in the inability to repeat spoken phrases. In contrast to svPPA cases, 
single word repetition can be spared and in contrast to nvPPA patients, lvPPA does not cause 
dysprosodic speech output with motor speech errors and agrammatism6,28. 
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1.1.2.3 The Corticobasal Syndrome  
Corticobasal degeneration (initially termed “corticobasal ganglionic degeneration”) and the 
closely related “corticobasal syndrome” exhibit complex motor and cognitive changes33–35. The 
term CBD is now used mainly to refer to the distinctive pathology, while CBS refers to the 
clinical syndrome. This distinction has not always been recognised36–38 but CBS/CBD have 
poor clinicopathological correlations: AD, PSP, and FTD pathologies can mimic the 
corticobasal syndrome39,40. I use CBS to refer to the clinical syndrome and CBD to refer to the 
pathology.  
 
Although previous criteria for CBD excluded “early dementia” in an attempt to increase 
diagnostic specificity33, cognitive decline is a common and early feature38,41–43. Despite the lack 
of gold standard diagnostic criteria, definitions have required the presence of an asymmetric, 
progressive motor syndrome with features including dystonia, myoclonus, bradykinesia, limb 
apraxia and levodopa-resistant parkinsonism. Higher cortical features include apraxia, alien 
limb phenomena, cortical sensory loss, cognitive and behavioural impairment and aphasia5. 
Language impairments and behavioural changes, including apathy, antisocial behaviour, 
personality changes, irritability and disinhibition, are common. Over half of CBS cases have 
significant behavioural changes5,19. 
 
Current consensus diagnostic criteria for CBD/CBS recognise four presenting phenotypes, 
including corticobasal syndrome (CBS), frontal behavioural-spatial syndrome (FBS), nonfluent 
variant of primary progressive apahsia (nvPPA) and a progressive supranuclear palsy syndrome 
(PSPS)5, with categories of “possible” and “probable” CBD. However, Alexander et al (2014) 
showed that even the Armstrong criteria lead to misdiagnosis in up to a third of CBD cases, and 
that no singular clinical features distinguish CBD from non-CBD cases of CBS. 
 
1.1.2.4 Progressive Supranuclear Palsy  
First described by Drs Steele, Richardson and Olszewski in 1964, progressive supranuclear 
palsy (PSP) is characterised by ocular, motor (akinesia and axial rigidity), cognitive and 
behavioural changes. Diagnostic criteria developed by Litvan (1996) required >40 years of age, 
progression, falls (often backwards) within a year of onset and vertical supranuclear gaze palsy 
or slowing of vertical saccades14. Patients meeting this criteria are generally considered to have 
“classical PSP”, increasingly referred to as PSP-Richardson syndrome (PSP-RS)15, which has 
strong clinicopathological correlations to PSP pathology in up to 95% of cases44. While the 
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Litvan criteria have good specificity, they have limited sensitivity for common clinical variants 
of PSP15. PSP pathology causes other syndromes and shows phenotypic overlap, leading to new 
intermediate diagnostic terms such as CBS-PSP5. The new diagnostic criteria proposed by the 
Movement Disorders Society recognise a number of distinct PSP variants which differ in their 
clinical presentation: oculomotor dysfunction (PSP-OM), postural instability (PSP-PI), 
Parkinsonism resembling idiopathic Parkinson’s Disease (PSP-P), frontal lobe cognitive or 
behavioural presentation (PSP-F), corticobasal syndrome (PSP-CBS), and speech/language 
disorders (PSP-SL)15. 
 
Most relevant for this thesis is the acknowledgement of PSP presenting with predominant 
cognitive and behavioural features including changes in personality, irritability, obsessive 
behaviours, and executive dysfunction15,45,46. Early reports suggested that approximately 10-
25% of cases will present with cognitive symptoms and 70% develop dementia47,48. However, 
cognitive presentations (including speech, language, personality) may account for the majority 
of cases49. Memory, visuospatial and language functions may also be impaired50. Apathy is 
common and profound in PSP51–53, affecting over 80% of patients54,55, and is included in the 
diagnostic criteria alongside impulsivity15. Loss of empathy and lack of insight are also 
recognised as features of PSP, overlapping with behavioural variant FTD18. Gilchrist et al., 
(2016) reported that 60% of PSP patients met criteria for bvFTD in terms of cognitive and 
behavioural changes. Many of these patients would likely now meet criteria for PSP-F. 
 
1.1.3 Epidemiology  
Frontotemporal dementia is a common cause of young-onset dementia56, generating 
disproportionate social and economic costs. Although considered rare disorders, FTD, PSP and 
CBS collectively account for a substantial burden of disease. The Pick’s Disease and 
Progressive supranuclear palsy Prevalence and INcidence Study (PiPPIN) study reported 
prevalence of 10.8/100,000 for all FTLD syndromes, with a similar prevalence of bvFTD, PPA, 
CBS and PSP19. This is consistent with previous epidemiological studies of FTD56,57. 
 
The inclusive PiPPIN study design, considering FTD, PSP and CBS together, aimed to capture 
transitional and intermediate clinical phenotypes. Despite significant progress in the 
development of novel syndrome-specific diagnostic criteria, the overlap and evolution of 
syndromes limits their use in epidemiological studies. Previous studies have been hindered by 
lack of gold standard consensus criteria and diagnostic uncertainty, restrictive age ranges, 
phenotypic variability and poor clinicopathological correlations, assessment in a single FTLD 
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syndrome and inclusion of “phenocopy” cases (non-progressive bvFTD cases, negative for 
C9orf72)58. Inclusive epidemiological studies using novel diagnostic criteria such as the 
Movement Disorder Society NINDS-SPSP criteria for PSP15, which increasingly recognise 
multiple clinical phenotypes49,59, are warranted. Poor clinicopathological correlations suggest 
the true prevalence of FTLD pathology is unclear. 
 
For this thesis, it is advantageous to draw on an epidemiological sample to assess apathy and 
impulsivity, minimising bias towards a subset of patients who are able to regularly attend 
tertiary clinics. Therefore, unless otherwise stated, all data from this thesis are derived from the 
PiPPIN study. 
 
1.1.4 Pathology  
Frontotemporal lobar degeneration (FTLD) is an umbrella term for the underlying pathologies 
associated with FTD (with or without motor neurone disease features), PSP and CBS. FTLD is 
characterised by abnormally aggregated proteins in neurons and/or glia, neuronal loss, 
microvacuolation and a variable degree of astrocytic gliosis9, which I discuss in relation to each 
syndrome in the next sections.  
 
1.1.4.1 Frontotemporal Dementia 
FTD can be defined by the pattern of accumulated proteins. Approximately half have 
phosphorylated tau (“Tau”) and half have transactive response DNA-binding protein 43-kDA 
(“TDP43”). A small minority of patients are both tau- and TDP-43-negative, many of whom 
present with fused in sarcoma protein inclusions (FUS)60,61. The clinic-anatomical profiles of 
some FTD types are consistently associated with a particular pathology. For example, svPPA 
and FTD-MND are closely associated with TDP pathology, with svPPA most linked to TDP of 
Type C specifically and FTD-MND with Type B10,40. Very young onset bvFTD is characteristic 
of underlying FUS pathology, while logopenic aphasia is commonly caused by Alzheimer type 
pathology rather than FTLD6. A progressively smaller minority are negative for these protein 
inclusions, termed dementia lacking distinctive histology (DLDH)62.  
 
There are 6 tau isoforms in human brain tissue, which contain either three (3R-tau) or four (4R-
tau) microtubule-binding repeats, located at the carboxy-terminal of the protein10,60,63. Under 
normal conditions, tau isoforms are generated through alternate splicing of the tau gene MAPT, 
located on chromosome 17. Misfolding of tau renders it insoluble, causing it to aggregate. 
Mutations in the MAPT gene occur either in the coding region outside of exon 10, leading to 
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accumulation of 3R and 4R tau in neurons, or within the coding region of exon 10, leading to 
4R tau in neurons and glia. Sporadic tauopathies, such as CBD and PSP, are often associated 
with 4R tau64, whereas Pick Bodies are predominantly associated with 3R tau65. Pick’s 
pathology includes silver-positive rounded inclusions of 3R tau and balloon neurons known as 
“Pick Cells”3. Hyper-phosphorylated, ubiquitinated TDP-43 pathology can be subdivided into 
type A-D, each of which is associated with particular phenotypes and some of which have been 
linked to specific genetic mutations66. 
 
1.1.4.2 Corticobasal Syndrome and Progressive Supranuclear Palsy 
CBS and PSP are referred to as primary tauopathies, reflecting their association with a specific 
4R tau pathology12. The distribution and composition of neuroglial inclusions differ between 
disorders; CBD is characterised by astrocytic plaques while PSP is associated with tuft-shaped 
astrocytes67. CBD tau-positive neuronal and glial inclusions contain astrocytic plaques of 4R 
tau and threadlike lesions in cardinal regions3. CBS is particularly heterogeneous and has poor 
clinicopathological correlations5,39. CBD pathology can mimic AD or PSP clinically, while 
CBS only reflects CBD pathology in 60% of cases39.  
 
PSP tau-positive neuronal and glial inclusions contain 4 repeat neurofibrillary tangles and tufted 
astrocytes3. Hyperphopshorylation and aggregation of tau occurs predominantly in the 
pallidum, subthalamic nucleus, red nucleus, substantia nigra, pontine tegmentum, striatum, 
oculomotor nucleus, medulla and dentate nucleus51. “Classical” PSP or PSP-Richardson’s 
Syndrome has high clinicopathological correlations44,68 (including in our Cambridge cohorts). 
A recent study identified clinical features that were predictive of PSP pathology, including 
ocular motor dysfunction (supranuclear gaze palsy), postural instability, akinesia and cognitive 
dysfunction59.  
 
In general, clinicopathological correlates remain uncertain in FTLD syndromes2,17 and post 
mortem studies are required for diagnostic confirmation.  
  
1.1.5 Genetics  
Although FTLD syndromes are mostly sporadic, a number of genetic mutations have been 
identified. SvPPA, PSP and CBS/D are essentially sporadic diseases, with only rare family case 
reports of mutations causing syndromes similar to PSP and CBD. However, under current 
consensus criteria15, mutations in for example MAPT are an exclusion criterion for PSP.  
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Behavioural variant FTD has high rates of disease causing mutations. Up to 30-40% of patients 
report a family history indicative of an autosomal dominant mutation69 and of these, half will 
have a recognised mutation70. The common mutations are: progranulin (GRN), mictrotubule-
associated protein tau (MAPT) or chromosome 9 open reading frame 72 (C9orf72; frequently 
associated with FTD-MND13,71,72)1,3,63,70. Additional rare genes, including TBK173, 
CHMP2B60, and FUS74 have been identified as causing FTD syndromes.  
 
1.1.6 A new dimensional approach to the FTLD spectrum  
Classifying patients using proposed diagnostic criteria can be useful for patients and their 
families, but phenotypic boundaries are not distinct. Despite discrete clinical presentation at 
diagnosis, syndromes may converge with disease progression, such that a patient can transition 
to eventually meet inclusion criteria for multiple variants19,75. This limits the relevance of 
diagnostic labels, prevents accurate epidemiological estimates and complicates treatment. It 
also speaks to the biological basis of phenotypic expression of neurodegeneration.  
 
In this thesis, I consider an alternative transdiagnostic approach, moving away from a classical 
categorical framework for diagnosing FTLD to embrace symptom commonalities across the 
spectrum of disorders (Figure 1). Considering FTLD syndromes together remains sensitive to 
the heterogeneity both within and across groups. For example, two bvFTD patients can meet 
diagnostic criteria without sharing a single core clinical feature. In contrast, although svPPA 
patients meet different diagnostic criteria to bvFTD, patients often develop similar behavioural 
changes. Stratifying patients based on the presence and severity of specific symptoms/signs 
provides a basis for examining their underlying neural correlates and may identify targets for 
symptomatic treatment. 
 
This dimensional approach to examine changes across neurodegenerative diseases is consistent 
with the recent Research Domain Criteria (RDoc), developed by the National Institute of 
Mental Health. RDoc is a research framework to classify mental disorders based on dimensions 
of observable behaviour and neurobiological measures. It considers the relevant symptom 
domains spanning a number of disorders, in contrast to categorical diagnostic criteria such as 
the International Classification of Diseases (ICD-10) (World Health Organisation, 1993) or 
Diagnostic and Statistical Manual of Mental Disorders (DSM) 5th Edition (American 
Psychiatric Association, 2013). By integrating information spanning from genes, molecules and 
cells to physiology, behaviour and self-report, RDoc aims to understand the full range of human 
behaviour from normal to abnormal (example provided in Figure 2). By adopting this approach, 
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a “neurological” RDoc76 would provide the necessary framework to examine the relationship 
between neurodegenerative diseases and their heterogeneity, by identifying overlapping 
domains of motor, cognitive and behavioural change.  
 
 
Figure 1: Transdiagnostic Methods.  
Patients often meet criteria for multiple variants, effectively sitting on the border between 
diagnostic groups. For example, an individual may meet criteria for both PSP-F under 
the Höglinger criteria or bvFTD with oculomotor features under the Rascovsky criteria, 
PSP-CBS under the Höglinger criteria or CBS-PSP under the Armstrong criteria. Under 
these circumstances, clinicians may argue for or against a particular diagnosis. This 
categorisation has implications for clinical studies targeting specific disease groups, which 
may exclude patients meeting alternative diagnostic criteria. Transdiagnostic methods, 
such as those employed by the PiPPIN study, are inclusive of all patients irrespective of 
their diagnostic label. This approach is particularly relevant for assessing symptom 
commonalities that span the entire FTLD spectrum, including apathy and impulsivity. 
 
1.1.7 Treatment  
There are currently no proven disease modifying treatments for FTLD and pharmacotherapy 
focuses primarily on management of distressing and disabling symptoms. Neurotransmitter 
replacement or augmentation therapy is the focus of symptomatic treatments, with evidence of 
syndrome-specific serotoninergic, dopaminergic and/or noradrenergic deficits77,78.  
 
Symptomatic treatments may improve akinetic-rigidity, dystonia, sleep disturbance, affective 
disorders, mood, anxiety, aggression, psychosis, myoclonus, and bowel and bladder 
dysfunction, but are largely prescribed based on small case studies, ‘expert opinion’ or 
analogous effects in other psychiatric or neurological disorders. There are limited randomised-
controlled clinical trials (RCTs), and those available are restricted by small sample sizes due to 
low prevalence of specific FTLD subtypes79,80. 
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Efforts to develop a disease-modifying treatment for FTLD primarily target the abnormal 
aggregation of proteins, with current studies focusing on the accumulation of 
hyperphosphorylated tau. However, the lack of suitable, FDA approved, disease-specific 
outcome measures is problematic for clinical trials, and novel biomarkers are warranted to 
accurately track disease progression. Delayed diagnosis has also hindered trials of disease 
modifying treatments; the repeated failure of clinical trials in Alzheimer’s Disease may reflect 
irreversible neuropathology and neurodegeneration at the time of intervention, emphasizing the 
need for early diagnosis and treatment. Insights from genetically predisposed individuals 
suggest brain changes may occur 5-10 years prior to clinical onset81. Identifying biomarkers of 
early or presymptomatic disease has become a major research priority. In the absence of an 
effective disease-modifying therapy, the emphasis on quality of life rather than quantity is 
apparent, highlighting the need to treat disabling and distressing symptoms more effectively.  
 
Furthermore, symptomatic treatment may potentially also alter the disease trajectory. Apathy, 
a common feature observed across FTLD syndromes, is reported to cause rapid cognitive and 
functional decline towards AD dementia in MCI patients82–84, suggesting that effective 
intervention targeting the underlying neurobiology of apathy may improve outcome for patients 
(see 2.0 Apathy section below and Chapter 6). Effective treatment of these complex disorders 
will almost certainly require a personalised combination of pathology-targeting, disease-
modifying treatments and symptomatic therapies. 
 
1.1.8 Interim Summary  
Advances in the clinical, pathological and genetic fractionation of FTLD associated disorders 
has supported new diagnostic criteria4–6, although accuracy in the face of widening phenotypic 
variation remains limited. The overlap and convergence of syndromes with disease progression 
suggests that transdiagnostic approaches may be more appropriate for the development of novel 
symptomatic treatments, embracing symptom commonalities. In the following sections, I 
discuss the applicability of such approaches to apathy and impulsivity, two common, 
multifaceted and often coexisting syndromes which occur across the FTLD spectrum.  
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Figure 2: The Research Domain criteria (RDoc).  
Developed by the National Institute of Mental Health to classify mental disorders, the 
RDoc includes five domains or systems, which can be categorized into constructs, sub-
constructs, molecules, circuits, self-report measures, and paradigms. Above is an example 
relevant to motivation. 
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1.2 Apathy 
Apathy is a common, multifaceted and highly debilitating construct spanning multiple 
neurological and neuropsychiatric diseases85–89. Apathy is increasingly recognised to 
negatively impact patient outcomes90 in Alzheimer’s Disease91,92, Huntington’s Disease93, 
Parkinson’s Disease83,88,91, stroke87,94–97, head injury98, pre-dementia states82–84 and FTLD 
syndromes92,99–103. Apathy has been linked to decreased functioning84,94, increased caregiver 
distress104, rapid cognitive and functional decline83,105,106, poor response to 
treatment/rehabilitation94,107, reduced quality of life97 and poor prognosis108. Crucially, apathy 
may represent a risk factor for conversion to dementia82,84. Despite awareness of its negative 
impact, apathy remains poorly understood and further investigations into its components and 
neural correlates are warranted. Apathy may represent a biomarker for early brain changes, a 
predictor of individual patient trajectories/outcomes and a target for treatment. 
 
1.2.1 Definition 
There remains no consensus regarding a definition for apathy. Apathy originates from the Greek 
word “apatheia” meaning ‘without passion’ and is defined in the Oxford English Dictionary as 
a ‘lack of interest, enthusiasm or concern’. Apathy may be a primary syndrome or a secondary 
symptom109, according to ones attribution of causality; the syndrome of apathy has been defined 
as a lack of motivation that is “not attributable to diminished level of consciousness, cognitive 
impairment (intellect), or emotional distress”, in contrast to reduced motivation as a 
consequence of these factors109.  
 
1.2.2 Proposed Diagnostic Criteria  
A gold standard clinical diagnostic criteria for apathy is lacking. Apathy is not referenced in 
the International Classification of Diseases (ICD-10) (World Health Organisation, 1993) and 
is mentioned in the Diagnostic and Statistical Manual of Mental Disorders (DSM) 5th Edition 
(American Psychiatric Association, 2013) only as a symptom (eg. of Schizophrenia and Major 
Depression) rather than independent syndrome. Several criteria exist, including DSM-like 
criteria proposed by Marin (1991), but lack of a consensus definition for apathy limit their 
applicability and they are rarely used in clinical practice. Stuss et al. (2000), emphasized that 
apathy should be defined as an absence of responsiveness to stimuli indicated by a lack of self-
initiated affective, behavioural or cognitive action. Similarly, Starkstein (2000) and Robert et 
al., (2009) define apathy in terms of loss of motivation, loss of goal directed behaviour, 
cognitive activities and/or emotions, and functional impairment in the absence of physical 
disability. Despite efforts to develop standardised criteria, diagnosis of apathy in the clinic is 
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often made either based on clinical interview or by employing currently available assessment 
tools developed for research purposes.  
 
1.2.3 Cognitive and Behavioural Framework 
Since Marin’s initial description, other proposed cognitive and behavioural frameworks for 
apathy remain largely descriptive and allusive. Apathy is increasingly recognised as a complex, 
multifaceted construct and its components and mechanisms remain controversial. 
 
The framework by Levy & Dubois (2006) has been highly influential. They defined apathy in 
terms of “quantitative reductions in self-generated voluntary and purposeful behaviour”, 
representing a behavioural and quantifiable construct rather than an emotional psychological 
state. The multifactorial nature of apathy has been highlighted by attempts to define subtypes 
relating to distinct underlying mechanisms of altered “goal-directed behaviour” (GDB) 
processing. The “goal” can be immediate and physical, such as relieving thirst, or long-term 
and abstract, such as having a family or being successful in one’s job110. Achieving GDB 
depends on a number of internal and external factors that determine intention to act, plan, 
initiate and execute actions and provide feedback regarding the completed action110,111.  
 
Subtypes of apathy have been proposed, and largely recognise three components of emotional, 
behavioural and cognitive processing. Stuss (2000), categorised apathy as a lack of response to 
stimuli in terms of either ‘affective’, ‘behavioural’ or ‘cognitive’ self-initiated actions, while 
Levy and Dubois (2006) proposed similar classification subtypes of ‘emotional-affective’, 
‘cognitive’ and ‘auto-activation’. Levy & DuBois (2006) related these subtypes to prefrontal-
basal ganglia circuits112, linking each to dissociable mechanisms of disrupted GDB processing 
(see figure 3). They proposed that ‘emotional-affective’ apathy results from changes in the 
orbital-medial prefrontal cortex or connected regions of the basal ganglia (ventral striatum). 
Disruptions in dorsolateral prefrontal cortex and its connections to the dorsal caudate nucleus 
were considered to cause executive dysfunction and ‘cognitive’ apathy. The auto-activation 
subtype was attributed to bilateral lesions of the associative and limbic territories of the globus 
pallidus, akin to akinetic mutism113.  
 
Apathy exists to varying degrees in healthy people, as part of a behavioural trait within the 
general population. Using the recently developed Apathy Motivation Index114, the healthy 
population showed three domains of apathy: (i) ‘behavioural activation’ reflecting self-
generated goal-directed behaviour and closely resembling the ‘cognitive’ and auto-activation’ 
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aspects of Levy & Dubois’ conceptualization of apathy; (ii) ‘emotional sensitivity’ quantifying 
responses to positive and negative affection, consistent with the ‘emotional-effective’ subtype; 
and (iii) ‘social motivation’ pertaining to an individual’s personal engagement in social 
interactions. Dissecting the components of motivation in the healthy population115–117 will 
provide critical insights into the underlying causes of apathy in disease populations.  
 
1.2.4 Assessment of Apathy  
There are several assessment tools to measure apathy, many of which attempt to quantify apathy 
in terms of the proposed subtypes described above118. The majority of available measures are 
questionnaires including the Apathy Evaluation Scale (AES; patient, informant and clinician 
versions109), Apathy Inventory119, Lille Apathy Rating Scale120, NPI apathy subscore121, AES-
10122, the Dementia Apathy Interview and Rating for apathy in Alzheimer’s Disease123 and the 
Apathy Motivation Index114. Assessment tools largely recognise apathy as a multifaceted 
construct, with typical sub-scores quantifying the “emotional-affective”, “cognitive” and “auto-
activation” domains of apathy. Clarke et al., (2011) examined 15 apathy scales and subscales 
and reported that the AES and the apathy subscale of the Neuropsychiatric Inventory were the 
most psychometrically robust measures for assessing apathy across any disease population. 
However, special considerations apply to apathy in FTLD.  
 
Assessment of apathy in dementia often requires multiple perspectives (eg. patient vs carer), 
due to cognitive impairment38,45,46,50,124,125 and loss of insight18. Development of analogous 
assessment tools for the patient, carer and clinician, such as the Apathy Evaluation Scale, have 
facilitated studies assessing consistency across raters, and revealed disagreement between 
assessors126, likely reflecting loss of patient insight and emotion recognition18 or increased carer 
distress127,128. In conditions characterised by cognitive impairment, behavioural measures of 
motivation may be more appropriate to quantify apathy objectively. Behavioural tasks 
minimize the influence of the rater and may more effectively capture the behavioural construct 
of apathy111.  
 
Furthermore, the identification of behavioural tasks to study apathy, linked to homologous tasks 
in preclinical models, can facilitate translational studies of novel treatments129–131. However, 
behavioural measures are not without their own limitations. First, some tasks developed to 
assess apathy in the healthy population are too complex for dementia patients, relying heavily 
on sequential decisions, physical effort and executive demands. Other tasks may be confounded 
by motor impairments in FTLD syndromes115,117,132,133. Second, the relationship between 
Chapter 1 
 15  
objective measures, used in preclinical and research populations, and subjective questionnaires, 
often the choice of assessment for large clinical trials, is unknown. A better understanding of 
the translational ability of these tasks, and their relevance to the behaviours reported as most 
problematic by patients and/or carers is needed to clarify the most appropriate outcome 
measures for future treatment trials.  
 
Tools designed for and validated in specific disease areas should only be used in the intended 
target population134. A recent systematic review assessing the validity and reliability of 
available apathy scales in neurodegenerative conditions concluded that validation studies were 
of average methodological quality and yielded inconsistent psychometric properties135, 
highlighting the need for more accurate assessment tools for the FTLD population.  
 
1.2.5 Prevalence  
Table 1: Prevalence of Apathy among Neurological Conditions  
Disease Prevalence 
Frontotemporal Dementia 89-100% 
Progressive Supranuclear Palsy 22-91% 
Corticobasal Syndrome 40% 
Mild Cognitive Impairment 14.7-39.8% 
Parkinson’s Disease 17.0-45.7% 
Huntington’s Disease 59-82% 
Stroke 15.2-42% 
Vascular Dementia 22.6-93.6% 
Traumatic Brain Injury 20-70% 
Amyotrophic Lateral Sclerosis 55.6% 
HIV 12% 
Cardiovascular Disease 29% 
(after Ishii et al., 2009) 
 
Apathy is a common neuropsychiatric feature of neurological disease, including FTLD 
syndromes (Table 1)102,136–138. Apathy is included in the diagnostic criteria for bvFTD, 
accounting for the high prevalence139. However, similar prevalence occurs in the language 
variants, particularly svPPA136, suggesting overlapping neurobiological changes. Litvan et al., 
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(1998) reported apathy prevalence of 40% in CBS, and over 90% in PSP68. However, efforts to 
estimate the prevalence of apathy among disease groups have been hindered by the lack of a 
gold standard clinical diagnostic criteria for apathy. Limitations to the available assessment 
tools and their use in unsuitable populations, may also lead to false prevalence estimates. 
 
1.2.6 Confounds in the Assessment of Apathy 
Estimating the prevalence of apathy is further complicated by its frequent overlap with 
depression, akinesia, anhedonia and fatigue107,140–143. Particular emphasis has been placed on 
dissociating apathy from depression82,107,141,142. Starkstein et al., (1992) reported that apathetic 
PD patients had slow but accurate responses on executive function (Trials Making Test, Part 
B) whereas depressed PD patients had inaccurate but consistent response speed, suggesting 
apathy and depression were dissociable. Apathy can also be clearly dissociated from depression 
in disorders such as PSP, where there is a high incidence of apathy but low incidence of a low 
mood disorder14. Indeed, a lack of correlation between apathy and depression has been reported 
in a combined sample of AD, FTD, PD, HD and PSP141. Recent findings have further 
demonstrated dissociable neurobiology for apathy and depression; Hollocks et al., (2015) 
reported that apathy, but not depression, was related to damage to cortical-subcortical networks 
associated with emotion regulation, reward and goal-directed behaviour in small vessel disease. 
These effects may relate to distinct subtypes of apathy. Using the Apathy Motivation Index, 
Ang et al., (2017) reported four subtypes of apathy-motivation in the healthy population, each 
of which differed in their association with depression, anhedonia and fatigue.  
 
The relationship between apathy and cognitive decline is unclear. Some suggest that apathy is 
associated with greater cognitive impairment68,84 while others fail to replicate this finding89. 
Mega et al., 1996 reported increased apathy with increased dementia severity, reporting 42% 
affected in MCI, 80% in moderate and 92% in severe cognitive impairment. However, apathy 
is also frequently reported in pre- and early dementia states, where its presence is predictive of 
a more aggressive dementia, characterised by rapid cognitive and functional decline82–84,109. 
Whether apathy precedes cognitive impairment warrants investigation and may be clarified 
through ongoing studies of presymptomatic genetically predisposed individuals.  
 
A major limitation of many studies of apathy is the bias towards recruitment of less apathetic 
individuals. Intuitively, those who present to clinic and take part in research studies are likely 
to be less apathetic than those who do not. Previous studies have also reported differences in 
apathy prevalence depending on one’s environment; Van Reekum et al., (2005) reported a 
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higher prevalence of apathy in AD nursing home residents, suggesting either that certain 
environments may prompt increased apathy or that individuals with increased apathy are more 
likely to reside in a home82–84104,127, highlighting the need to embed studies of apathy in 
epidemiological studies rather than tertiary care settings.  
 
1.2.7 Neurobiology 
Apathy is proposed to reflect disrupted connections between the pre-frontal cortex and basal 
ganglia structures involved in controlling self-generated, goal-directed behaviour111,113,144–147. 
Apathy often occurs following direct focal lesions to the frontal lobe113,148,149, and is a common 
feature of neurodegenerative diseases affecting the prefrontal cortex, including bvFTD150,151. 
Apathy is also frequently reported following damage to the associative and limbic territories of 
the basal ganglia through focal lesions to the caudate nuclei, internal pallidum and thalamic 
nuclei152–154 or neurodegenerative diseases primarily affecting the basal ganglia such as 
PSP53,68, HD93 and PD53,88,91.  
 
The similarities in behavioural disturbances that occur as a consequence of either focal basal 
ganglia lesions/diseases or damage to the prefrontal cortex highlight their anatomical 
relationship and functional dependence. Physiological, anatomical and lesion studies in 
monkeys show these regions to be highly interconnected155–157. Alexander et al., (1986, 1990) 
suggested that connections between the PFC and BG formed a series of heterogeneous frontal-
subcortical loops112,158,159, organized into several structurally and functionally distinct circuits. 
Each pathway was proposed to influence, through direct and indirect pathways, distinct areas 
of the frontal lobe and involve dissociable parts of the striatum, globus pallidus, substantia nigra 
and thalamus. Three to five parallel and contiguous pathways are generally considered, but the 
number is arbitrary, with a functional gradient rather than discrete circuits160,161. The archetypal 
circuits include a motor circuit originating in the supplementary motor area, an oculomotor 
circuit originating in the frontal eye fields and three behaviourally relevant circuits originating 
in the prefrontal cortex112. The three prefrontal circuits originate in the dorsolateral prefrontal 
cortex, lateral orbitofrontal cortex and anterior cingulate112 and project to the dorsolateral 
caudate nucleus, ventromedial region of the caudate an ventral striatum/nucleus accumbens 
respectively (Figure 3). The cortico-striatal pathways do not work in isolation but converge 
along the circuit, forming interactive networks162,163. Successful goal-directed behaviour 
requires efficient reward evaluation, learning and flexibility to develop appropriate plans of 
action and inhibit inappropriate choices162.  
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Figure 3: Parallel fronto-subcortical circuitry underlying executive dysfunction, apathy 
and disinhibition (after Bonelli and Cummings, 2007; Chudasama and Robbins, 2006) 
 
Neuroimaging supports the fronto-subcortical circuitry underlying apathy. Structural magnetic 
resonance imaging studies of apathy have implicated the medial prefrontal cortex138, 
dorsolateral prefrontal cortex100,102, anterior cingulate102, temporal lobe and caudate101 and their 
connections. Indeed, substantial white matter abnormalities are increasingly recognised to 
accompany apathy97,164–167. Hollocks et al., 2015 directly measured the white matter changes in 
apathetic individuals with small vessel disease and reported damage to cortical-subcortical 
networks associated with emotion regulation, reward and goal-directed behaviour. Reduced 
median fractional anisotropy (FA; a marker of white matter tract integrity) was significantly 
associated with apathy with strongest effects in limbic tracts including anterior cingulum, fornix 
and uncinate fasciculus. Hahn et al, (2013) reported a negative correlation between apathy 
scores and FA in the genu, body, and splenium of the corpus callosum, the left anterior and 
posterior cingulum, the right superior longitudinal fasciculus, and bilateral uncinate fasciculi in 
Alzheimer’s Disease. Reduced FA in the uncinate fasciculus has also been linked to apathy in 
bvFTD164.  
 
Positron emission tomography (PET) studies using 18F-fluorodeoxyglucose have reported 
glucose hypometabolism in the dorsolateral and frontal medial cortex bilaterally in association 
with apathy168, in addition to the ventral polar frontal cortex168,169, while post mortem studies 
report a correlation between NPI apathy and neurofibrillary tangles in the anterior cingulate in 
AD170. 
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1.2.8 Neuropharmacology 
A number of neurotransmitters have been implicated in modulating the fronto-subcortical 
circuits discussed above, including dopamine (DA), serotonin (5-HT) and noradrenaline 
(NA)77,171. Dysfunction of these neurotransmitter systems is recognised in FTLD syndromes, 
and may contribute to apathy. 
 
Treatment of apathy has focused largely on dopaminergic intervention, which is widely 
implicated in the brain’s reward and motivational circuitry (incentive salience) in both human 
and animal studies162,172–178. In PD, the severity of apathy differs between ‘on’ and ‘off’ 
dopaminergic medication states116,179, suggesting apathy is at least in part a dopamine-
dependent syndrome. Apathy following lesions to the basal ganglia is also responsive to 
dopamine treatment, leading to increased reward sensitivity, reduced apathy, greater motivation 
and increased social interactions180. There is evidence of nigrostriatal and mesocortical 
dopamine disruption in FTD and PSP, with low levels of dopamine in the striatum, substantia 
nigra and frontal lobes77,181,182. Apathy may therefore arise from disruption of mesocortical 
pathways due to degeneration of dopaminergic neurons in ventral tegmental area51,183 and 
reduced D2 receptor binding in the frontal lobes in FTD184 and PSP15.   
 
Apathy often does not respond to dopamine treatment140 suggesting additional neurotransmitter 
involvement. There is increased interest in the influence of noradrenaline, which is proposed to 
control the effects of the mesolimbic DA system on mediating reward185. Dopamine and 
noradrenaline systems have mutual connections to the prefrontal cortex, which may account for 
their coexisting influence on motivation186. Noradrenaline modulates cortical and subcortical 
structures (Figure 4), influencing arousal and behaviour187. It also facilitates attentional shifting 
and behavioural flexibility by regulating exploratory behaviour and promoting focus onto 
behaviourally relevant stimuli188. Dysfunction of NA projections from the locus coeruleus (LC) 
to the ventral striatum has been associated with increased apathy in PD patients189. The LC is 
also affected in PSP, and there is accumulating evidence of an early noradrenergic deficit, with 
significant neuronal loss and tau pathology in the LC190. Studies assessing the influence of 
noradrenaline for the treatment of apathy in FTLD syndromes are warranted.  
 
1.2.9 Treatment  
There are no formally approved drugs for apathy and a recent review concluded that there was 
limited and inconsistent evidence for the efficacy of any drug191, highlighting the urgent need 
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to identify novel treatment targets. Pharmacological efforts have targeted the dopaminergic, 
cholinergic, serotonergic and noradrenergic systems.  
 
Dopaminergic therapies have controversial results. For example, levodopa therapy in PD had a 
positive influence on the subjective evaluation of motivation, but contrasting effects on reward 
sensitivity179. Despite dopaminergic cell loss, PSP patients are generally unresponsive to 
dopamine therapy182, likely reflecting the multi-focal nature of structural brain changes, 
including loss of postsynaptic receptors15, which are relatively preserved in PD183. Small case 
studies of dopamine agonists including selegiline192 and amantadine193 have reported some 
benefit in treating apathy following traumatic brain injury and following stroke180. Ropinirole, 
a dopamine agonist, reduces apathy following prefrontal cortex lesions194 and following 
subthalamic nucleus stimulation in PD195. Bromocriptine has shown some benefit in treating 
apathy following TBI196 and akinetic mutism197. There have been some case reports of 
improved apathy and amotivation with bupropion treatment198, a non-selective catecholamine 
and indolamine reuptake inhibitor. Dopamine-resistant apathy is increasingly recognised199, 
providing supportive evidence against DA being the sole underlying cause.  
 
Serotonergic deficits in FTLD syndromes suggests serotonin reuptake inhibitors may be useful 
for treating apathy80,200. However, evidence supporting their use in FTLD syndromes is 
limited201 and they may even cause apathy by altering the balance between serotonin and 
dopamine89. 
 
A modest effect of acetylcholinesterase inhibitors on improving apathy has been reported in 
Alzheimer’s Disease202, PD203 and TBI204. However, a recent review suggested the small effect 
sizes made the clinical relevance of cholinesterase inhibitors doubtful, and concluded that there 
was insufficient evidence to determine their efficacy for the treatment of apathy in 
neurodegenerative diseases191.  
 
There is increased interest in the potential use of noradrenergic therapies for apathy78, although 
studies have so far been inconclusive. Atomoxetine is reported to improve cognitive functions 
in PD, including attention, decision-making and response control130,205, but its effect on apathy 
specifically are unknown. Randomised controlled trials of methylphenidate (acting on NA and 
DA) for apathy in AD have reported contrasting results206,207. 
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Figure 4: The Noradrenergic System (from Espay et al., 2014) 
 
In order to clarify the impact of these neurotransmitter systems on apathy, randomised, placebo-
controlled clinical trials in larger samples with apathy as the primary target and outcome 
variable are warranted. Studies would likely benefit from stratifying patients based on the 
presence and severity of apathy, rather than using categorical diagnostic criteria. Apathy 
symptoms and subtypes should be carefully defined. Advances in neuroimaging and 
biomarkers may help to clarify the relationship between apathy and treatment response, and 
explain why some patients may respond, while others do not129. 
 
1.2.10 Interim Summary  
Numerous assessment tools for apathy exist, but the number of options limits comparisons 
between studies, without yet resolving the optimal choice of tool for any given condition. Focus 
has been on the development of subjective self-rated questionnaires, which may be 
inappropriate for FTLD syndromes. Objective measures that have been developed in the 
healthy population may not be readily applicable to patients. Nonetheless, apathy is highly 
prevalent in FTLD and is associated with negative outcomes. Improved knowledge of the 
neurobiological basis of apathy is needed, which I propose will benefit from dimensional and 
transdiagnostic approaches to assess brain-behaviour relationships and identify novel treatment 
targets.  
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1.3 Impulsivity  
1.3.1 Definition 
Impulsivity is a multifaceted construct, reflecting actions that are poorly conceived or without 
foresight, prematurely executed, unduly risky or inappropriate to the situation, often with 
undesirable consequences208. There remains no single definition that encapsulates the range of 
behaviours associated with impulsivity. Instead, research efforts have focused on fractionating 
impulsivity into its major components, each of which are considered to reflect aspects of poor 
cognitive control that differ in their biological basis. These include a failure to inhibit actions 
(“disinhibition”), inability to wait for higher but delayed rewards (“delay intolerance or 
impulsive choice”), sampling insufficient information before making a decision (“reflection 
impulsivity”) and poor responses to reward values (“reward responsiveness/risk taking”).  
 
Impulsive actions are not always pathological, and many aspects of daily life require rapid 
decision making to achieve goals, and may consequently result in poor decisions with 
associated negative outcomes. Adolescents are also recognised as more impulsive than older 
adults209, which some suggest reflects immature development of the inferior frontal cortex in 
children210, a brain region consistently implicated in studies of response inhibition211. 
Impulsivity can therefore be viewed as part of a normal personality trait. But, problematic and 
excessive impulsivity is common in psychiatric154,212–214 and neurological diseases144,215–217.   
 
1.3.2 Diagnostic Criteria 
Impulsivity is recognised in the Diagnostic and Statistical Manual (DSM-IV) as a symptom 
under the criteria for impulse control disorders (ICDs) such as Pathological Gambling. 
However, there remains no specific criteria for impulsivity, despite its frequent occurrence in 
the absence of impulse control disorders218. Some argue that the DSM-IV lacks biological 
footing and suggest an alternative approach to classifying impulsive “endophenotypes” by 
assessing behavioural and cognitive processes that reflect deficits in specific neural systems219. 
This would avoid common limitations to the classical categorical approach to diagnosis of 
complex neurocognitive behavioural constructs including: patients with the same diagnosis 
having very different symptoms (for example, PSP is now recognised to have multiple different 
clinical presentations under newly proposed diagnostic criteria15), and patients with different 
diagnoses but presenting with the same symptoms (for example, FTLD disorders such as 
bvFTD and PSP, which can both present with profound apathy and impulsivity4,164,201,220).  
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A dimensional approach would facilitate reporting of impulsivity constructs across diagnostic 
groups, and target individuals who are impulsive irrespective of other confounds. This in turn, 
may identify common neurobiological changes associated with impulsivity across disease 
groups. For example, despite differences between the clinical syndromes of Parkinson’s disease 
and bvFTD, both disorders are characterised by impulsivity and reflect dysfunctional frontal 
cortico-striatal pathways221.  
 
1.3.3 Prevalence  
Impulsivity is commonly reported across a number of psychiatric disorders, including attention 
deficit hyperactivity disorder (ADHD)213,214,222, schizophrenia212, obsessive compulsive 
disorder (OCD)223, and neurological diseases, including PD86,130,216,224,225, PSP15,50,201,205,226, 
and FTD, where disinhibition is a diagnostic criterion for bvFTD5,102,137,138,144,164,217. 
Impulsivity is also common in populations of substance abuse including heroin227, 
cocaine227,228, and alcohol229,230.  
 
Similar to the apathy literature, studies commonly evaluate impulsivity within diagnostic 
groups, rather than across all individuals presenting with impulsivity. Transdiagnostic 
approaches assessing impulsivity constructs across disorders may provide more accurate 
estimates of its frequency within the population219. Chamorro et al., (2012) assessed impulsivity 
in the general population by analysing data from 34,653 face-to-face surveys in adults aged 18+ 
between 2004 and 2005. They reported impulsivity in 17% of the sample, as determined by 
endorsement of the following question: “Most of the times throughout your life, regardless of 
the situation or whom you were with, have you often done things impulsively?”231. Impulsivity 
was common among males and younger individuals and associated with drug dependence, 
dependent and schizotypal personality disorders, bipolar disorder and ADHD, in addition to 
negative outcomes such as dangerous behaviours such as reckless driving, shoplifting, domestic 
violence and suicide. The term “impulsivity” covers a broad range of components and this study 
did not clarify which component(s) of impulsivity were observed. Indeed, conflicting and 
unclear definitions of impulsivity complicate consistent reporting, and likely arise from distinct 
manifestations of impulsive behaviour across conditions232. Furthermore, studies often select 
different assessment tools to measure impulsivity without clarifying or understanding which 
aspects of impulsivity they measure. For example, the Go/NoGo and stop signal tasks were 
initially used interchangeably to measure response inhibition, but they are now recognised to 
reflect distinct pharmacological changes233. As our understanding of the components of 
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impulsivity and their associated neurobiology improves, appropriate tasks to measure and 
manipulate them should be clarified.  
 
1.3.4 Assessment of Impulsivity 
A range of assessment tools are available to quantify impulsivity; including questionnaire based 
and behavioural based measures. Impulsivity can be assessed in humans using self-report 
measures including the Barratt Impulsiveness Scale (BIS)234 and Behavioural Activation 
System/Behavioural Inhibition system (BIS/BAS) scale235. The BIS and BIS/BAS include 
several subscores that recognise the multifactorial nature of impulsivity. For example, the BIS 
includes subscores of attention, motor, self-control, cognitive complexity, perseverance, and 
cognitive instability and the BIS/BAS includes a Behavioural Inhibition score and Behavioural 
Activation subscores of drive, funseeking and reward responsiveness.  
 
However, differences in terminology across questionnaires hinder direct comparisons. How do 
the BIS subscores relate to the BIS/BAS subscores? Furthermore, questionnaires developed 
within the healthy or psychiatric population may not be appropriate for neurological conditions, 
particularly where cognitive and functional decline is severe. For example, the BIS includes a 
question: “I often squirm at plays or lectures”, to which patients are often either unable to 
understand (‘squirm’) and require prompting, or are too functionally impaired to be able to 
attend such events and/or lack the ability to project themselves into an unfamiliar situation.  
 
Carer-rated questionnaires assessing a range of behaviours relating to disinhibition are more 
commonly used in neurodegenerative populations. These include the Neuropsychiatric 
Inventory236, Cambridge Behavioural Inventory 237,238 and Frontal Systems Behaviour Scale239, 
all of which contain subscales related to disinhibition. Although these questionnaires show 
good discrimination of frontotemporal dementia from other diseases, such as Alzheimer’s 
Disease150,237,238, they are inherently subjective and vulnerable to caregiver distress104,240. Carer 
ratings may therefore vary greatly, and objective measures of disinhibition may be more 
appropriate.  
 
Fractionation of impulsivity into multiple components has enabled development of behavioural 
tasks and paradigms targeting distinct aspects of impulsivity and facilitating comparisons 
between animal to human studies. Impulsivity can be measured in terms of: response inhibition, 
including action restraint on the Go/NoGo task and action cancellation on the Stop Signal Task 
(SST)233; reflection impulsivity as measured by information sampling tasks241, delay 
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intolerance or impulsive choice on delayed discounting paradigms242,243 and reward 
responsiveness/risk taking as measured by the Cued Reinforcement Reaction Time Task147 or 
Gambling Tasks244.  
 
Response inhibition can be measured in terms of action restraint on the Go/NoGo task and 
action cancellation on the stop signal task, which are widely recognised as dissociable 
components with distinct sub processes and psychopharmacology (see section 1.3.6). Action 
restraint reflects the inhibition of a motor response before the response has been initiated, while 
action cancellation describes the inhibition of a motor response during its execution. The tasks 
require subjects to repeatedly respond to visual stimuli by making a motor “Go” responses 
(often a button press, lever or touch screen). On a subset of trials, a ‘stop’ signal in the form of 
a visual or auditory signal informs the subject to inhibit the ‘Go’ response. The tasks are similar 
in format, and were previously used interchangeably to describe dysfunctional action 
inhibition233. However, the Go/NoGo contains a decision making component which is 
eliminated from the stop signal task. Another key difference is the positioning of the stop signal 
relative to the go response, which is close to the endpoint of the go response in the SST, 
allowing calculation of the stop signal reaction time – the major outcome measure (which 
cannot be calculated from the Go/NoGo task)233. Poor performance on tasks of response 
inhibition are reported across a number of psychiatric and neurological conditions, and in 
substance abuse populations131,205,214,220,228,245.   
 
Individuals select responses based on sensitivity to expected rewards, biased by discounting of 
future outcomes according to their availability and effort costs. Impulsive people tend to choose 
immediate gains, with discounting of future outcomes of their choices227. Delayed discounting 
paradigms measure this type of impulsive choice208,242,246, often in the context of hypothetical 
monetary rewards on questionnaire-based tasks242.  
 
Incentive motivation can also be measured on tasks such as the Cued Reinforcement Reaction 
Time task147. This task measures the ability of an individual to adapt performance in response 
to a change in reward probability (see Chapter 2 for details). Healthy controls decrease reaction 
times in response to increased probability of reward, known as reward-related speeding.  
 
Gambling also reflects choice impulsivity. It is often assessed using gambling tasks such as the 
Cambridge Gambling Task244 and Iowa Gambling Task247. The Cambridge Gambling task 
requires subjects to determine the probability of a yellow token being placed under a red or 
green box, and place a bet according to their certainty. Bets are presented in ascending or 
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descending order, in order to dissociate motor impulsivity from risk-taking behaviour. Unlike 
other gambling tasks, the CGT examines decision making, without confounds of learning and 
working memory, by clearly presenting all information needed to make a decision throughout 
the task. Patients with frontal lobe lesions place high bets in both ascending and descending 
conditions, reflecting risky behaviours248. Compared to healthy controls, bvFTD patients fail to 
inhibit prepotent responses on the IOWA, favoring short-term gains which lead to long term 
losses2. Despite the inclusion of disinhibition in the criteria for PSP and bvFTD, pathological 
gambling is uncommon in FTLD syndromes249, in contrast to PD225,250. 
 
Reflection impulsivity, often measured by the Information Sampling Task (see Chapter 2 for 
details), is less widely studied and reflects the tendency to gather and evaluate information 
before making a decision241. Inaccurate or inadequate reflection will consequently lead to ill-
informed or risky decisions232. ADHD and AD patients gather less information and make riskier 
and less accurate decisions than healthy controls251. Impulsive individuals therefore obtain 
insufficient information before reaching a decision, leading to risky behaviours and negative 
consequences.  
 
Critically, the relationship between questionnaire based and behavioural based measures of 
impulsivity are unclear. Whether they relate to a unitary construct of impulsivity is 
controversial219. Indeed, questionnaires may not reflect behavioural measurements in either 
humans or experimental animals196, with direct implications for translational studies. For 
example, Clark et al., (2006) suggested their definition of reflection impulsivity corresponded 
somewhat to the construct of non-planning impulsivity on the BIS234, but found no correlation 
between performance on the information sampling task and these ratings241. Although 
correlations between different questionnaires are reported252, questionnaires and behavioural 
tasks are poorly correlated and rarely exceed r=0.4, with significant correlations only observed 
in large studies196. When measuring impulsivity in FTLD therefore, one should perhaps not 
focus on which type of FTLD, but which type of impulsivity, and choose outcome measures 
accordingly. 
 
1.3.5 Neurobiology  
There is considerable evidence to suggest that different types of impulsivity can be dissociated 
in terms of their underlying neural substrates, providing support for a multifaceted rather than 
unitary construct. For example, lesions of the subthalamic nucleus cause impairments in action 
cancellation  (SSRT), but do not affect premature responding/impulsive choice on delayed 
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discounting tasks, which are instead sensitive to lesions of the nucleus accumbens core 
region233. Dalley et al, (2011) proposed distinct neuronal circuitry underlying “waiting” and 
“stopping” impulsivity, implicating both cortical and subcortical regions. “Waiting” 
impulsivity reflects “limbic” fronto-striatal circuits including the ventromedial prefrontal 
cortex and ventral striatal regions, and regulates reward anticipation and discounting253,254, 
while “stopping” impulsivity is associated with the inferior frontal cortex and dorsal striatum, 
and mediates response inhibition. Within this “stopping” network, the right inferior frontal 
gyrus (RIFG) in particular is considered critical for inhibitory control, specifically action 
cancellation, through top-down response control processes208,211,255, while the basal ganglia are 
implicated in both action cancellation and action inhibition233. 
 
Neuroimaging and lesion studies in FTD predominantly associate disinhibition with the 
orbitofrontal and ventromedial prefrontal cortex, temporal pole regions and their white matter 
connections102,138,144,148. Reports of alternative neural correlates100 likely reflect use of different 
outcome measures. In PSP, impulsivity may arise from striatal or frontal lobe dysfunction; loss 
of subthalamic inhibition may disinhibit thalamocortical projections and cause a bias towards 
action rather than restraint215,220, or alternatively cortical neuropathology/degeneration in 
prefrontal and premotor circuits may impair correct responding by preventing accumulation of 
evidence166,183,220,256,257. The importance of cortico-striatal circuits in disinhibited behaviours is 
apparent, with studies implicating both frontal (OFC and IFC) and striatal (nucleus accumbens) 
regions111,221.  
 
1.3.6 Neuropharmacology  
The neuropharmacology of impulsive behaviours are often studied in terms of impulsive action 
on the Go/NoGo and SSRT tasks, impulsive choice/reward processing on gambling tasks and 
delay intolerance on temporal discounting tasks. Psychopharmacological dissociations in terms 
of dopaminergic, serotonergic and noradrenergic influence between types of impulsivity and 
associated tasks are reported233,258. For example, serotonin influences action restraint 
(Go/NoGo) while having no effect on action cancellation (SST), which is sensitive to 
noradrenergic modulation259. Impulsive behaviours common to FTLD syndromes likely arise 
from deficits in multiple processes reflecting dysfunctional neurotransmitter systems.  
 
Dopamine is critical to reward processing and cognitive performance, and dopamine 
dysregulation has been linked to impulsivity. Dopamine replacement therapy may cause 
impulsive behaviours (increased risk-taking260), delay aversion261 and impulsive control 
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disorders225,250,262, depending on basal level of dopamine function in underlying cortico-striatal 
circuitry261. The emergence of impulse control disorders (ICDs) in PD patients on medication 
are proposed to reflect “overdosing” of the ventral striatum, which remains relatively intact in 
early PD225,263,264. Whether dysregulation of dopamine in FTLD51,77,181–183 influences 
impulsivity is unclear. 
 
Serotonin is widely implicated in action restraint response inhibition233,258,265 and may mediate 
the motivational properties of reward147 through interactions with the mesolimbic DA 
system178,196,266. Serotonergic deficits are reported in bvFTD and PSP51,77,168,181–183 and there is 
accumulating evidence to suggest these deficits contribute to characteristic behavioural 
disturbances, including impulsivity267. In bvFTD, increased serotonergic neurotransmission 
following citalopram (a serotonin reuptake inhibitor) improved action restraint on the Go/NoGo 
task and caused partial restoration of corticostriatal circuitry131. These findings were consistent 
with a study in PD, which also reported increased prefrontal activation268. Serotonin depletion 
is also implicated in incentive motivation and decision-making, although reported effects are 
inconsistent147,233,269. While the influence of serotonin on response inhibition is clear, its impact 
on the remaining components of impulsivity requires clarification196. 
 
Noradrenaline has been implicated in multiple types of impulsivity, including action 
cancellation, reflection impulsivity, risk taking and reward processes78,130,270. Noradrenergic 
influences underlying impulsivity have largely been studied in the context of PD, although there 
is increased evidence of an early noradrenergic deficit in PSP. Atomoxetine, a selective 
noradrenaline reuptake inhibitor, improves response inhibition in PD130,205,271, reducing 
SSRT205, increasing activation of the right inferior frontal gyrus and improving connectivity 
between the IFG and pre-supplementary motor cortex205,245,271, consistent with reports in 
healthy volunteers272 and ADHD214. These findings in humans are broadly consistent with 
animal studies of atomoxetine, which report a dose-dependent speeding of SSRT and decrease 
in premature responding on the 5-choice serial reaction time task222,233. Together, these findings 
suggest loss of NA neurons and their projections to the cortex273 may contribute to 
impulsivity274. 
 
1.3.7 Prognosis and Treatment 
Impulsivity is associated with negative outcomes and impulsive behaviours such as excessive 
gambling, hyper-sexuality, inappropriate social conduct and binge eating are difficult to 
manage and cause significant carer distress102,104. An impulsive personality trait may also be a 
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risk factor for substance abuse and other addictions. Individuals who strongly discount future 
outcomes, a component of impulsivity, generally lack self-control and engage in additive 
disorders such as pathological gambling, cigarette smoking and substance abuse254. 
 
There are no treatments for impulsivity that are specifically licensed for FTLD syndromes. The 
multifaceted nature of impulsivity, reflecting involvement of multiple cortico-striatal pathways 
and neurotransmitter systems, makes it unlikely that a single treatment will benefit impulsivity 
as a whole. Instead, treatments targeting the dopaminergic, serotonergic and noradrenergic 
systems may differentially benefit distinct aspects of impulsivity as discussed above.  
 
Drugs targeting the noradrenergic, dopaminergic and serotonergic systems, such as 
atomoxetine, citalopram and methylphenidate have been approved for the treatment of 
psychiatric illnesses including depression, ADHD, schizophrenia and obsessive compulsive 
disorder. Recent studies have highlighted the potential of these drugs to treat impulsivity in 
FTLD syndromes115,130,131,205,245,268,271,275, and warrant further investigation. Effective 
measurement of impulsivity components and clarification of their associated neurobiology will 
facilitate personalised treatment targeting the underlying neural systems involved. 
 
1.3.8 Interim Summary 
Fractionation of impulsivity into multiple components has enabled development of numerous 
assessment tools to target distinct aspects of this multifaceted behavioural construct. The neural 
correlates of response inhibition are well established, but the systems regulating the remaining 
components of impulsivity are less clear and warrant further investigation to inform future 
treatment studies. 
 
1.4 The Relationship between Apathy and Impulsivity in FTLD Syndromes  
An important aim for this thesis is to examine whether apathy and impulsivity coexist in FTLD 
syndromes, although this may at first glance seem paradoxical2,86,100,104,201,224. They are both 
included in the diagnostic criteria for behavioural variant FTD4, and in newly proposed criteria 
for PSP15, but also occur frequently across the full spectrum of disorders associated with 
frontotemporal lobar degeneration19,50,276. Apathy and impulsivity may be concurrent in an 
individual patient75,150, contradicting the notion that they represent opposite ends of a 
dopamine-dependent behavioural spectrum86. Indeed, the co-existence of apathy and 
impulsivity suggests either that there is a coinciding neurobiological basis for these behavioural 
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changes220, or that the widespread pathology in FTLD syndromes leads to simultaneous deficits 
in anatomically and pharmacologically different networks. 
 
Both apathy and impulsivity are recognised as multifaceted constructs (described above and by 
111,208,216), with multiple contributory factors. These factors may be expressed in terms of 
common brain network pathology86,100,101,216,268,275,277, overlapping cognitive processes of 
motivation, reward and decision making111,220,224,278, and pharmacology147,208,233, as discussed 
in previous sections.  
 
The presence of both apathy and impulsivity in FTLD syndromes creates a major challenge for 
the development of new therapeutic strategies. There are common limitations to previous 
studies of apathy and impulsivity, including:  
i) The assessment of either apathy or impulsivity alone, despite their frequent co-
existence. 
ii) The assessment of behavioural changes within single diagnostic groups. 
iii) The use of limited sets of tasks or questions which relate to just one aspect of these 
multifactorial constructs.  
 
In this thesis, I adopt an alternative dimensional approach to assess apathy and impulsivity 
transdiagnostically, across the behavioural and language variants of frontotemporal dementia, 
progressive supranuclear palsy and the corticobasal syndrome. Similar approaches have been 
proposed by the National Institute of Mental Health in their Research Domain Criteria 
Framework279,280, and by Robbins et al., (2012). Such methods accommodate the 
commonalities of apathy and impulsivity across disorders and reveal their cognitive and 
anatomical bases. The ability to measure the components of apathy and impulsivity and their 
associated neural correlates across diagnostic groups would provide better targets for 
pharmacological manipulations, and facilitate new treatment strategies and strengthen 
translational models. 
 
1.5 A Transdiagnostic Approach to Apathy and Impulsivity in FTLD Syndromes.  
1.5.1 Thesis Overview 
To elucidate the physiological, pharmacological and genetic causes of apathy and impulsivity, 
and to design appropriately stratified and powered clinical trials of candidate treatments, one 
needs four critical items. First, a clear definition of the cognitive and behavioural components 
of apathy and impulsivity, from which to develop robust and targeted assessment tools. Second, 
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one needs knowledge of how these different components are represented transdiagnostically, 
across disorders associated with frontotemporal lobar degeneration. Third, one requires 
evidence for the neural basis of the components, both to generate surrogate markers in 
experimental medicines studies and to validate preclinical models of behavioural disorders. 
And finally, one requires knowledge of the prognostic implications associated with these 
components. 
 
This thesis employs data from the Picks Disease and Progressive Supranuclear Palsy Prevalence 
and INcidence (PiPPIN) study, an epidemiological study of FTLD syndromes in 
Cambridgeshire and Norfolk, in an attempt to address these outstanding issues. The PiPPIN 
study combined detailed neuropsychiatric and behavioural assessment of apathy and 
impulsivity from multiple perspectives (patient, carer, clinician, objective tests), with MRI 
imaging, genetic analysis and pathological post mortem diagnostic confirmatory analysis. 
Taken together, this assessment battery aimed to capture the major domains of apathy and its 
principal confounds, including motivation, anhedonia, depression/mood and akinesia and the 
major domains of impulsivity, including reward sensitivity, response inhibition and information 
sampling (see Chapter 2 for full details).  
 
1.5.2 Thesis Aims 
The aims of my thesis are as follows:  
To: 
1) Determine the frequency and characteristics of apathy and impulsivity in FTLD 
syndromes (Chapter 3), as measured by different tools. 
2) Examine the neurocognitive components of apathy and impulsivity in FTLD syndromes 
by employing data reduction techniques, specifically principal component analysis 
(Chapter 3).  
3) Determine the neural correlates of the components of apathy and impulsivity, using 
voxel based morphometry for volumetric analysis of grey and white matter (Chapter 4) 
and diffusion tensor imaging tract based spatial statistics (Chapter 5) for analysis of 
white matter tract integrity. 
4) Investigate the impact of the identified apathy and impulsivity components on patient 
prognosis and survival (Chapter 6), drawing on previous studies which link apathy to 
negative outcomes. In the event of a strong link between apathy/impulsivity and disease 
progression, it remains elusive whether effective symptomatic treatment could prove 
disease-modifying.  
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1.5.3 Thesis Hypotheses 
The hypotheses of my thesis, developed in the experimental chapters 3-6, are as follows:  
 
1) Apathy and impulsivity in FTLD syndromes are multifactorial constructs, but with 
common and overlapping features across diagnostic groups.  
2) Subjective and objective measures of apathy and impulsivity relate to the same 
components, consistent with previous translational studies. 
3) Distinct frontostriatal, frontotemporal and brainstem circuits support the 
components of apathy and impulsivity. 
4) Components of apathy have significant implications for prognosis, warranting 
further investigation into effective symptomatic treatments which may also prove 
disease-modifying. 
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Chapter 2 | The Pick’s disease and Progressive supranuclear palsy 
Prevalence and Incidence (PiPPIN) Study Methods. 
 
The Pick’s disease and Progressive supranuclear palsy: Prevalence and INcidence study was an 
epidemiological study of FTLD syndromes in Cambridgeshire and Norfolk, aiming to a) 
provide more accurate estimates of prevalence and incidence of the FTLD spectrum disorders 
based on newly proposed diagnostic criteria and b) enable deep phenotyping of FTLD disorders 
in terms of neuropsychiatric, behavioural, imaging and genetic analysis.  
 
Accurate epidemiological estimates of these conditions will have direct implications for 
treatment studies (both disease modifying and symptomatic), healthcare planning and policy, 
research design and carer and patient support. The extensive neuropsychiatric and behavioural 
assessment battery, MRI imaging and serum collection for genetic analysis included in the 
PiPPIN study protocol provides a long-term resource for studies evaluating the impact of 
behavioural changes on disease. The value of this information is increased if the cohort studied 
is representative of the full spectrum of disorders. Improved knowledge of disease 
characteristics and their underlying neurobiology may also provide a means to validate 
preclinical models and inform future clinical studies.  
 
In the introduction, I highlighted the importance of effective measurement and improved 
symptomatic treatment of apathy and impulsivity in FTLD syndromes. Achieving these goals 
requires a detailed understanding of the components and neural correlates of apathy and 
impulsivity across the FTLD spectrum.  
 
The PiPPIN study provided the ideal arena for such an analysis, employing a broad range of 
assessment tools to capture the major domains of apathy and its principal confounds, including 
motivation, anhedonia, depression/mood and akinesia and the major domains of impulsivity, 
including reward sensitivity, response inhibition and information sampling. Importantly, the 
study gained insight from various perspectives through carer, patient and clinician ratings, 
objective tasks and neuroimaging. Patient and carer perspectives were measured by 
questionnaires of the type commonly used in clinical trials, enabling assessment of potential 
discrepancies between carer and patient perspectives. Objective neuropsychological and 
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behavioural tests were employed to bridge between preclinical and clinical studies, supporting 
translational models.  
 
In the following chapter I describe the methods of the PiPPIN study in detail, focusing on the 
cohort (patient demographics), assessment tools and acquisition methods. I also outline the 
analytical methods employed to examine the data, the results of which are discussed throughout 
chapters 3-6, including basic statistical techniques (chapter 3), multivariate principal 
component analysis (chapter 3), voxel-based morphometry (chapter 4), diffusion tensor 
imaging (chapter 5), and logistical regression (chapter 6). Detailed imaging-specific analysis 
methods are provided in the relevant chapters.  
 
2.1 The PiPPIN Study Objectives 
The PiPPIN study was designed to address the following major objectives: 
1. To apply revised and validated diagnostic criteria for each disorder to estimate the 
lifetime risk, prevalence, incidence and mortality of the principal syndromes of the 
FTLD spectrum. The epidemiology of PiPPIN is addressed elsewhere19. 
2. To acquire detailed neuropsychological and behavioural tests, combining patient, carer 
and clinician based assessments with objective behavioural and neuropsychological 
measures, in order to determine the multifactorial basis of behavioural change in FTLD 
associated syndromes, focussing on apathy and impulsivity. 
3. To enable long term evaluation of clinicopathological correlations and genetic factors 
associated with the FTLD spectrum diseases.  
 
My work addresses aim 2 detailed above, with the following additional objectives:  
1. To determine the components of apathy and impulsivity transdiagnostically, across the 
FTLD spectrum, using data-reduction techniques, specifically principal component 
analysis. 
2. To examine the neural correlates of apathy and impulsivity components across FTLD 
syndromes, in terms of volumetric grey and white matter change (voxel based 
morphometry and diffusion tensor imaging).  
3. To evaluate the impact of apathy and impulsivity on prognosis and survival in the 
PiPPIN cohort.  
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2.2 Patient Demographics  
Diagnosis was based on current diagnostic criteria for behavioural variant frontotemporal 
dementia [bvFTD]4, Primary Progressive Aphasia syndromes [PPA]6, Progressive 
Supranuclear Palsy [PSP] (Litvan et al., 1996, with variation in falls extending from 1 to 3 
years, as in Bensimon et al., 2009) and the Corticobasal Syndrome [CBS]5, following clinical 
interview, physical examination, relevant exclusionary tests and brain imaging. The study was 
undertaken prior to the revised MDS criteria for PSP15. The primary progressive aphasias were 
subtyped6 to the non-fluent agrammatic variant (nvPPA), the semantic variant (svPPA), and a 
third group that included logopenic variant (lvPPA) and mixed aphasia (primary progressive 
aphasia as the prominent syndrome but not fitting criteria for one of the 3 defined subtypes, 
termed PPA). Diagnostic criteria were applied by a trained neurologist and included clinical 
interview, neurological and physical examination, cognitive and functional tests and brain 
imaging. Where there was diagnostic ambiguity a second neurologist reviewed the case and a 
consensus was reached. For cases that were unable or unwilling to be assessed in person, 
including because of death, diagnosis was based on available clinical records. 
 
Two-hundred and four patients were identified, 167 of whom were assessed in person by a 
member of the study team. Eighteen either died before neuropsychological assessment or were 
unable to undertake testing over and above diagnostic confirmation, leaving 149 patient 
datasets for analysis. Fifty healthy age-/sex-matched controls were recruited from the Medical 
Research Council’s Cognition and Brain Sciences Unit volunteer panel, with no significant 
neurological or psychiatric history.  
 
2.3 Ethical Approval & Sponsorship 
The PiPPIN study was approved by the Cambridge 2 Research Ethics Committee.  The study 
was jointly sponsored by the University of Cambridge and Cambridge University Hospitals 
Foundation NHS Trust. 
 
2.4 Locations 
The investigators were based in the Herchel-Smith Building at the University of Cambridge 
where regional National Health Service clinics for PSP, FTD and CBD are held. MRI scans 
were performed at the Wolfson Brain Imaging Centre (WBIC) at the University of Cambridge 
on the Cambridge Biomedical Campus. Neuropsychological and behavioural assessments were 
conducted at the Herchel Smith Building or in participants own homes, or in the case of healthy 
volunteers the Medical Research Council’s Cognition and Brain Sciences Unit.  
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2.5 Recruitment  
Patients were recruited from the counties of Cambridgeshire and Norfolk (combined population 
1.69 million (2013 UK Office for National Statistics mid-year estimate). The study aimed to 
identify all cases with a reference diagnosis between January 1st 2013 and December 31st 2014. 
Recruitment relied on multi-source identification from primary, secondary and tertiary care, 
self-referral and relevant patient charities. Patients were recruited from regional specialist 
clinics for FTD; for disorders of movement, memory and cognition; and early dementia. 
Additional contact through person, letter and email was made before and during the study, to 
maintain raised awareness. Direct referrals from neurological and psychiatric services were also 
accepted, with help from the National Institute for Health Research Clinical Research Network 
Dementias and Neurodegeneration Speciality (DeNDRoN) and the West Anglia Clinical 
Research Network. Patients were also recruited through self- or carer-referral, local newspaper 
advertisements for the PiPPIN study, and letters of invitation to members of the local and 
national charities (including the UK FTD support group and the PSP Association). Patients 
were not required to travel to the study center, as home or nursing home assessment by the 
study team was available.  
 
A personal consultee process was employed to assess the potential participation of patients who 
lacked mental capacity, in accordance with UK law. Firstly, their willingness to consider 
research participation at a level compatible with their cognitive abilities was evaluated. 
Secondly, a nominated individual was consulted, which included the spouse, holder of Lasting 
Power of Attorney, IMCA, an appropriate next of kin or chosen personal consultee as outlined 
in the Mental Capacity Act (2005).  
 
2.6 Protocol Overview 
The study was comprised of three tiers (see Figure 5). Tier 1 included participants with a FTLD 
diagnosis but who were unwilling to participate in further assessments, to enable upper 
estimates of prevalence and incidence in Cambridgeshire and Norfolk to be calculated. Tier 2 
participants were invited to undergo multiple neuropsychiatric and behavioural assessments, 
focusing on apathy, impulsivity and related behavioural changes. Tier 3 included deep 
phenotyping of patients in terms of imaging, genetics and neuropathology. Reasons for 
participant drop out included; death, severe cognitive impairment, and contraindication to MRI 
scan (see inclusion and exclusion criteria below). Other samples within PiPPIN that lie outside 
of this thesis include DNA (EDTA), RNA (PAXgene), serum and plasma markers. These are 
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not analysed further as part of my thesis. Genetic screening results (17 known genetic causes 
of FTLD and non-FTLD) in forty-six patients are presented by Gilchrist et al., (2016).  
 
Figure 5: Overview of the Three PiPPIN Study Tiers. 
 
2.7 Inclusion and Exclusion criteria 
Inclusion and exclusion criteria differed depending on the Tier and are detailed in Table 2.  
 
Table 2: Inclusion and Exclusion Criteria for the PiPPIN Study 
TIER INCLUSION EXCLUSION 
1 
Subjects greater than 18 years old with relevant 
diagnoses. 
NONE 
2 
Subjects included in tier one who are willing to 
participate in tier two and have either provided 
informed consent (if they have mental capacity to 
do so) or where participation is agreed after 
consultation with a nominated Consultee. 
End stage disease. Visual, hearing and 
language impairment would lead to a 
pragmatic reduction in the protocol, but 
participation would still be possible. 
 
3 
Subjects included in tier two who have capacity 
to consent to individual elements of tier three. 
Contraindication to MRI. 
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2.8 Power and Group Size Calculations 
Based on previous epidemiological studies56 we expected that half of the regional cases of FTD, 
PSP and CBD were already known to our specialist clinics at the CUHT.  We anticipated around 
30-40 new cases reported from the region each year. We proposed to estimate age-adjusted 
prevalence, separately for tier one and tier two, using census data and with statistical support 
from the Cambridge Institute of Public Health. Tier one was most inclusive, but lacked 
standardised diagnostics. Tier two provided higher diagnostic accuracy. The prevalence data 
was used to estimate incidence with well-known epidemiological caveats for a recruitment 
phase. Tier one (c. 250) and tier two (c. 150) are powered (>0.8) to detect small to medium (d 
= 0.2 - 0.3) group effects and medium transdiagnostic correlations, and to identify >4 
neurobiologically distinct components of apathy and impulsivity (GPower software), but the 
sample sizes were driven by epidemiological recruitment rather than target sample sizes.  
 
2.9 Neuropsychological and Behavioural Assessment Battery 
Patients underwent a clinical assessment battery (Table 3), including a semi-structured 
interview for clinical history and demographic data, questionnaire based assessments of 
behavioural changes, focussing primarily on apathy, impulsivity and related motivational 
changes, and various behavioural tasks. The following principles were applied in selecting the 
PiPPIN test battery: to employ a variety of tests to examine the multifaceted constructs of 
apathy and impulsivity, to include clinically standard tests as well as experimental paradigms; 
to include questionnaires to be completed be patients and carers to provide complementary 
perspectives; to include both subjective symptom-based questionnaires and objective 
neuropsychological tests for both patients and controls; to measure potential confounds of 
apathy and impulsivity including symptoms of depression and akinesia; to prioritize untimed 
tests in view of likely akinesia in many participants; and to use only tasks that have been 
published and used with independent cohorts.   
 
Patient self-assessment of apathy (Apathy Evaluation Scale [AES]109), impulsivity (Barratt 
Impulsiveness Scale[BIS]234, Behavioural Inhibition System/Behavioural Activation System 
Scale [BIS/BAS]235), motivation (Motivation and Energy Inventory [MEI]281), depression 
(Beck Depression Inventory [BDI]282), pleasure (Snaith Hamilton Pleasure Scale [SHAPS]283), 
sleep (Parkinsons Disease Sleep Scale [PDSS]284) and quality of life (Short form health survey 
– 36 [SF-36]285) were obtained. Patients also completed visual analogue scales (see Table 3 for 
details) and the Kirby delayed discounting paradigm242.  
Chapter 2 
 39  
Carer based assessments of behavioural change included the carer-rated apathy evaluation scale 
(AES-I109), Neuropsychiatric Inventory (NPI121), Cambridge Behavioural Inventory-Revised 
(CBI-R237). Clinician assessments included the clinician Apathy Evaluation Scale (AES-C109), 
and structured interview. 
 
Cognitive and functional impairment were measured using standard cognitive (Addenbrookes 
Cognitive Examination Revised [ACE-R]125, Mini Mental State Examination [MMSE], Frontal 
Assessment Battery [FAB]286) and functional rating scales (Frontotemporal Dementia Rating 
Scale [FRS]287 and Progressive Supranuclear Palsy Rating Scale [PSP-RS]14).  
 
Computer-based behavioural tests included measures of response inhibition (‘NoGo’ and 
‘Stop-signal’(Cambridge Cognition Ltd.)), reflection impulsivity (Information Sampling Task 
[IST]241), and reward responsiveness (Cued Reinforcement Reaction Time Task [CRRT]147, 
modified Cambridge Gambling task [CGT] (Cambridge Cognition Ltd.)). In view of the motor 
impairments that are characteristic of some FTLD spectrum disorders, oculomotor tests of 
impulsivity (using a  standard lightweight head mounted saccadometer) were also employed in 
the form of ‘NoGo’ saccadometry220 to enable direct comparisons with the motor Go/NoGo 
task.  
 
2.9.1 Description of Questionnaires 
The apathy evaluation scale (AES) is a commonly used measure for apathy assessment across 
several disease populations, although some of the questions are not well suited to people 
affected by severe physical disability, as they refer to motivation for activities that are 
impossible. All versions demonstrate good internal consistency, with the AES-I and AES-C 
also demonstrating good test-retest reliability and the AES-C reporting good inter-rater 
reliability118,134. Consistent with the multidimensional nature of apathy, the scale assesses 
emotional, behavioural and cognitive constructs, with higher total scores indicating more severe 
symptom presentation109. Disadvantages of the AES include limited convergent validity, often 
failing to correlate with other measures of apathy such as the NPI apathy subscore118. The 
PiPPIN study included all three versions of the Apathy Evaluation Scale, in order to assess the 
degree of agreement between patient (AES-P), clinician (AES-C) and carer (AES-I) ratings. 
Discrepancies may arise from patient loss of insight, a core feature of FTD, CBS and PSP18 or 
carer distress127,128.  
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The Cambridge Behavioural Inventory-Revised (CBI-R)237 assesses behavioural change, 
specifically memory/orientation, everyday skills, sleep, self care, abnormal behaviours, mood, 
beliefs, eating habits, stereotypical behaviours and motivation. The CBI-R, an abbreviated 
version of the original CBI238, was developed to evaluate behavioural changes associated with 
various forms of dementia. Although reliability studies are lacking, the scale has demonstrated 
high internal consistency and is reported to effectively differentiate between disease states, 
including Huntington’s disease (HD), Parkinson’s disease (PD), Alzheimer’s disease (AD), 
svPPA and bvFTD237.  
 
The Neuropsychiatric Inventory121,236 was developed to assess psychopathology in dementia 
patients. The scale evaluates twelve aspects of neuropsychiatric disturbance. The apathy 
subscale of the NPI was reported to be among the most psychometrically robust measures for 
assessing apathy across any disease population134.  
 
The self rated BIS234 and BIS/BAS235 subjectively quantified impulsivity. The BIS is a widely 
cited scale for the assessment of impulsivity234. Reflecting the multifactorial structure of 
impulsivity, it examines attention, motor and non-planning domains, with higher scores 
indicating a more impulsive profile.  
 
Similarly, the BIS/BAS scale is multifaceted and follows Gray’s biopsychological theory of 
personality that claims two general motivational systems underlie goal-directed behaviour, 
including the behavioural activation system regulating appetitive behaviours, and the 
behavioural avoidance system controlling aversive motives235. The questionnaire is internally 
consistent, being initially based on a principal component analysis and having gone through 
several cycles of item generation and testing, though in healthy college students. The 
motivational properties of the BIS/BAS suggest it may also be a useful measure of apathy. 
 
The MEI281 and SHAPS283 measure motivation and anhedonia respectively, which may relate 
to or influence apathetic and impulsive states and were therefore included in the analysis. 
Motivation may underlie clinical presentations of apathetic or impulsive behaviours, with 
apathy reflecting low motivation and impulsivity high motivation, although the relationship has 
not been fully clarified.  
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Table 3: Summary of PiPPIN Assessment Battery 
Measurement  
Test 
Type 
Description Rater Outcome Measures 
Addenbrooke’s 
Cognitive 
Examination Revised 
(ACE-R) 
CT 
Standard assessment tool used to indicate severity of cognitive impairment. 
Normative values based on 63 controls aged 52-75 and 142 dementia patients 
aged 46-86. Cut-off <88 gives 94% sensitivity and 89% specificity for 
dementia Cut-off <82 gives 84% sensitivity and 100% specificity for dementia 
C 
ACE-R /100 
Attention & Orientation /18 
Memory /26 
Fluency /14 
Language /26 
Visuospatial /16 
Mini Mental State 
Examination (MMSE) 
CT Standard assessment tool used to indicate severity of cognitive impairment. C MMSE /30 
Frontotemporal 
Dementia Rating 
Scale (FRS) 
CT 
Assessment tool used to stage disease severity in FTD based on functional 
dependence and behavioural changes.  
I 
Logit score indicating severity of disease 
% score/100  
Frontal Assessment 
Battery (FAB) 
CT 
Sensitive to frontal lobe dysfunction. The assessment explores: 
conceptualization, mental flexibility, motor programming, sensitivity to 
interference, inhibitory control, and environmental autonomy. 
C 
Total score /18 
 
Progressive 
Supranuclear Palsy 
Rating Scale (PSP-
RS) 
CT 
Assessment tool measuring disability due to PSP. Contains six categories: daily 
activities (by history), behaviour, bulbar, ocular motor, limb motor and 
gait/midline. 
C Total /100 
Apathy Evaluation 
Scale (AES)  
Q 
18 item questionnaire assessing emotional, behavioural and cognitive 
constructs of apathy, with higher total scores indicating more severe symptom 
presentation 
P, I, C 
Total score /72  
Subscores: Cognition, Emotion, Behaviour 
Barratt Impulsiveness 
Scale (BIS)  
Q 
30 item self-report questionnaire reflecting the multifactorial structure of 
impulsivity by assessing attention, motor and non-planning domains, with 
higher scores indicating a more impulsive profile. 
P 
Total score /120,  
Subscores: Attention, Motor, Self Control, 
Cognitive Complexity, Perseverance, 
Cognitive Instability 
Behavioural 
Inhibition System 
Behavioural 
Activation System 
(BIS/BAS)  
Q 
24 item self-report questionnaire based on Gray’s biopsychological theory of 
personality that claims two general motivational systems underlie goal-directed 
behaviour, including the behavioural activation system regulating appetitive 
behaviours, and the behavioural avoidance system controlling aversive 
motives. 
P 
Total Score  
Subscores: BIS, BAS Drive, Funseeking, 
Reward Responsiveness 
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Measurement  
Test 
Type 
Description Rater Outcome Measures 
Cambridge 
Behavioural 
Inventory (CBI-R)  
Q 
45 item questionnaire developed to evaluate multiple behavioural changes 
associated with various forms of dementia. 
C 
Total Score /180 
Subscores: Memory/Orientation, Everyday 
Skills, Self Care, Abnormal, 
Behaviour, Mood, Beliefs, Eating Habits, 
Sleep, Stereotypical Behaviour, Motivation 
Neuropsychiatric 
Inventory (NPI) 
Q 
12 item questionnaire assessing the severity and distress of various behavioural 
disturbances including delusions, hallucinations, agitation/aggression, 
depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, 
disinhibition, irritability/lability, motor disturbance, night time behaviours, 
appetite/eating 
 
Total /36 
Scores on each of the items can also be used 
as individual subscores. 
Motivation and 
Energy Inventory 
(MEI) 
Q 
27 item questionnaire developed to evaluate reductions in motivation and 
energy in depression research, although commonly used in other disease areas.  
P Total Score /144 
Snaith Hamilton 
Pleasure Scale 
(SHAPS)  
Q 14 item questionnaire measuring hedonic capacity (anhedonia).  P Total Score /56 
Beck Depression 
Inventory (BDI) 
Q 
21 item questionnaire widely used to measure the severity of depression. The 
latest version, BDI-II, is designed for individuals aged 13 and over. Cut of 
scores are well established: 0-9: minimal depression, 10-18: mild depression, 
19-29: moderate depression, 30/63: severe depression 
P 
Total Score /63 
 
Visual Analogue 
Scales (VAS) 
Q 
14 words including: stimulated, interested, clear headed, tired, apathetic, 
depressed, happy, calm, alert, motivated, sad, excited, impulsive, bored. Each 
item is scored by placing an X on a horizontal line representing low to high 
endorsement.   
P Total score /140  
Parkinson’s Disease 
Sleep Scale (PDSS) 
Q 
15 item questionnaire employing a visual analogue scale to assess frequently 
reported symptoms associated with sleep disturbance in Parkinson’s Disease. 
P Total Score /150 
Obsessive Compulsive 
Inventory Revised 
(OCI_R) 
Q 
18 item questionnaire developed to assess behavioural changes in obsessive 
compulsive disorder.  
P Total Score /72 
Short Form 36 health 
survey (SF-36) 
Q 
36 item questionnaire assessing quality of life. Lower scores reflect more 
severe disability. 
P Total Score /100 
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Measurement  
Test 
Type 
Description Rater Outcome Measures 
Kirby Delayed 
Discounting  
Q 
Serial forced choice paradigm. Choice between two rewards of varying 
magnitude at different time delays. Delayed discounting is the tendency to 
prefer small immediate rewards over larger delayed rewards 
P 
Value of delayed discounting (k) at large, 
medium and small rewards. This represents 
the point at which individuals prefer an 
immediate smaller reward over a larger 
delayed reward.  
Information Sampling 
Task (IST) 
B 
Reflection impulsivity task measuring the amount of information accumulated 
before making a decision. 
P 
Proportion of correct trials; Box Latency; 
Colour Latency;  Boxes opened; Total 
Correct; Sampling error; Discrimination error 
(fixed and decreasing conditions) 
Cued reinforcement 
reaction time (CRRT) 
B 
Reward sensitivity task measuring motivationally driven behaviour and the 
ability of an individual to adapt performance in response to a change in reward 
probability. 
P 
Reward related speeding (First & second half 
of trials); 
Difference in Speeding from first to second 
half (learning); Total Errors 
Stop signal task (SST)  B 
Action cancellation task, assessing the ability to inhibit a motor response 
during its execution. The major outcome measure is the stop signal reaction 
time.  
P 
SSRT; Median reaction time on correct GO 
trials; Proportion of successful stops 
Motor NoGo  B 
Action restraint task, testing the ability to inhibit a motor response before the 
response has been initiated. 
P 
Reaction time on GO correct; 
Commission/omission errors; Dprime 
Saccade NoGo S 
Action restraint saccade task, testing the ability to inhibit a prepotent saccade 
response following a visual cue 
P 
Reaction time on GO correct; 
Commission/omission errors; Dprime 
Cambridge Gambling 
Task  (CGT)* 
B Gambling task designed to measure risk-taking and decision making behaviour. P 
Delay aversion; Deliberation time;  
Overall proportion bet; Quality of decision 
making; Risk adjustment;  
Risk taking; Total 
 
Test type included questionnaires (Q), Clinical Test (CT) behavioural tasks (B) and a saccade task (S). Tests were completed by the patient 
(P), carer (C) or investigator (I). *Cambridge Gambling Task was discarded from further analysis after it became clear that patients could 
not perform the task, despite simplification. 
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In view of the common possibility for phenomenological confusion between apathy and 
depression, the BDI-II282 was included to assess depression in this population. Apathy and 
depression are widely recognised to be dissociable constructs reflecting distinct neuronal 
circuitry107,141. The regional clinical practice is to focus on mood (low, sad, guilty, hopeless, 
etc) in the diagnosis of depression, and not the physical symptoms (weight change, poor sleep, 
change of libido, etc), as these may arise in FTLD syndromes for reasons other than depression.  
 
The Kirby227,242,288, a delayed discounting paradigm, provided a more objective measure of 
impulsivity. Delayed discounting is the tendency to prefer small immediate rewards over larger 
delayed rewards, for example £10 today versus £12 tomorrow. This self-report questionnaire 
reflects everyday life decisions, whereby individuals who prefer immediate over larger deferred 
rewards are more likely to engage in impulsive behaviours such as pathological gambling, 
smoking, and drug and alcohol abuse254. For example, drug addicts choose to accept short-term 
“highs” at the cost of long-term good health208. A high delayed discounting rate reflects an 
impulsive profile288. Schizophrenia patients212, Parkinson’s disease patients289 and substance 
abusers227 have been reported to discount more steeply than healthy controls. 
 
2.9.2 Description of Behavioural Tasks 
2.9.2.1 Motor and Saccade Go/NoGo Task 
The Go/NoGo task implicates response choice selection and action restraint, reflecting a key 
aspect of response inhibition. Response inhibition can also be measured in terms of action 
cancellation on the stop signal task, which involves the cancellation of an already selected 
response. Go/NoGo and SST are recognised to have distinct neural underpinnings, as discussed 
in previous chapters. 
 
The saccadic NoGo task220 (Figure 6) used direct binocular infra-red scleral oculography, 
projecting laser cues from a head-mounted sacodometer (OberConsulting, Poland). Each 
session comprised of 300 trials, following 10 calibration trials. Participants fixated on one green 
dot and one red dot at 0 degrees, adjacent on a screen at approximately 1.5m distance. After 
300ms, one of the central cues was removed and a red dot was presented at -10 degree or +10 
degree horizontal displacement (randomised, 50:50). In 50% of trials, the green central cue 
remained and participants responded by making a saccade to the horizontal red cue (Go trials). 
In NoGo trials, the red central cue remained and participants were required to refrain from 
making a saccade to the target. Data were downloaded and analysed using LatencyMeter (Ober 
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Consulting Version 6.5), and an automatic trials validation was used to eliminate abnormal 
saccades based on the position and velocity profile of each individual trace.  
 
The motor NoGo task was analogous to the saccadic task but used a joystick operated by the 
dominant hand (except where physical disability impaired hand use, in which case the most 
physically able hand was used). Stimuli were presented on a laptop screen positioned 1 meter 
from the subject, with the initial red and green cues presented in the top center of the screen. 
Subjects were instructed to initiate movement (Go trials, green central cue remaining) or inhibit 
movement (NoGo trials, red central cue remaining) in the direction of the presented arrow 
pointing left or right.   
 
 
Figure 6: Saccadometer used for NoGo task (Image from Ober Consulting) 
 
Outcome measures for the saccade and motor NoGo tasks were identical to facilitate direct 
comparisons, and included average reaction times for each trial type, commission and omission 
errors. Specifically, variables included: Go Correct Right Direction (GCRT), Go Incorrect 
Wrong Direction (GIWD), NoGo Correct (NC), and NoGo Incorrect (NI).  Mean reaction times 
(in miliseconds) for each of the Go responses and the mean number of each response type were 
calculated. Outliers greater than three standard deviations from the mean (within patient or 
control group) were excluded from each outcome variable. To provide a measure of 
performance accuracy, the sensitivity index or dprime was calculated (d’), representing the 
difference between the correct “hit” rate and incorrect “false-alarm” rate. The hit rate reflected 
the proportion of Go trials to which the subject correctly responded Go (in either direction) and 
the false alarm rate reflected the portion of all NoGo trials whereby the patient incorrectly 
responded Go. The formula for calculating d’ is detailed below, where GCRD, GCWD, GIRD, 
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GIWD, NI and NC represent the total number of Go Correct Right Direction, Go Correct Wrong 
Direction, Go Incorrect Right Direction, Go Incorrect Wrong Direction, NoGo Incorrect and 
NoGo Correct responses irrespectively for each subject.  Where either hit rate or false alarm 
rate were 0 or 1 values were adjusted up or down to 0.99 or 0.01 to allow Z transformation. 
Higher d’ reflected improved performance.  
 
Equation 1: Formula for Calculating Dprime 
 
𝑑′ = 𝑍 (
𝐺𝐶𝑅𝐷 + 𝐺𝐶𝑊𝐷
𝐺𝐶𝑅𝐷 + 𝐺𝐶𝑊𝐷 + 𝑁𝐼
) − 𝑍 (
𝐺𝐼𝑅𝐷 + 𝐺𝐼𝑊𝐷
𝐺𝐼𝑅𝐷 + 𝐺𝐼𝑊𝐷 + 𝑁𝐶
) 
 
2.9.2.2 Cued Reinforcement Reaction Time Task (CRRT) 
The CRRT is an assessment of incentive motivation, designed to assess responsiveness to 
reward signals on an odd one out task147 (Figure 7). The task was simplified from the original 
CRRT to 2 colour (probability) options instead of 3 and 50 trials instead of 100. The task was 
run on a laptop with responses recorded by a 3-button box (dominant hand). Forty practice trials 
without feedback were used to familiarize the participant with the task and to titrate reaction 
time thresholds for each individual (to ensure motivationally relevant signals were tailored to 
individual differences in cognitive speed)147, using a cut-off value for reward feedback of mean 
reaction time minus one standard deviation. Participants were presented with a cue (coloured 
rectangle), signaling the probability of reward following a correct response, either 20% or 80%. 
Participants were informed that the chance of receiving feedback was dependent on the colour 
of the box surrounding the presented circles, but were not informed which colour was more 
likely to give feedback.  
 
Participants were instructed to identify the ‘odd-one-out’ of three presented circles as quickly 
as possible. Feedback was; 100 points for a correct and fast response, 1 point for a correct but 
slow response and 0 points for an incorrect response. Participants aimed to obtain as many 
points as possible, for which normal controls demonstrate a “reinforcement-related speeding” 
effect: responding quicker under the anticipation of increased probability of reward147,290. In 
order to assess the impact of learning, the mean reaction time at both reward probability values 
for the first half (FH) and second half (SH) of trials was calculated, followed by the reward-
related speeding effect (First half mean RT 20% probability – First half mean RT 80% 
probability). The difference in reinforcement related speeding was also calculated (Speeding 
SH – Speeding FH). Additional outcome variables included total errors and total score. 
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Figure 7: The Cued Reinforcement Reaction Time Task.  
Outcome is indicated as incorrect (0 points), correct but slow (1 point) or correct and fast 
(100 points). Taken from Cools et al., 2005. 
 
2.9.2.3 Information Sampling Task (IST) 
The Cambridge Neuropsychological Test Automated Battery (CANTAB) IST241 was 
administered on a touch screen computer to assess reflection impulsivity using five fixed 
condition and five descending win condition trials. Participants were presented with a 5x5 
matrix of 25 grey boxes which, when selected, turned blue/yellow (Figure 8). On fixed trials, 
participants were instructed to open as many boxes as they liked, before deciding whether there 
were mostly blue or yellow boxes. On decreasing trials, every selected box subtracted 10 points 
from a starting sum of 250, to encourage faster decision making based on limited information. 
Correct responses were rewarded by gaining 100 points and incorrect were punished by losing 
100 points. Outcome measures included the time and information required to reach a decision 
and subsequent accuracy of that decision230(Cambridge Cognition Ltd.). Specifically, these 
included the probability of being correct at the time of making the decision, mean box opening 
latency, mean colour decision latency, mean boxes opened per trial, incorrect decisions based 
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on insufficient evidence (sampling error), incorrect decision based on available evidence 
(discrimination errors) and total correct decisions. In a study of impulsive responding, measured 
by decision making on the IST, chronic drug users were reported to sample less information 
than control subjects and respond at a lower probability of making a correct response290. 
Impulsive individuals appear to obtain insufficient information before reaching a decision, 
leading to risky behaviours and negative consequences216. 
 
Figure 8: The Information Sampling Task (CANTAB) 
 
2.9.2.4  Stop Signal Task (SST)  
The SST is a response inhibition (impulse control) task focusing specifically on action 
cancellation214 (Figure 9). The SST was administered using the CANTAB and a two button 
press pad. In the first practice session (16 trials), stimuli were presented on a computer screen 
and participants were instructed to press the right/left button as quickly as possible in response 
to the corresponding right/left arrow. The second part consisted of 64 trials, by which 
participants were instructed to continue responding as quickly as possible, but to refrain from 
responding when they heard an auditory signal (beep), presented in 25% of trials (randomly 
dispersed). The delay between presentation of the arrow stimuli and the stop signal varied, 
known as the stop signal delay), in order to give an estimate of the stop signal reaction time 
(SSRT; the time it takes to successfully inhibit a response). Outcome measures were generated 
using the CANTAB and included SSRT, total correct responses on stop and go trials, direction 
errors on stop and go trials, and mean/median reaction times for all go trials.  
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Figure 9: The Stop Signal Task (CANTAB) 
 
2.9.2.5 Cambridge Gambling Task (CGT) 
The CGT (Figure 10) is a unique task assessing decision-making and risk taking behaviour in 
the absence of learning or information retrieval. The CGT dissociates risk taking from 
impulsivity, as participants have to wait for a risky bet in the ascending condition248.  
 
The task was administered using the CANTAB and consisted of a neutral part and two gambling 
parts. Participants were presented with a row of red and blue boxes at the top of the screen, and 
were instructed to guess which colour box a yellow token was placed under. Participants 
responded by touching the boxes containing the words ‘Red’ or ‘Blue’ at the bottom of the 
screen. In the gambling stages, participants started with 250 points and could select how 
confident they are with their decision by gambling a certain proportion of these points, which 
were displayed on the right hand side of the screen in either ascending (part 1) or descending 
(part 2) order. Participants were instructed to obtain as many points as possible, with the total 
accumulated points displayed on the screen throughout.  
Note: The CGT was removed from the protocol after 37 participants due to floor effects and 
difficult task engagement by FTLD patients, even following simplification of the task. This 
highlights the need to develop a disease-specific task to look at gambling behaviours in FTLD 
syndromes.  
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Figure 10: The Cambridge Gambling Task (CANTAB) 
 
2.10 Imaging Methods 
The imaging acquisition and sequences included in the PiPPIN protocol are provided below. 
Detailed voxel-based morphometry and diffusion tensor imaging analysis methods are 
described in chapter 4 and 5 respectively. 
 
Magnetic resonance imaging (MRI) was performed at the Wolfson Brain Imaging Centre, using 
a TIM-Trio 3T scanner (Siemens, Germany http://www.medical.siemens.com/). Scans obtained 
included optimized T1 and volumetric T2, diffusion weighted imaging for analysis of white 
matter tracts; perfusion MRI; SWI and multi echo BOLD sensitive echoplanar fMRI. Total 
scanning time was <1h. 
 
T1-weighted magnetization-prepared rapid acquisition gradient-echo (MPRAGE) images were 
acquired with a TR=2300ms, TE=2.86ms, matrix=192×192, in-plane resolution of 
1.25x1.25mm, 144 slices of 1.25mm thickness, inversion time=900ms and flip angle =9°. 
Diffusion-weighted images (DWI) were acquired using a 63-direction gradient sequence with 
the following parameters: b value 1000s/mm2; TR 7800ms; TE 90ms; axial in-plane acquisition 
matrix 96×96; field of view 192×192 mm; slice thickness 2mm and a total of 63 contiguous 
slices with in-plane resolution 2mm isotropic. Additionally, a single b value of 0 s/mm2 image 
with no diffusion weighting was acquired. Other sequences acquired but not used as part of this 
thesis include a localizer; BOLD fMRI eyes-closed resting state; axial PD-T2.  
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2.11 Statistical Analysis 
2.11.1 Demographics and Clinical Features 
Statistical analysis of behavioural data used SPSS v22.0 (IBM). Comparisons between groups 
were made using Student’s T-tests or analysis of variance (ANOVA) followed by post hoc t-
tests and correction for multiple comparisons. Pearson’s correlations for parametric data were 
used to examine the relationship between variables. Pearson’s correlation is highly robust 
against deviations from normality within the data. Comparisons were made for demographic 
data and disease characteristics, including age, gender, cognitive and functional measures, and 
the major outcome variables for each of the questionnaires and objective behavioural tasks 
employed in the principal component analysis. 
 
2.11.2 Principal Component Analysis 
Principal Components Analysis (PCA) was used to identify the components of apathy and 
impulsivity that best explained the data variance, reducing the dimensionality and increasing 
reliability by combining data from multiple tests. PCAs were run on patient and control data 
combined (n=199: noting that there were no major differences to the component structure if 
using only 149 patients’ data) using varimax rotation. Varimax rotation ensures orthogonality 
and maximises the dispersion of loadings within components to facilitate interpretation. The 
correlation matrix was used for extraction of components and component scores were generated 
using the regression method. Kaiser-Meyer-Olkin and Bartlett’s test of sphericity were used to 
determine the adequacy of the sample size for PCA analysis.  
 
As many of the individual tasks give rise to multiple outcome measures (for example the 
Cambridge Behavioural Inventory produces 10 sub-scores, see Table 3 & 4), a hierarchical, 
two-step PCA approach was employed (Figure 11). First, task-specific ‘local’ PCAs (LPCA) 
with varimax rotation were performed separately on the individual questionnaires and 
behavioural measures. Input variables included the established outcome measures or sub-scores 
for each questionnaire/behavioural test (see Table 4). Selection of components used Kaiser’s or 
Cattell’s criteria, whichever was more inclusive, plus an additional criterion of explaining 
>10% of the initial variance. To ensure all measures were standardised, the correlation matrix 
was used for extraction of components. Component loadings above 0.50 were considered 
meaningful and component scores were computed using the regression method. Second, the 
components extracted from each of the local PCAs were included in a final PCA (FPCA), which 
also included total scores or d-prime from the tests which were not subject to local PCA (Table 
4). Criteria for component selection were the same.  
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Figure 11: Principal Component Analysis Data Reduction Method.  
Local PCAs were carried out on all questionnaires and behavioural tasks independently, 
where appropriate. Components were then extracted from a final PCA. Note: the 
Go/NoGo task was run as both a motor and saccade task (2 variables). 
 
2.11.3 Tasks Excluded from the Principal Component Analysis  
Some of the PiPPIN assessment battery were disease-specific for non-FTLD disorders and were 
therefore excluded from the PCA analysis. For example, the Obsessive Compulsive Inventory 
(OCI-R) is designed for obsessive compulsive disorder patients and may not be readily 
applicable to FTLD patients. In addition, the Parkinson’s disease sleep scale (PDSS) is specific 
to Parkinson’s disease and was developed to measure changes in sleeping behaviours rather 
than apathy/impulsivity. The SF-36 was also excluded as it is not specific to apathy, impulsivity 
or related behavioural change. 
 
Cognitive and functional measures including the ACE-R, MMSE, FRS, FAB, and PSPRS were 
not included in the PCA and were instead used to correlate components with to determine the 
impact of cognitive and functional status on component scores. 
 
In practice, it became clear that some questionnaires and behavioural tasks were inappropriate 
for the disease group. Both the Visual Analogue Scales (VAS) and Cambridge Gambling Task 
were particularly difficult for patients. It became clear through the administration of the VAS 
that answers were heavily confounded by patients understanding of the key words, and patients 
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often placed an “X” either at the extremes or elsewhere on the sheet of paper. The Cambridge 
Gambling Task (CGT) was removed from the protocol after 37 participants due to floor effects 
and difficult task engagement by FTLD patients, even following simplification of the task. This 
highlights the need to develop a disease-specific task to look at gambling behaviours in FTLD 
syndromes, which is sensitive to the cognitive and motor deficits of this cohort.  
 
2.11.4 Relationship of Components to Other Measures 
In order to examine the relationship between the extracted components of apathy/impulsivity 
and other confounding factors, component scores were correlated with age, measures of 
cognition (ACE-R, MMSE), function (FAB) and disease severity (FRS, PSP-RS) in SPSS v22 
(IBM). Component scores were also compared across groups using an ANOVA with post-hoc 
t-tests and correction for multiple comparisons. 
 
2.11.5 Imaging Analyses 
The neural correlates of the extracted components were analysed through voxel based 
morphometry of grey and white matter (in SPM) and diffusion tensor imaging of white matter 
tract integrity (using tract based spatial statistics in FSL). For full details see Chapter 4 for 
VBM and Chapter 5 for DTI.  
 
2.11.6 Survival Analysis using Logistic Regression 
Logistic regression was used to examine the prognostic implications of the identified 
components. I focused on the impact of apathy on disease progression and survival, based on 
previous reports linking apathy to rapid cognitive and functional decline in other related 
neurological diseases, such a PD83 and AD82,84. See chapter 6 for full details.  
 
2.12 Conclusion  
The PiPPIN assessment battery measured multiple aspects of apathy and impulsivity. The 
following experimental chapters (3-6) employ these measures to assess the components, neural 
correlates and prognostic implications of these behavioural changes across FTLD syndromes.  
 
  
 
5
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Table 4: Variables Used for Local Principal Component Analysis 
*Saccade and Motor versions of the Go/NoGo were used.
Test Outcome Measures/Subscores Comment 
AES Cognitive, Emotion, Behavioural  Included all sub-scores for patient, carer and clinican versions in LPCA. 
BIS 
Attention, Cognitive instability, Motor, Perseverance, Self-control, Cognitive 
complexity 
Included all in LPCA 
BIS/BAS BIS, BAS-Drive, Fun-seeking, Reward-Responsiveness Included all in LPCA 
BDI 
One outcome measure to give overall rating of depression. Scores indicate 
minimal (0-9), mild (10-18), moderate(19-29) and severe (30-63) depression. 
Included directly in FPCA. Due to a single outcome measure, it was not 
considered useful to run a LPCA (one was attempted and revealed too many 
components). 
SHAPS 
One outcome measure to give overall rating of anhedonia. Higher scores reflect 
more severe symptom presentation. 
Included directly in FPCA, due to a single outcome measure. 
MEI 
One outcome measure to give overall rating of motivation. Higher scores indicate 
higher motivation levels. 
Included in directly in FPCA, due to a single outcome measure. 
CBI_R 
Memory and orientation, Everyday skills, Self-care, Abnormal behaviour, Mood, 
Beliefs, Eating habits, Sleep, Stereotypic and motor behaviours, Motivation 
Included all in LPCA 
NPI Severity and distress of a number of psychiatric symptoms.  
Included directly in FPCA. For relevance purposes, scores on the apathy and 
disinhibition subscores were included in FPCA. 
KIRBY K_Large, K_Medium, K_Small 
Included directly in FPCA as a single outcome measure “Kirby Difference”: the 
difference between K_large and K_small. This variable reflects the change in 
delayed discounting of reward. 
Go/NoGo *  
Twelve outcome measures covering latency and errors of commission and 
omission. 
Included directly in FPCA a single outcome measure “dprime”. 
SST 
Direction errors, Proportion of successful stops, reaction times, SSD (50%), 
SSRT 
Included in LPCA: Proportion of successful stops, SSRT, Mean RT on Correct 
Go trials 
IST 
Eight outcome measures including errors, latency, total correct trials, mean 
number of boxes opened per trial, and probability of the participant’s decision 
being correct based on the available evidence at the time of decision.  
Included all in LPCA. 
CRRT Reaction times and errors 
Included in LPCA: Speeding first half (reaction time difference), Speeding 
second half, Difference in speeding, Error  
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Chapter 3 | The Components of Apathy and Impulsivity in 
Frontotemporal Lobar Degeneration Syndromes. 
 
In this Chapter, I describe the demographics and disease characteristics of the PiPPIN cohort 
and the associated neuropsychological and behavioural results. I then present findings from the 
principal component analysis, adopting a dimensional reduction technique to combine scores 
from multiple tests to identify components that best explain the variability within the dataset. 
 
3.1 Key Features 
The key demographics and disease characteristics, neuropsychological and behavioural 
features of the PiPPIN cohort are detailed below.  
 
3.1.1 Cohort 
Two hundred and four cases of frontotemporal lobar degeneration were identified within the 
PiPPIN catchment area over 24 months. Of these, 200 cases were used for epidemiological 
estimates (see19) and 167 were seen by a member of the study team. Patients met current 
consensus clinical diagnostic criteria for bvFTD4, svPPA, nvPPA, PPA other (those with a 
primary progressive aphasia not fitting criteria for one of the 3 defined subtypes6), CBS5 or 
PSP14. Datasets from 149 patients were used for neuropsychiatric and behavioural analysis and 
a subset of 100 underwent MRI imaging analysis (these subsets being the focus of this thesis). 
Thirty three patients have subsequently donated their brain for post mortem studies, allowing 
pathological confirmation of their diagnosis. The results are presented in Table 5 below.  
 
Table 5: Pathologically Confirmed Cases 
Clinical Diagnosis 
Pathological Diagnosis 
FTD-TDP-43 CBD PSP 
FTD-Tau 
(Pick’s 
Disease) 
AD 
CBS (N=15) 1 6 1 1 6 
PSP (N=9) 0 0 9 0 0 
bvFTD (N=4) 3 1 0 0 0 
svPPA (N=2) 2 0 0 0 0 
nvPPA (N=2) 0 0 0 0 2 
PPA Other (N=1) 0 0 0 0 1 
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Participants were tested while on their usual medication. Forty percent of patients were taking 
antidepressant medications (for either affective or behavioural indications), 4% were taking 
antipsychotic medication, and 29% were taking dopaminergic medication (for movement 
disorder). Thirty-seven percent were taking other medications that may act on the central 
nervous system including benzodiazepines (for anxiolysis, sedation or myoclonus), 
antiepileptic mediation, analgesics (opioid, gabapentin, pregabalin) including one case on 
cholinesterase inhibitors.  
 
3.1.2 Demographics, Clinical Features, Cognitive Status and Disease Severity.  
Details of participant demographics, cognitive, functional and motor features by diagnosis are 
provided in Table 6. Patients demonstrated cognitive and functional impairment across groups 
compared to controls, as measured by the ACE-R, MMSE, FAB, FRS and PSPRS. Additional 
motor features were also present in some patients across diagnostic groups, including akinesia, 
rigidity, dystonia, apraxia, vertical gaze palsy, postural instability, and myoclonus. Years from 
symptom onset were estimated based on recall of initial relevant symptoms.  
 
3.1.3 Neuropsychiatric and Behavioural Features of the PiPPIN cohort  
The neuropsychological and behavioural performance of patients and controls are presented in 
Table 7 and 8. Patients and controls were matched for age and gender. Patients demonstrated 
cognitive and functional impairment across groups compared to controls, as measured by the 
ACE-R, MMSE, and FAB (Table 7 and 8). Patients had significant cognitive deficits compared 
to controls in addition to significantly higher apathy (AES), impulsivity (BIS), depression 
(BDI) and anhedonia (SHAPS) with lower levels of motivation (MEI). Patients also 
demonstrated significant impairments on behavioural tasks of reflection impulsivity 
(Information sampling task), incentive motivation (Cued reinforcement), response inhibition 
(limb-motor and saccade tasks) and action cancellation (Stop-Signal task). The BIS/BAS and 
Kirby responses did not differentiate patients and controls.  
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Table 6: Demographics, Cognitive, Functional and Motor Features of the PCA Sample by 
Diagnosis. 
 PSP CBS svPPA PPA bvFTD nvPPA Control 
N 41 37 12 11 32 16 50 
Age 72.9 ±8.5 69.7±7.8 71.1±4.1 73.1±4.9 64.0±7.3 71.6±9.1 70.6±6.5 
Gender (M:F) 21:20 18:19 7:5 5:6 18:14 7:9 23:27 
Duration (of 
symptoms) 
4.5±3.4 4.1±2.3 5.7±2.9 4.1±2.2 4.9±3.0 2.0±2.0 NA 
ACE-R  
(Max 100) 
75.5±14.6 65.7±21.3 29.2±14.7 58.5±20.5 59.0±26.9 64.4±21.0 95.6±4.4 
MMSE  
(max 30) 
25.0±4.8 22.0±6.6 11.8±8.7 21.0±5.1 21.4±7.6 23.0±6.3 29.3±1.2 
FRS % Score  
(max 100) 
40.9±25.1 31.4±23.3 20.9±14.6 66.3±28.4 26.8±18.0 63.7±28.4 92.1±10.8 
FAB  
(Max 18) 
10.5±4.0 10.0±4.4 9.4±3.8 10.0±4.4 9.4±5.3 9.2±4.4 16.8±1.2 
PSP-RS 
(Max 100) 
43.8±14.8 39.6±16.1 NA 5.3±4.7 16.1±10.0 8.4±6.2 NA 
Akinesia (N) 35 27 2 2 22 31 0 
Rigidity (N) 35 27  0 1 6 1 0 
Dystonia (N) 25 24 0 0 2 0 0 
Apraxia (N) 22 33 2 8 8 11 0 
Vertical Gaze PalsyϮ  
(N) 
41 19 0 2 3 1 0 
Postural 
instability/Falls* (N) 
41 24 0 1 7 2 0 
Myoclonus (N) 3 22 0 3 3 5 0 
Ϯ or slowing of vertical saccades; * or wheelchair dependence 
Abbreviations: Progressive Supranulcear Palsy (PSP), Corticobasal Syndrome (CBS), semantic varient 
Progressive Aphasia (svPPA), other Progressive Aphasia (PPA), behavioural variant Frontotemporal 
Dementia (bvFTD), nonfluent variant Progressive Aphasia (nvPPA), Addenbrooke’s Cognitive 
Examination Revised (ACE-R), Mini Mental State Examination (MMSE), Frontotemporal dementia 
Rating Scale (FRS), Frontal assessment battery (FAB), Progressive supranuclear palsy rating scale 
(PSP-RS).  
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Table 7: Neuropsychiatric and Behavioural Results 
 Variable 
Controls 
(n=50) 
Patients 
(n=149) 
T Stat 
Group 
Difference 
D
em
o
g
ra
p
h
ic
s 
&
 C
o
g
n
it
io
n
 
 
Age 70.6 ±6.5 69.9 ± 8.2 0.9 NS 
Gender M:F 23:27 76:73 (χ2=-0.6) NS 
ACE-R Total (max 100) 95.6 ±4.4 64.7 ± 22.6 12.7 ** 
MMSE Total (max 30) 29.3 ±1.2 22.3 ± 6.8 9.6 ** 
PSP-RS NA 31.5±20.1 NA NA 
FAB 16.8±1.2 9.9±4.4 14.4 ** 
FRS % Score (max 100) 92.1 ±10.8 37.9 ± 26.5 18.5 **  
Q
u
es
ti
o
n
n
a
ir
es
 
Apathy Evaluation Scale (AES, max 72): 
-carer 
-patient 
-clinician 
 
24.2 ±5.7 
25.7 ±5.6 
25.9 ±7.3 
 
48.1 ±12.4 
36.1 ±9.4 
43.6 ±10.0 
 
-16.7 
-7.8 
-11.8 
 
** 
** 
** 
Barratt Impulsiveness Scale (BIS, max 120) 57.0 ±7.4 63.6 ±8.1 -4.6 ** 
Behavioural Inhibition System/Behavioural 
Activation System (BIS/BAS): 
-BIS subscore 
-BAS drive 
-BAS funseeking 
-BAS Reward Responsivness 
 
 
19.9 ±3.4 
10.0 ±2.1 
10.7 ±2.2 
15.8 ±2.4 
 
 
20.6 ±4.5 
10.9 ±3.2 
11.3 ±3.0 
16.6 ±2.7 
 
 
-1.0 
-1.9 
-1.2 
-1.7 
 
 
NS 
NS 
NS 
NS 
Motivation and energy inventory (MEI, max 144) 108.9 ±17.2 81.1 ±26.4 7.0 ** 
Beck depression inventory (BDI, max 63) 4.2 ±4.0 13.0 ±10.1 -6.7 ** 
Snaith Hamilton pleasure scale (SHAPS, max 56) 18.6 ±4.4 22.5 ±4.8 -4.5 ** 
Neuropsychiatric inventory (NPI, fraction with 
positive response): 
-Apathy subscore 
-Disinhibition subscore 
 
 
0.000 ±0.0 
0.020 ±0.1 
 
 
0.616 ±0.5 
0.336 ±0.5 
 
 
-13.3 
-6.5 
 
 
** 
** 
Cambridge behavioural inventory (CBI-R, max 
180) 
5.2 ±5.6 66.7 ±35.2 -18.2 ** 
Kirby (difference) 0.005 ±0.04 0.019 ±0.1 -1.6 NS 
B
eh
a
v
io
u
ra
l 
T
a
sk
s 
  
Information Sampling Task (IST) 
-Probability of being correct Fixed 
-Probability of being correct Decreasing 
 
0.87 ±0.1 
0.81 ±0.1 
 
0.75 ±0.1 
0.67 ±0.2 
 
4.9 
5.4 
 
** 
** 
Cued reinforcement reaction time (CRRT) 
-Reward related speeding 
-Total Errors 
 
-43.4 ±90.9 
3.8±3.4 
 
196.3 ±739.1 
4.2±5.7 
 
-2.4 
-0.5 
 
* 
NS 
Cambridge Gambling task 
- Deliberation time 
- Risk adjustment 
 
2240. ±767 
1.57 ±1.1 
 
7053. ±4449 
0.23 ±0.9 
 
1.4 
4.1 
 
** 
** 
Stop Signal Task (SST) 
-Stop signal reaction time (SSRT) 
 
181.1 ± 41.7 
 
439.8 ±190.4 
 
-3.1 
 
** 
Motor Go/NoGo Dprime 4.4 ±.3 3.2 ± 1.3 7.8 ** 
Saccade Dprime 2.4 ±.9 0.75 ± 1.1 7.4 ** 
Objective measures corrected for outliers +/-3SD of the mean. Independent samples t-test uncorrected 
for multiple comparisons are shown outside parentheses: **p<0.001, *p<0.05, NS not significant.  
Significance after Bonferroni correction is indicated by (**). Note that some measures are not 
independent, for example, MMSE is a component of the ACE-R, and NPI subscales are component of 
the total NPI score. CGT task data from 37 participants only. 
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Table 8: Summary of Patient Characteristics by Diagnostic Group 
 Variable PSP CBS bvFTD PPA 
 N 41 37 32 39 
D
em
o
g
ra
p
h
ic
s 
&
 C
o
g
n
it
io
n
 
 
Age 72.1±8.3 69.4±8.2 63.9±8.0 71.0±7.3 
Gender M:F 21:20 18:19 18:14 19:20 
ACE-R Total (/100) 75.5±14.6 65.7±21.3 59.0±27.0 54.8±23.6 
MMSE Total (/30) 25.0±4.8 22.0±6.6 21.4±7.6 19.9±7.8 
FRS % Score (/100) 40.9±25.1 31.4±23.3 23.4±6.0 50.1±31.8 
Q
u
es
ti
o
n
n
a
ir
es
 
Apathy Evaluation Scale (AES /72): 
-carer 
-patient 
-clinician 
 
48.4±10.9 
39.1±11.2 
47.1±11.0 
 
48.6±11.2 
36.1±6.8 
45.2±8.2 
 
54.3±9.4 
32.3±9.6 
43.2±7.3 
 
42.6±14.9 
35.2±7.8 
36.9±9.9 
Barratt Impulsiveness Scale (BIS /120) 65.2±7.3 61.8±10.2 63.3±6.7 63.2±8.0 
Behavioural Inhibition 
SystemBehavioural Activation System 
(BIS/BAS): 
-BIS subscore 
-BAS drive 
-BAS funseeking 
-BAS Reward Responsivness 
 
 
19.8±3.2 
11.0±3.1 
10.7±2.8 
16.2±2.7 
 
 
21.9±3.3 
9.9±3.4 
10.3±3.7 
17.3±2.2 
 
 
19.3±3.3 
12.6±3.2 
12.7±3.2 
16.7±3.6 
 
 
21.8±7.0 
10.5±7.0 
11.8±2.1 
16.5±2.2 
Motivation and energy inventory (MEI 
/144) 
70.7±29.5 74.1±23.5 96.9±23.9 90.3±15.9 
Beck depression inventory (BDI /63) 17.8±11.5 14.3±8.0 9.3±6.1 7.8±9.4 
Snaith Hamilton pleasure scale 
(SHAPS /56) 
22.3±4.3 24.1±5.1 26.8±18.0 20.25±3.5 
Neuropsychiatric inventory (NPI, 
fraction with positive response): 
-Apathy subscore 
-Disinhibition subscore 
 
 
0.63±0.5 
0.23±0.4 
 
 
0.78±0.4 
0.19±0.4 
 
 
0.68±0.5 
0.56±0.5 
 
 
0.40±0.5 
0.40±0.5 
Cambridge behavioural inventory 
(CBI-R /180) 
56.0±32.4 73.5±30.6 85.6±26.2 55.7±41.1 
Kirby (difference) 0.035±0.06 0.017±0.04 -0.0002±0.08 0.008±0.03 
B
eh
a
v
io
u
ra
l 
T
a
sk
s 
  
Information Sampling Task (IST) 
-Probability of being correct Fixed 
-Probability of being correct Decrease 
 
0.743±0.1 
0.678±0.1 
 
0.705±0.1 
0.617±0.2 
 
0.846±0.1 
0.721±0.2 
 
0.706±0.1 
0.654±0.1 
Cued reinforcement reaction time 
(CRRT) 
-Difference Speeding 
-Total errors 
 
 
31.6±581.3 
3.8±3.2 
 
 
183.4±235.1 
4.0±4.2 
 
 
-1.81±305.9 
2.4±2.1 
 
 
657.8±1230.9 
6.8±10.3 
Stop Signal Task (SST) 
-Stop signal reaction time (SSRT) 
 
431.7±146.1 
 
435.2±189.3 
 
367.4±154.7 
 
512.6±251.5 
Motor Go/NoGo Dprime 3.3±1.1 2.8±1.4 4.0±1.5 3.1±1.4 
Saccade Dprime 0.71±.9 0.98±1.2 1.1±1.4 0.4±1.0 
Demographics and disease characteristics by diagnostic group, split into equally weighted groups of 
PSP, CBS, bvFTD and PPA. Note that PPA included 16 nvPPA, 12 svPPA and 11 “PPA other” cases 
(2 lvPPA and the remaining not meeting criteria for either svPPA or nvPPA and therefore unspecified.
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3.1.4 Neuropsychiatric and Behavioural Assessment Correlations and Comparisons 
3.1.4.1 Apathy and Impulsivity  
The well-established measures of apathy and impulsivity were positively correlated in this 
cohort; the more apathetic an individual rated themselves, the more impulsive. Significant and 
strong positive correlations were observed between total scores on the self-rated Apathy 
Evaluation Scale and the Barratt Impulsiveness Scale (Pearson’s r =.495, p<0.001**, see Figure 
12), tools that are frequently used to measure apathy and impulsivity respectively. This 
provided initial supportive evidence suggesting that apathy and impulsivity are related in the 
PiPPIN cohort.  
 
 
 
Figure 12: Correlation between the Self-rated Apathy Evaluation Scale and Barrett 
Impulsiveness Scale 
 
3.1.4.2 Patient and Carer Ratings on Analogous Tests  
The discrepancy between raters was explored by employing tests with analogous versions for 
the clinician, patient and carer. The Apathy Evaluation Scale had three versions, which are 
compared in a correlation analysis below. Although the CBI was designed for the carer, rather 
than the patient, the PiPPIN study also collected self-reported change as measured by the first 
question in each of the subdomains of the questionnaire, to provide an additional measure of 
rater agreement/disagreement. Note that the below analysis uses patient data only (N=149). 
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The Apathy Evaluation Scale  
Correlation analysis of patient, carer and clinician ratings on the apathy evaluation scale 
revealed a discrepancy (Figure 13). Clinician ratings correlated with both patient and carer 
ratings (Pearson’s Correlation: carer vs clinician r=.586, p<0.001**, patient vs clinician r=.719, 
p<0.001**), likely reflecting clinician dependency on insights reported by the patient and close 
relatives in a limited clinical setting. Only ~5% of the variance in carer ratings was accounted 
for by patient ratings (Pearson’s Correlation: carer vs patient r=.234 p<0.05*), emphasising a 
clear discrepancy in their interpretation of apathy as measured by the AES.  
Figure 13: Correlation Analysis between the Carer, Patient and Clinician Apathy 
Evaluation Scale. 
 
ANOVA revealed significant differences between all raters (F2,270=27.7, p<0.001: Tukey HSD 
post hoc patient vs carer <0.001, vs clinician <0.001, carer vs clinician p=0.004), with carers 
reporting highest scores on average, followed by the clinician and patient (Figure 14). The 
underlying causes of this discrepancy are unclear. Possible explanations include patient lack of 
insight into their behavioural change and/or the influence of carer distress. 
 
Figure 14: Box Plot Showing AES Scores by Rater 
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Apathy as rated by the carer and clinician correlated strongly with markers of functional 
decline, including the FRS and PSP-RS (Table 9). Clinician ratings also correlated weakly with 
the FAB, while carer ratings correlated weakly with cognitive decline as measured by the 
MMSE. Patient ratings bore no relationship to cognitive and functional markers.  
 
Higher scores on the AES and PSP-RS reflect increased apathy and functional decline 
respectively, hence the observed positive correlation. In contrast, lower scores reflect increased 
cognitive and functional impairment on the FRS, FAB, ACE-R and MMSE, accounting for the 
negative correlation with apathy ratings.  
 
Table 9: Correlation of the Apathy Evaluation Scale Versions with Cognition and 
Functional Measures  
 FRS PSP-RS FAB ACE-R MMSE 
AES Carer -0.720** 0.408** -0.178 -0.196 -0.250* 
AES Patient -0.102 0.195 -0.171 -0.047 -0.084 
AES Clinician -0.483** 0.445** -0.242* -0.108 -0.172 
 
Note: Higher scores on the ACER, MMSE, FRS, and FAB indicate better performance while 
higher scores on the PSP_RS indicate more severe disability. 
 
 
The Cambridge Behavioural Inventory  
The CBI also revealed discrepancies between carer and patient ratings of behavioural change, 
showing and overall significant difference in total scores (carer mean 14.0, patient mean 10.8, 
t=3.4 p=0.001). In line with the discrepancy observed on the AES, carers generally rated higher 
than patients (6/10 questions, Figure 15), including for all questions which showed significant 
differences; CBI 1 ‘Has poor day-to-day memory [eg. About conversations, trips, etc]’ (t=2.6, 
p<0.05), CBI 9 ‘Has difficulties with electrical appliances’ [e.g. TV, radio, cooker, washing 
machine] (t=6.8, p<0.001), CBI 14 ‘Has difficulties grooming self [e.g. shaving or putting on 
make-up]’ (t=3.7, p<0.001) and CBI 41 ‘Shows less enthusiasm for his or her usual interests’ 
(t=4.0, p<0.001). Questions reflecting higher average endorsement by patients than carers (for 
example, visual hallucinations, cries), were infrequent in this population and discrepancies were 
marginal.  
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Correlation analysis of the CBI total scores for carers again showed strong correlations with 
cognitive and functional measures, while patient ratings correlated only with functional 
measures (Table 10). Once again, higher scores on the CBI and PSP-RS reflect increased 
behavioural change and functional impairment respectively, with lower scores on all other 
measures reflecting greater impairment.  
 
Figure 15: Discrepancy between Carer and Patient Scores on the Cambridge Behavioural 
Inventory (T-test, *p<0.05, **p<0.001). 
 
Table 10: Correlation of CBI Versions with Measures of Cognition, Function and Disease 
Severity 
 FRS PSP-RS FAB ACE-R MMSE 
CBI Carer -0.841** 0.338** -0.268* -0.344** -0.401** 
CBI Self -0.327** 0.436** -0.148 -0.096 -0.174 
 
Together, these findings highlight important discrepancies between carer, clinician and patient 
ratings, which have implications for clinical trial design (see discussion).  
0 0.5 1 1.5 2 2.5
* day-to-day memory
** difficulties electrical appliances
** difficulties grooming self
laughs at things others do not find funny
cries
visual hallucinations
prefers sweet foods more than before
sleep is disturbed at night
rigid and fixed in ideas and opinions
** less enthusiasm
Carer Patient
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3.2 Principal Component Analysis Results 
3.2.1 Cohort 
Principal component analysis was carried out on patient and control data combined (N=199: 
noting that there were no major differences to the component structure if using only 149 
patients’ data).  
 
3.2.2 Local Principal Component Analyses (LPCA) 
The results of the local principal component analyses are presented in Table 11. Kaiser-Meyer-
Olkin (KMO) and Bartlett’s test of sphericity were used to determine the adequacy of the 
sample size for PCA analysis for each test. Varimax rotation was used and the correlation matrix 
extracted components meeting Kaiser’s and/or Cattell’s criteria (whichever was more 
inclusive). An additional threshold of accounting for >10% of the initial variance was included 
for local PCAs. Scores were generated using the regression method.  
 
3.2.3 Final Principal Component Analysis (FPCA) 
The sample size was adequate for analysis (KMO=0.743) and correlations between items were 
sufficiently large for PCA (Bartlett’s test of sphericity231=508.013, p <0.001). Eight 
components were extracted from the final PCA (initial eigenvalues range: 1.039-4.963). The 
rotated component matrix is provided in Table 12. Note that assessments that are traditionally 
considered to be associated with apathy and impulsivity load onto the same factors (for 
example, AES and BIS), reflecting a high positive correlation between components of apathy 
and components of impulsivity. Inclusion of the CGT task data from 37 participants did not 
alter the factor structure, but in view of limited numbers this test was removed from the main 
analyses.  
 
Components were named based on their major contributors. Short summary terms are adopted 
that encapsulate the main elements of the component in terms of strongly weighted processes 
or tasks. The weighting of each questionnaire or behavioural test onto the separate components 
is detailed in Table 12. Component 1 reflected patient ratings on questionnaires of apathy, 
impulsivity and related changes, termed “Patient-Rated Change”. Higher scores reflected 
increased questionnaire endorsement of apathy (AES), impulsivity (BIS), depression (BDI), 
anhedonia (SHAPS) and low motivation (demonstrated by the negative MEI loading).
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Table 11: Local Principal Component Results 
Test Name Summary of Components Extracted from LPCAs 
AES 2 components (Eigenvalues Initial: 5.226, 1.455 respectively; Rotated: 3.478, 3.203 respectively) accounting for 74.2% of the total variance. 
1. + AES-Patient (cognition 0.855, emotion 0.811, and behaviour 0.723) & AES-Clinician (cognition 0.669, emotion 0.755, and behaviour 0.645) 
2. + AES-Informant (cognition 0.939, emotion 0.865, and behaviour 0.862) & AES-Clinician (cognition 0.547 & behaviour 0.547 subscores) 
BIS 2 components (Eigenvalues Initial: 1.982, 1.342 respectively; Rotated: 1.968, 1.342 respectively) accounting for 55.4% of the total variance. 
1) + Attention(0.762), self-control(0.759), cognitive complexity(0.674), perseverance(0.594) 
2) + Motor (0.695), cognitive instability(0.795) 
BIS/BAS 2 components (Eigenvalues 2.107, 1.041 respectively; Rotated: 2.107, 1.041 respectively) accounting for 78.7% of the total variance. 
1) + BAS drive(0.851), fun seeking(0.874) and reward responsiveness(0.777) 
2) + BIS (0.978)  
CBI 2 components (Eigenvalues Initial 5.808 and 1.152 respectively; Rotated 3.957, 3.002 respectively) accounting for 70.0% of the total variance. PC1 
was named “behaviour” and PC2 “everyday skills”. 
1) + Memory/orientation (0.683), abnormal behaviour (0.838), mood (0.717), beliefs (0.541), eating habits (0.728), stereotypic behaviour (0.882), 
motivation (0.654). 
2) + Everyday skills (0.855), self-care (0.927), sleep (0.693), motivation (0.568). 
SST 1 component (Eigenvalue 2.306) extracted, accounting for 76.9% of the total variance.  
1) Proportion of successful stops (0.691) 
2) SSRT (0.983) 
3) Median Correct reaction time on GO Trials (0.929) 
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Test Name Summary of Components Extracted from LPCAs 
IST 3 components (Initial Eigenvalue 5.137, 2.953, 1.892 respectively; Rotated: 4.317, 2.938, 2.243, 1.598 respectively) extracted, accounting for 71.3% 
of the total variance.  A fourth component also just met Kaiser’s criteria for extraction, however it accounted for <10% of the initial variance and so 
was discarded for FPCA (also supported by examination of the scree plot).  
1) Probability of being correct decreasing/fixed (loading 0.912/0.947) 
Mean boxes opened per trial decreasing/fixed (loading 0.646/0.926) 
Total correct decreasing/fixed (loading 0.833/0.926) 
2) Mean Box latency decreasing/fixed (loading 0.779/0.724) 
Mean Colour latency decreasing/fixed (loading 0.876/0.903) 
3) Sampling error decreasing/fixed (0.879/0.720) 
-Mean boxes opened per trial decreasing/fixed (-0.641/-0.557) 
CRRT 2 components (Initial eigenvalues 2.324, 1.001 respectively; Rotated: 2.000, 1.325 respectively) extracted, accounting for 58.1% of the total variance.  
1) Difference in speeding on the first and second half of trials (0.782) 
Total Error (0.750) 
-Speeding on 20% to 80% probability of reward trials, first half of trials (-0.909) 
2) Speeding from 20% to 80% probability of reward on the second half of trials (0.965) 
Difference in speeding on the first and second half of trials (0.591) 
 
Note the MEI, SHAPS and BDI total scores were moved directly to FPCA. These scales are designed to give one outcome measure and were 
therefore not appropriate for LPCA. The NPI subscores ‘apathy’ and ‘disinhibition’, the Kirby difference between K_Small and K_large and 
the Go/NoGo motor and saccade dprime scores (calculated as d' = Z(hit rate) - Z(false alarm rate)) were also moved directly to FPCA. Scores 
were z transformed prior to FPCA input. 
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Component 2 and 3 were associated with carer ratings of patient change, with higher scores 
reflecting increased endorsement of abnormal behaviours. Component 2, termed “carer rated 
change in everyday skills and self care”, had strong loadings from the carer AES, CBI 
(specifically everyday skills, self care, sleep and motivation subscores) and the NPI apathy 
subscore. The carer AES also loaded onto component 3 “Carer rated change in Complex 
Behaviours”, in addition to the remaining subscores of the CBI (abnormal behaviour, eating 
habits, stereotypic behaviours) and the NPI disinhibition subscore. The final questionnaire 
based component, component 5, was termed “Impulsivity self report”, to reflect increased 
ratings on BIS-motor and -cognitive instability and BAS subscores of the BIS/BAS. 
 
Higher scores on component 4 were associated with poor performance the Go/NoGo motor and 
saccade tasks (lower dprime), information sampling task (more errors, increased box/colour 
latency) and cued reinforcement reaction time task (no reward-related speeding and increased 
error) and was termed “Impulsive/Reward-related behaviours”. In contrast, higher scores on 
component 6, termed “Goal directed decision making”, reflected accurate performance on the 
information sampling task (increased probability of being correct at the time of decision) and 
sensitivity to reward on the cued reinforcement reaction time task (reward-related speeding).  
 
Component 7 was named “SST performance”, with high scores reflecting shorter SSRT and 
Go reaction times (negative loading). Component 8 captured the incentive motivation elements 
of the Kirby and behavioural avoidance on the BIS/BAS, and was termed “Outcome 
Sensitivity”. Higher scores reflect reduced difference in temporal discounting from small to 
large values of K on the Kirby and increased behavioural avoidance. 
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Table 12: Rotated Component Matrix Extracted from Final Principal Component Analysis 
INPUT 
VARIABLE 
COMPONENT STRUCTURE 
PC1 
Patient Rated 
Change 
PC2 
Carer Rated 
Everyday Skills 
& Self Care 
PC3 
Carer Rated 
Challenging 
Behaviours 
PC4 
Impulsive/ 
Reward Related 
Behaviours 
PC5 
Impulsivity Self 
Report 
 
PC6 
Goal-directed 
Decision 
making 
PC7 
Stop Signal 
Task 
 
PC8 
Outcome 
Sensitivity 
Eigenvalue I/R 4.963/3.438 2.183/2.284 1.664/2.145 1.514/1.819 1.385/1.640 1.186/1.284 1.111/1.245 1.039/1.188 
AES 1 0.832 -0.069 -0.121 0.151 -0.078 -0.003 -0.041 -0.069 
BIS 1 0.735 0.086 0.083 0.221 0.080 -0.003 -0.095 -0.052 
BDI-T 0.756 0.345 0.100 0.073 0.158 0.097 -0.026 -0.030 
MEI-T -0.837 -0.232 -0.061 -0.109 -0.023 0.034 0.142 0.007 
SHAPS-T 0.688 0.147 0.281 -0.067 -0.276 -0.136 0.068 0.075 
AES 2 0.067 0.714 0.529 0.074 0.035 0.006 -0.110 -0.151 
CBI 2 0.233 0.831 -0.084 0.151 -0.113 0.023 -0.155 0.042 
NPI-A 0.192 0.705 0.355 0.119 -0.086 0.048 0.029 -0.050 
CBI 1 0.035 0.118 0.880 0.078 0.104 -0.135 -0.066 -0.069 
NPI-D 0.135 0.083 0.825 -0.008 -0.017 0.039 0.017 0.092 
IST 2 0.170 0.030 -0.037 0.683 -0.128 0.365 -0.166 0.006 
CRRT 1 0.007 0.014 -0.006 0.658 -0.013 -0.104 0.390 0.109 
Go/NoGo -0.259 -0.135 -0.113 -0.642 0.130 0.042 0.259 0.007 
Saccades -0.162 -0.198 -0.081 -0.530 -0.319 0.221 0.018 0.158 
BIS 2 0.022 -0.121 -0.015 -0.100 0.841 -0.023 -0.065 0.077 
BISBAS 1 -0.198 -0.005 0.265 0.083 0.631 0.375 -0.209 -0.011 
IST 1 -0.188 -0.204 -0.080 -0.177 0.013 0.556 0.311 0.052 
CRRT 2 0.084 0.162 -0.037 0.063 0.078 0.725 -0.031 -0.078 
SST 1 0.183 0.109 0.021 0.044 0.167 -0.087 -0.793 0.030 
BISBAS 2 0.068 0.090 -0.088 0.042 0.242 -0.179 0.141 0.804 
Kirby 0.199 0.230 -0.126 0.040 0.220 -0.151 0.215 -0.658 
IST 3 0.255 0.382 -0.198 -0.167 0.335 -0.007 0.283 -0.001 
Numbers (1, 2, 3) indicate the different components extracted from LPCA for AES, CBI, BIS, BIS/BAS, IST, SST, CRRT. Additional input variables included 
the total score for BDI, MEI and SHAPS, NPI apathy and disinhibition subscores, Kirby difference value representing the difference in delayed discounting 
for low versus high rewards and Dprime performance accuracy values for Go/NoGo tasks. High scores on component 1-5 and 8 indicate worse performance, 
whereas low scores on component 6 and 7 indicate worse performance. Initial (I) and rotated (R) eigenvalues are reported. 
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3.2.4 Component Scores across Diagnostic Groups  
The components were not specific to individual disease groups, but reflected the transdiagnostic 
nature of apathy and impulsivity. Figure 16 shows the distribution of component scores (1-8) 
in each of the six patient groups and controls. ANOVAs confirmed a significant effect of group 
(and post hoc t-tests comparing each patient group to controls) with respect to component 1 
(F6,192=6.35, p<0.001: post hoc control vs PSP p<0.001, vs CBS p<0.05); Figure 16A) 
component 2  (F6,192=17.1, p<0.001: post hoc control vs PSP p<0.001, CBS p<0.001, vs bvFTD 
p<0.001, vs svPPA p< 0.05); Figure 16B) component 3  (F6,192=19.9, p<0.001: post hoc control 
vs bvFTD p0.001, vs svPPA p<0.001); Figure 16C) component 4  (F6,192=15.9, p<0.001: post 
hoc control vs PSP p<0.001, vs CBS p<0.001, vs PPA p<0.001, vs bvFTD p<0.05, vs nvPPA 
p<0.001; Figure 16D). Component 5 (F6,192<1), 6  (F6,192<1), 7  (F6,192=1.7, ns), and 8  
(F6,192=2.0, p=0.07) (Figure 16 E-H) revealed no significant differences.  
 
Figure 16 bars indicate post hoc Tukey tests for each group versus controls (thick =p<0.001, 
dotted p<0.05, Stars represent extreme outliers (3*interquartile range [IQR]), circles represent 
mild outlier (1.5*IQR)).  
 
3.2.5 Relationship of Components to Measures of Cognition and Function  
Parametric Pearson’s correlation analyses (see Table 13) revealed that the patient rated change 
component (PC1) was related to disease severity (FRS) and frontal dysfunction (FAB). Higher 
scores on components 2-4 correlated with more severe disease (FRS), greater cognitive decline 
(ACE-R, MMSE) and frontal dysfunction (FAB). Component 2 was positively correlated with 
the PSP-RS, reflecting greater PSP-like cognitive and motor impairment. Performance on 
behavioural impulsivity tasks (component 4) was negatively correlated with PSP-RS. Executive 
function, measured by ACE-R fluency, correlated with components 1-4 and 7. 
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Figure 16: Box Plots of Component Scores by Diagnosis (PC1-8) 
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Table 13: Pearson’s correlations between the eight orthogonal components identified by principal components analysis and demographic, 
cognitive and severity ratings  
 
Component 
 
Age FRS % ACE-R ACE-R 
Fluency 
MMSE PSP-RS FAB 
1) Patient Rated Change 0.050 -0.271** -0.125 -0.277** -0.085 0.134 -0.258* 
2) Carer Rated Change: Everyday Skills & Self Care -0.047 -0.658** -0.343** -0.335** -0.346** 0.550** -0.342** 
3) Carer Rated Change: Challenging Behaviours -0.172* -0.524** -0.357** -0.388** -0.335** -0.224 -0.308** 
4) Impulsive/Reward-related Behaviours -0.006 -0.213* -0.354** -0.428** -0.293** -0.281* -0.397** 
5) Impulsivity Self Report -0.106 0.041 0.087 -0.030 0.109 0.078 -0.001 
6) Goal-directed decision-making 0.055 0.017 0.104 0.037 0.077 0.074 0.023 
7) Stop Signal Task  -0.037 0.080 0.172* 0.190* 0.170* -0.170 0.228* 
8) Outcome Sensitivity 0.032 0.066 -0.029 0.035 -0.057 -0.130 -0.036 
*p<0.05; **p<0.001 (uncorrected, approximating p<0.05 corrected for multiple comparison). 
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3.3 Discussion  
The data described above provide three critical insights into apathy and impulsivity in FTLD 
disorders, in addition to confirming their multifactorial nature. First, apathy and impulsivity are 
common in all syndromes associated with frontotemporal lobar degeneration, not only those 
which include apathy and impulsivity as diagnostic criteria.  Second, they are positively 
correlated, such that apathetic individuals are also more impulsive. Third, the components that 
reflect patients’ own ratings of apathy and impulsivity are distinct from those based on carer 
observations and objective behavioural measures. 
 
In this cross-sectional study, disease progression may have blunted the phenotypic boundaries 
between syndromes in comparison to their initial presentation75,291. This emphasizes the 
advantages of transitioning from a traditional ‘nominal’ diagnostic classification (for example, 
ICD or DSM) to dimensional approaches such as the Research Domain Criteria (RDoc) with 
data-driven methods as described here. The recognition of apathy and impulsivity across 
syndromes highlights the limitations of diagnostic criteria, which overlook these symptom 
commonalities, and means that symptomatic therapies in one illness may help patients and 
carers affected by another131,205,268. Current criteria do not fully recognise the extent of 
behavioural changes in syndromes for which the behavioural disorder is not part of the 
diagnostic criteria (for example, nvPPA6, PSP14), or the emergence of behavioural disorders 
with disease progression (for example, svPPA6). A clinical trial for such symptoms would be 
most powerful if stratifying patients into ‘apathetic’ and/or ‘impulsive’ groups across the FTLD 
spectrum, rather than diagnostic groups which include patients with and without the relevant 
symptoms. For example, both semantic and behavioural variants of frontotemporal dementia 
were strongly weighted to component 3 (Figure 16). Although svPPA is primarily diagnosed 
as a language disorder with predominant temporal lobe atrophy the spread of pathology to 
orbitofrontal systems and increasing behavioural change indicate partial convergence of svPPA 
and bvFTD phenotypes30.  
 
The data revealed that apathy and impulsivity were positively correlated in FTLD syndromes. 
Measures of apathy and impulsivity showed a strong positive relationship, both through simple 
Pearson’s correlation analysis (Figure 12) and PCA, where measures loaded onto the same 
components (Table 12). Component 1 reflected increased patient rated apathy (AES) and 
impulsivity (BIS), while Component 3 had strong loadings from the Carer rated AES and NPI 
Disinhibition subscore, in addition to behavioural changes captured by the CBI. Objective 
measures also supported this finding; Component 4 had strong loadings from measures of 
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response inhibition (Go/NoGo), information sampling (IST) and incentive motivation (CRRT). 
This contradicts theoretical models in which impulsivity and apathy represent opposite 
extremes of a single spectrum. Some authors have proposed that impulsivity represents a 
dopamine-dependent spectrum of motivational or goal-directed control86,100,224 while apathy 
reflects an independent noradrenaline-dependent spectrum of arousal and uncertainty78,189. 
However, noradrenaline is also implicated in impulsivity205 and dopamine in apathy86,180, 
indicating overlapping pharmacology. Although this study did not directly measure or 
manipulate such neurotransmitters, the results are relevant to the pharmacological analysis of 
apathy and impulsivity. Specifically, the positive correlation suggests either that there is a 
common neurobiological basis for apathy and impulsivity, or that the widespread pathology in 
FTLD syndromes leads to simultaneous deficits in anatomically and/or pharmacologically 
different networks (see subsequent Chapters 4 and 5).  
 
The cognitive components of apathy and impulsivity differed according to the assessor: patient, 
carer or experimentalist. This was also observed through comparisons of analogous test 
versions of the AES and CBI, which highlighted discrepancies between carer and patient ratings 
of apathy and behavioural changes respectively. The separation of patients’ (component 1, 5 
and 8) and carers’ (components 2 and 3) ratings may reflect patients’ lack of insight into 
disease-related changes or their difficulty with semantics and grammar in questionnaires. It is 
unlikely that patients lack insight into all aspects of their disease, but clearly they differ from 
carers in terms of their awareness of certain symptoms. Carer ratings may be biased by personal 
distress104 or  education about the illness. Indeed, carer ratings of apathy on the AES were 
higher than both patient and clinician ratings (Figure 14). Eliciting and quantifying behavioural 
disorders through an interview with carers and/or questionnaires is a feature of both clinical 
practice and research but may not quantify the differences between a patient’s own symptoms 
(the usual target of treatment in medicine) and the behavioural signs reported by carers (a major 
contributor to burden and patient risk). These findings suggest that clinical trials in syndromes 
associated with frontotemporal lobar degeneration must distinguish whether treatments are for 
patients’ or carers’ wellbeing and chose outcome measures accordingly. 
 
Critical for translational studies, the subjective questionnaires did not load onto the same 
components as objective behavioural measures (components 4, 6 and 7). The identification of 
homologous tasks in preclinical models and clinical populations can successfully facilitate 
translational therapeutics130,131,205, but may not readily apply to FTLD.  
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The data confirmed that impulsivity is multifaceted. For example, response inhibition 
(Go/NoGo) was associated with component 4, whereas action cancellation performance (SST) 
loaded onto component 7, consistent with prior evidence of separate neural pathways and 
pharmacology130,205,208,268. However, motor and saccade Go/NoGo performances were highly 
correlated, both loading negatively onto component 4 (reflecting lower dprime and therefore 
poor performance), supporting the use of saccadometry to evaluate cognitive-behavioural 
systems in patients with severe limb-motor deficits220. 
 
In other neuropsychiatric studies of impulsivity such as addiction, the BIS and BIS/BAS 
questionnaires have been used to quantify individual differences228,229. Similar questions partly 
explain their presence on Component 5 “Impulsivity Self-Report” (e.g. BIS/BAS: ‘I often act 
on impulse’ versus BIS: ‘I act on impulse’). But, the transdiagnostic plots (Figure 16) suggest 
that such responses do not readily distinguish patients affected by FTLD. 
 
Similarly, the last and weakest component, termed “Outcome Sensitivity” due to strong 
loadings from the Kirby and BIS/BAS’s BIS subscore, did not reflect group differences, 
consistent with this component being a trait in the general population rather than a disease- 
specific deficit. The BIS subscore reflects a system for relaying cues of punishment, non-reward 
and novelty, to regulate behaviour292. Studies of addiction have also reported no significant 
differences between controls and substance abusers on the BIS subscore228. In the Kirby 
paradigm, steeper discounting has been reported in drug addiction, schizophrenia and PD289.  
 
The PiPPIN study and the described statistical analyses have a number of methodological and 
interpretative limitations. Although the PiPPIN study aimed to assess the multifaceted 
constructs of apathy and impulsivity, some patients could not perform on certain tasks, and the 
Cambridge Gambling Task proved especially difficult despite its successful application in 
milder neuropsychiatric populations. The task was withdrawn after 37 participants (note 
including the CGT in a subsidiary PCA did not alter the factor structure). Alternative tasks 
(including the CRRT) and questionnaires remained in the full battery to assess abnormalities in 
incentive motivation and reward. Pathological gambling is uncommon even in bvFTD, and the 
impairment may arise partly from executive deficits.  
 
Some of the assessment tools were disease-specific, or developed for a particular cohort, 
limiting their generalisation. For example, the FRS measure of disease severity in FTD may not 
be directly applicable to PSP and CBS. It could therefore be argued that one should assess the 
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neural correlates of performance separately within each diagnosis. However, reducing the 
analysis to a multiplicity of tests of individual symptoms within syndromes would have 
significant drawbacks, not just in terms of the severe loss of power to detect correlations in 
small sub-cohorts. It would also belie the evidence of clinical overlap and convergent 
symptomatology across the separate diagnostic groups. Moreover, the use of factor loadings 
for each component for each patient provides a more principled means to accommodate 
syndromic variance, without bias or diagnostic circularity.  
 
The PiPPIN study sought to obtain the maximum information about potential aspects of apathy 
and impulsivity, whilst bearing in mind the tolerance and frailty of patients with FTLD 
associated disorders. However, a neuropsychological test battery is necessarily selective and 
conclusions can only relate to the patients studied and the domains of cognition and behaviour 
assessed. There were representative test types (questionnaires, objective and observer 
characteristics) and tests that were widely used in the literature to capture different aspects of 
reward motivation, effort mood, movement, inhibition and impulsivity. Questionnaires are 
clearly limited in their ability to determine the underlying cause of behavioural change. For 
example, “he/she shows less enthusiasm for his or her usual interests” or “he/she shows little 
interest in doing new things” on the CBI-R attempts to assess changes in motivation, but might 
be confounded by learned restrictions arising from physical motor impairments. In addition, 
performance on questionnaires and behavioural tasks may be influenced by semantics and 
executive function. By employing many tasks across a number of populations, I suggest that 
the extracted dimensions of apathy and impulsivity more accurately capture the essence of these 
behavioural changes than the use of single questions or tasks in isolation. 
 
The variables used and the testing methodology were specifically designed to overcome 
limitations in this patient group. For example, I used d-prime as the major outcome measure 
for the Go/NoGo tasks, to provide an indication of performance based on the ratio between 
correct responses and false alarms, rather than the number of commission and omission errors 
or reaction times. For the Kirby, I proposed that apathy/impulsivity may exhibit as more change 
in the rate of temporal discounting (k) or insensitivity to perceived value of reward (no 
difference in k high - k low [Kirby difference]). However, the Kirby difference variable and the 
component weighted towards the Kirby (component 8) failed to show differences between 
groups. A subsidiary PCA using the original outcome measures (discounting rate at high, 
medium and low rewards) did not impact the structure of extracted components, suggesting that 
the Kirby measure may not be especially useful in the context of this patient population. 
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Additional tasks that quantify apathy in the healthy population are especially challenging in 
FTLD disorders (and were therefore not employed), because of sequential decisions, physical 
effort and strong executive demands. For example, grip-force effort115,116,133 might be 
confounded by the movement disorders in several FTLD syndromes. Akinesia, depression and 
executive deficits in particular may confound the assessment of apathy.  
 
Akinesia may readily be confused with apathy by observers. However, it is unlikely that the 
apathy identified across diagnostic groups is driven solely by akinesia, as it does not mirror the 
severity of apathy across groups (see Table 6, Figure 16). Motor features were indirectly 
measured, in terms of physical signs (including akinesia in the PSPRS) and as reaction times 
in objective behavioural tests. The correlations between the principal components and PSPRS 
were very limited (Table 13). Depression can also confound the assessment of apathy. Indeed, 
patient rated apathy, depression and anhedonia scores were positively correlated (component 
1), despite distinctions between the proposed underlying neurobiology of these 
complications141. However, self-rated depression symptom scores as measured the BDI-II, are 
distinct to the clinical disorder of depression that is primarily a mood disorder. Apathy and 
depression may have common symptoms, and both contribute to high scores on a questionnaire 
such as the BDI-II, even as distinct pathological entities.  The role of executive function in task 
performance must also be considered. Executive deficits are part of the diagnostic criteria for 
bvFTD, and supportive criteria for PSP, and yet they are common in other disorders associated 
with frontotemporal lobar degeneration50 However, a deficit in executive function cannot 
account for the fractionation of apathy and impulsivity as revealed by the PCA. Rather, the 
separate impairments in behavioural control, inhibition, goal-directed behaviour and 
appropriate planning of responses can be construed as a part of the complex dysexecutive status 
resulting from frontotemporal lobar degeneration. Indeed, verbal fluency, a marker of executive 
function293, correlated with components 1-4 and 7, in keeping with the association between 
executive functions and frontal lobe function294. In summary, the executive dysfunction in the 
PiPPIN cohort is best seen as encompassing – but not causing – the observed components of 
apathy and impulsivity. 
  
Years from symptom onset was estimated based on recall of initial relevant symptoms. 
However, this is clearly not equivalent to disease duration, as the underlying pathological 
processes associated with FTLD syndromes often occurs years before the onset of symptoms 
(at least in context of genetic FTLD81). Even the estimate of symptom duration is not 
straightforward, as for many of the FTLD syndromes, the initial relevant symptoms may not be 
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recognised and may have an insidious onset, especially symptoms and signs related to social 
behaviours. Events such as falls in progressive supranuclear palsy are usually more clear-cut, 
but may not be the presenting feature, even in PSP. Nevertheless, the estimate of symptom 
duration provides additional interesting information regarding the PiPPIN cohort tested 
throughout this thesis. 
 
It is possible that the PiPPIN cohort is biased or unrepresentative of the full spectrum of 
disorders associated with FTLD. However, the PiPPIN study used multiple sources of referral 
in community as well as specialist services, to reach all regional patients, and the attrition from 
case identification (n=204) to neuropsychological assessment (n=149) and MRI (n=70) 
included all disorders.  
 
Finally, this work relies on clinicopathological correlations and the current consensus criteria, 
acknowledging that for some disorders (nvPPA, CBS and bvFTD) the clinicopathological 
correlations are weaker than others (svPPA, PSP). 
 
3.4 Conclusion  
In conclusion, apathy and impulsivity are common and overlapping consequences of FTLD. 
Carer and patient ratings reflect distinct insights into problematic disease features, while the 
lack of correlation between subjective questionnaires and objective tasks in FTLD syndromes 
highlight the need for improved, disease-specific assessment tools to facilitate clinical trials. A 
dimensional, transdiagnostic approach to investigate and treat complex behavioural changes is 
advantageous and provides new insights into the components of apathy and impulsivity across 
FTLD syndromes.  
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Chapter 4 | The Neurobiology of Apathy and Impulsivity in 
Frontotemporal Lobar Degeneration Syndromes as Measured by 
Voxel Based Morphometry. 
 
In this chapter, I examine the neural correlates of the eight extracted components from Chapter 
3 in terms of grey and white matter structural change. Voxel based morphometry has been used 
to examine the neural changes associated with the FTLD syndromes, although previous studies 
often focus on a specific variant. Identifying the neurobiology associated with the components 
of apathy and impulsivity transdiagnostically will reveal the underlying systems associated with 
ratings from multiple perspectives and may provide targets for novel treatment development.   
 
4.1 Introduction  
4.1.1 Voxel Based Morphometry 
Magnetic Resonance Imaging (MRI) has been widely used for differential diagnosis of disease, 
tracking disease progression and identifying the neural correlates associated with specific 
disease features. The characteristic loss of neurons, or brain atrophy, that occurs in 
neurodegenerative conditions can be detected as structural changes on MRI. Analysis of MRI 
by experienced radiologists and/or manual selection of regions of interest have largely been 
replaced by automated techniques in the research setting, which facilitate comparisons across 
large groups. Voxel based morphometry (VBM) is an unbiased, quantitative, automated 
technique295,296 used frequently to statistically identify differences in brain anatomy between 
groups, most commonly in terms of tissue loss in diseased patients. Studies comparing VBM 
to manual and visual measurements of brain regions have reported similar results, providing 
some biological validity for the technique297,298. 
 
Voxel based morphometry studies have provided insights into the neurobiology of the FTLD 
syndromes and their associated behavioural changes. Most studies have focussed on FTD, PSP 
or CBS/D in isolation, although comparative studies have also been conducted, aiming to 
identify regions of atrophy that can effectively dissociate the FTLD syndromes or distinguish 
them from other neurodegenerative conditions. The substantial overlap in clinical phenotypes, 
particularly within the spectrum of FTLD disorders, complicates accurate diagnosis. As new 
therapies are developed to treat specific pathologies, imaging methods to improve accurate ante 
mortem diagnosis are warranted to stratify patients more effectively for targeted treatment. 
Chapter 4 
80 
4.1.2 Structural Neural Correlates of the FTLD syndromes 
Specific patterns of atrophy have been associated with the behavioural and language variants 
of frontotemporal dementia. Semantic variant primary progressive aphaisa (svPPA) reflects 
atrophy largely in the anterior temporal region, whereas bvFTD affects the dorsolateral and 
frontal lobes. SvPPA is associated predominantly with progressive atrophy in the left anterior 
temporal and inferior temporal regions299–301, orbitofrontal lobe, and insula caudate302–304. 
Behavioural variant frontotemporal dementia is also associated with frontal, temporal and 
insula degeneration144,151,299,300. A recent voxel based morphometry study revealed selective 
atrophy of the anterior cingulate and frontal insula cortices early in the course of bvFTD, while 
additional white matter and posterior grey matter structures densely connected to these sites 
degenerated with advancing disease16.  
 
VBM studies of PSP have reported predominant atrophy in brainstem structures, including the 
midbrain, pons, thalamus, striatum and caudate nucleus166,183,305–307. Similar patterns of atrophy 
have been confirmed by pathological studies14,190,308 and are highly consistent with the 
anatomical distribution of tau protein deposits308. The classical PSP supranuclear gaze palsy 
has been linked to neuronal loss in the nucleus raphe interpositus of the midbrain309, while 
motor deficits correlate with atrophy of the caudate and motor cingulate. Behavioural 
disturbances and executive dysfunction in PSP were initially considered to result largely from 
neurodegeneration in subcortical structures which disrupt cortical-subcortical circuitry14,310. 
However, frontal atrophy, specifically in the orbitofrontal and medial corticies, are increasingly 
recognised183,257,311. A correlation of frontal neuropsychological deficits with frontal 
hypometabolism and total frontal atrophy has also been documented257,312. 
 
VBM studies of CBD have reported a largely asymmetric (left>right) pattern of brain atrophy 
involving the bilateral premotor cortex, superior parietal lobes, posterior cingulate cortex, 
occipital cortex and striatum (caudate, putamen)305. Both grey and white matter loss occurs in 
the posterior frontal and parietal cortex and basal ganglia36,305,306,311. Changes are also observed 
in the premotor cortex and frontal subcortical white matter, most significantly affecting the 
junction of the superior frontal sulci and the precentral sulci bilaterally305, a region thought to 
contain the frontal eye fields313.  
 
Despite the substantial overlap in clinical features of PSP and CBS/D, structural imaging 
studies have identified several brain regions that are differentially atrophied, facilitating 
accurate dissociation of the two syndromes. Overall, atrophy in CBD is markedly more severe 
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than PSP at autopsy for any given disease severity314. Greater brainstem atrophy is observed in 
PSP compared to CBS/D and greater cortical atrophy in CBS/D than PSP. Indeed, Boxer et al., 
(2006) reported that the degree of atrophy in the midbrain, pontine tegmentum and left frontal 
eye field could differentiate PSP and CBS/D groups with 93% accuracy. Soliveri et al., (1999) 
also reported midbrain atrophy in 89.3% of PSP patients compared to only 6.3% in CBD36. 
Increased atrophy of the brainstem in PSP has been linked to significantly more microglial 
burden in this brain region than in CBD315. In a study of autopsy proven PSP and CBD, Josephs 
(2006) concluded that midbrain and superior cerebellar peduncle atrophy was indicative of PSP 
while frontoparietal lobe and pallidum atrophy in the absence of brainstem atrophy reflected 
CBD pathology. Premotor cortices and supplementary motor area appear affected in both 
pathologically confirmed PSP and CBD, and are therefore not appropriate for differentiating 
between the two clinical syndromes306.  
 
4.1.3 Neural correlates of FTLD-associated Apathy and Impulsivity. 
Voxel based morphometry analysis has provided important insights into the neuroanatomical 
correlates of cognitive and behavioural deficits associated with FTLD syndromes. Studies have 
focussed on behavioural variant FTD, as neuropsychiatric changes are widely recognised and 
form part of the diagnostic criteria.  
 
Studies of bvFTD have consistently linked behavioural changes to atrophy of the 
frontotemporal  lobes138,316, with specific regions linked to different behavioural features. 
Disinhibition has been linked to the orbitofrontal cortex102,144,217,317, temporal lobe100,144, right 
nucleus accumbens (ventral striatum)100, and the ventromedial prefrontal cortex138. Hornberger 
et al., (2011) reported a correlation between atrophy of the orbitofrontal cortex/temporal pole 
and disinhibition as measured by both the subjective Neuropsychiatric Inventory disinhibition 
frequency score and objective Hayling Test144. In addition to VBM, PET studies have reported 
significant changes in glucose metabolism bilaterally in the orbitofrontal cortex, anterior 
cingulate cortex, hippocampus/amygdala and nucleus accumbens in disinhibited FTD 
patients168.  
 
Studies assessing the neural correlates of apathy have been less conclusive, implicating the 
medial prefrontal cortex138, dorsolateral prefrontal cortex100,102, orbitofrontal cortex100, anterior 
cingulate102, temporal lobe and caudate101, reflecting the anatomic organisation of fronto-
subcortical circuits. Hypometabolism in the frontal medial and dorsolateral cortices bilaterally 
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have also been reported168, in addition to the ventral polar frontal cortex, which is also 
implicated in impulsivity168,169.  
 
Increased awareness of the neuropsychiatric, cognitive and behavioural features of PSP has 
prompted research into their associated neurobiological underpinnings. Apathy and impulsivity 
are particularly common53,54,68, but have largely been overlooked previously due to prominent 
motor features. Limited imaging studies suggest frontal atrophy in mesio-frontal targets of 
striatal projections likely account for the associated behavioural deficits in PSP166,183.  
 
It has become increasingly clear that there are similarities in the neurobiological changes 
implicated in apathetic and impulsive behaviours in FTLD disorders. This likely reflects the 
disruption of overlapping fronto-subcortical pathways, specifically those involving the 
orbitofrontal cortex which has been implicated in personality, social conduct and inhibition and 
the anterior cingulate, which are highly involve in cognitive control and motivational 
states112,310. 
 
4.1.4 Examining the Neural Correlates of Apathy and Impulsivity Components across 
the FTLD Spectrum 
An important caveat to consider when interpreting the results of previous studies assessing the 
correlation between brain changes and behaviour, is the lack of accurate, disease-specific 
assessment tools available to quantify behavioural change in FTLD syndromes, particularly in 
the context of apathy. Development of numerous assessment tools for impulsivity likely 
accounts for the variability in the reported neural correlates100,144. Furthermore, the available 
subjective and objective measures may bear little relationship to each other in FTLD syndromes 
(loading onto distinct components; Chapter 3). This may lead to inconsistent findings when 
examining the underlying neurobiological changes associated with apathy and impulsivity. 
Given these limitations, I suggest it may be more appropriate to assess the neural correlates of 
the psychological constructs underlying apathy and impulsivity and employ these as covariates 
in an imaging design matrix. 
 
Differences in patient populations may also account for the variability in imaging findings. 
Previous studies have often focused on behavioural changes within each of the FTLD variants 
in isolation, with a particular focus on bvFTD patients, despite their presence across disorders. 
This risks overlooking other variants in which behavioural changes are also prominent. 
Understanding the complex relationship between brain changes and clinical features across 
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groups may provide insights into the neural systems underling symptom commonalities. One 
of the advantages of using dimensional weighting rather than individual diagnostic 
classification in an imaging analysis, is that it enables better characterization of the neural 
systems underlying given behaviours. This approach is especially important when a set of 
behaviours are manifest across multiple conditions such as component 2 and 4, which were 
particularly abnormal in multiple disorders (see Chapter 3, Figure 16). To reduce the analysis 
to a myriad of “symptoms within syndromes” would greatly reduce both statistical power and 
insight into the commonality of disordered behaviour in FTLD syndromes.  
 
Here, I employ voxel based morphometry to determine the grey and white matter neural 
correlates of the eight extracted components of apathy and impulsivity.  
 
4.2 Methods 
4.2.1 Cohort 
Of the 149 participants included in the PCA analysis, a subset of 70 patients (PSP 22, CBS 13, 
bvFTD 14, nvPPA 12, svPPA 4, other PPA 5) and 27 controls underwent MRI. The imaging 
subset were representative of the cohort, with no significant differences between the imaging 
subset (n=70) and the non-imaged patients (n=79) in terms of demographics, disease 
characteristics and the major outcome variables included in the analysis (Table 14). Most 
patients underwent MRI on the same day as cognitive assessment (median and mode=0 days). 
 
4.2.2 Imaging Acquisition 
Magnetic resonance imaging (MRI) was performed at the Wolfson Brain Imaging Centre, using 
a TIM-Trio 3T scanner (Siemens, Germany http://www.medical.siemens.com/). T1-weighted 
magnetization-prepared rapid acquisition gradient-echo (MPRAGE) images were acquired 
with a TR=2300 ms, TE=2.86 ms, matrix=192×192, in-plane resolution of 1.25x1.25mm, 144 
slices of 1.25mm thickness, inversion time=900 ms and flip angle =9°.  
 
Preprocessing used diffeomorphic anatomical registration using exponentiated Lie algebra 
(DARTEL) in SPM12 following brain extraction. The T1 images were segmented using default 
settings to output the DARTEL import images for grey and white matter. Then a study-specific 
template was created using 5 age-matched participants from each of the diagnostic groups (to 
reduce group bias). The remaining subjects’ data were warped to the template. Next, the grey 
and white matter template segments were affine-transformed to MNI space. The affine template 
transformation was applied to the maps of the individual participants together with smoothing 
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by an 8mm isotropic full width at half maximum Gaussian kernel. The total intracranial volume 
was calculated using Tissue Volumes function in SPM12, and study-specific masks created 
from voxels with a value of > 0.1 in >80%318 of the images. 
 
4.2.3 Voxel-Based Morphometry  
Due to orthogonality of PCA components, their neural correlates were identified by a general 
linear model, using the smoothed normalised grey and white matter segments. The design 
matrix included the eight mean centered Principal Component Factor scores, age, gender and 
total intracranial volume and an intercept. Both positive and negative contrasts were examined 
from the General Linear Model for all eight principal components. Significant effects were 
identified using cluster-level statistics (FWEc p<0.05, corrected for multiple comparisons) 
above a height threshold of p<0.005 (unc). The non-stationary cluster extent correction was 
applied in view of the non-uniformity of the data. 
 
4.3 Results 
The components of apathy and impulsivity were correlated with distinct grey and white matter 
abnormalities, in corticospinal, frontotemporal, frontostriatal and subcortical systems. Figures 
17 and 18 illustrate the distributions of significant clusters.  
 
Significant grey matter correlates were identified for components 2, 3, 4 and 7 (Figure 17, 
Appendix A) and white matter correlates for components 1, 2, 3 and 7 (Figure 18, Appendix 
B). Note that patients’ (component 1) and carers’ (components 2 & 3) ratings were associated 
with distinct white matter correlates. The patient ratings of component 1 were related to 
impairments in the corticospinal tracts, from the mid centrum semiovale, through corona radiata 
to the upper brainstem. In contrast, the carer ratings correlated with frontostriatal and brainstem 
systems. Specifically, carer rated change in everyday skills and self care (component 2) 
reflected localised brainstem white matter changes (medulla, pons, and lower midbrain largely 
sparing the thalamus, and white matter deep to the middle frontal gyrus) (Figure 18), with grey 
matter changes extending from the caudate, putamen and thalamus into multiple cortical 
regions including medial and lateral premotor and sensorimotor cortex, and scattered foci in 
prefrontal, parietal and occipital cortex (see Figure 17). Carer rated behavioural change 
(component 3) was associated with widespread but complementary changes in both grey and 
white matter of the temporal pole, frontal pole, orbitofrontal and medial frontal cortex and their 
connecting tracts (Figure 17 & 18).  
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Performance on the motor/saccade response inhibition, cued reinforcement and information 
sampling tasks (component 4) reflected grey matter change in multiple regions including 
thalamus, lateral temporal cortex, posterior and dorsal-anterior cingulate cortex, and parieto-
occipital cortex (Figure 17). Performance on the Stop-Signal task (component 7) reflected 
localised grey matter change in the right inferior frontal region, anterior cingulate and white 
matter change in the left frontal lobe (Figures 18 and 19).  
 
Component 5 “Impulsivity Self-Report”, Component 6 “Goal-Directed Decision Making” and 
Component 8 “Outcome Sensitivity” did not reveal any significant anatomical correlates. 
 
4.4 Discussion 
These imaging results build on the major findings of the previous chapter, briefly that a) apathy 
and impulsivity are present across the frontotemporal lobar degeneration spectrum, b) apathy 
and impulsivity are positively correlated and c) the components that reflect patients’ own 
ratings of apathy and impulsivity are distinct from those based on carer observations and 
objective behavioural measures.  
 
Here, I show that the anatomical networks associated with apathy and impulsivity in this cohort 
correspond with established networks for goal-directed behaviour, social cognition, motor 
control and vegetative functions. Specifically, carer ratings (AES, NPI, CBI) reflect widespread 
disruption in frontostriatal and brainstem systems required for motivation and arousal, while 
patient ratings (AES, BIS, SHAPS, BDI, MEI) correlated with changes in cortico-spinal tracts 
which I suggest reflects patients’ awareness of their motor deficits despite lack of insight into 
cognitive decline. Objective measures reflected localised changes in previously identified task-
specific brain regions (e.g. SST and right inferior frontal gyrus). 
 
Although patients with frontotemporal dementia are said to lack insight, component 1 
correlated with well-defined and largely symmetric neural systems including the corticospinal 
tracts. PSP and CBS cases scored highly on Component 1, but the neural correlates differ from 
atrophy patterns identified by voxel based morphometry studies of PSP and CBD versus 
controls183,306,319–322, which highlight deficits in the medial frontal cortex, parietal lobe and 
brainstem. The observed neural correlates may reflect patients’ awareness of motor deficits, 
while their insight into cognitive decline and behavioural change remains limited; the latter 
changes being identified by carers. 
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Figure 17: Grey Matter VBM Neural Correlates of Apathy and Impulsivity in FTLD 
Syndromes. 
VBM analysis revealed distinct neural grey matter correlates for principal components 
2-4 and 7. Components 2-4 represent negative correlations, with higher component scores 
reflecting a loss of grey matter in the relevant brain regions. Component 7 was positively 
correlated with the highlighted brain regions, with higher component scores representing 
increased grey matter in these areas.  
 
 
R 
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Figure 18: White Matter VBM Neural Correlates of Apathy and Impulsivity in FTLD 
Syndrome.  
VBM analysis revealed distinct neural white matter correlates for principal components 
1-3 and 7. PC 1-3 represent negative correlations, with higher component scores reflecting 
a loss of white matter in the relevant brain regions. PC7 was positively correlated with 
the associated brain regions, with higher component scores reflecting increased white 
matter in the highlighted areas.   
 
 
 
 
 
R 
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Table 14: Comparison of Imaging Subset (N=70) and Non-Imaging Subset (N=79) of the 
PCA Sample (N=149) 
 Variable 
Imaged 
(N=70) 
Non Imaged 
(N=79) 
T Stat 
P value 
(unc) 
D
em
o
g
ra
p
h
ic
s 
&
 C
o
g
n
it
io
n
 
 
Age 68.2±8.2 70.4±8.6 1.6 0.12 
Gender M:F 39:31 37:42 (2=1.2) 0.33 
ACE-R Total (max 100) 67.3±22.2 58.9±23.0 -1.7 0.10 
MMSE Total (max 30) 23.0±6.8 20.7±6.7 -1.6 0.12 
FRS % Score (max 100) 41.4±27.9 32.5±23.6 -1.8 0.08 
Q
u
es
ti
o
n
n
a
ir
es
 
Apathy Evaluation Scale (AES, max 72): 
-carer 
-patient 
-clinician 
 
46.5±12.6 
36.6±9.2 
43.1±9.6 
 
50.8±11.7 
34.5±10.2 
45.1±11.3 
 
1.8 
-0.8 
0.76 
 
0.08 
0.44 
0.45 
Barratt Impulsiveness Scale (BIS, max 
120) 
64.1±7.9 61.5±8.8 -1.1 0.29 
Behavioural Inhibition 
System/Behavioural Activation System 
(BIS/BAS):  
-BIS subscore 
-BAS drive 
-BAS funseeking 
-BAS Reward Responsivness 
 
 
20.8±4.7 
11.0±3.3 
11.2±2.9 
16.4±2.7 
 
 
19.9±3.5 
10.8±2.9 
11.7±3.8 
17.4±2.8 
 
 
-0.6 
-0.2 
0.5 
1.2 
 
 
0.54 
0.83 
0.60 
0.25 
Motivation and energy inventory (MEI, 
max 144) 
80.5±27.2 83.8±22.6 0.4 0.69 
Beck depression inventory (BDI, max 63) 13.1±10.7 12.7±7.6 -0.2 0.88 
Snaith Hamilton pleasure scale (SHAPS, 
max 56) 
22.3±5.1 23.1±3.8 0.6 0.58 
Neuropsychiatric inventory (NPI, fraction 
with positive response): 
-Apathy subscore 
-Disinhibition subscore 
 
 
.59±.50 
.35±.50 
 
 
.66±.48 
.31±.47 
 
 
0.7 
-0.5 
 
 
0.46 
0.65 
Cambridge behavioural inventory (CBI-
R, max 180) 
62.0±35.7 73.8±33.7 1.8 0.08 
Kirby (difference) 0.01±0.05 0.04±0.07 1.5 0.13 
B
eh
a
v
io
u
ra
l 
T
a
sk
s 
  
Information Sampling Task (IST)  
-Probability of being correct Fixed 
-Probability of being correct Decreasing 
 
0.75±0.15 
0.67±0.17 
 
0.71±0.11 
0.66±0.08 
 
-0.8 
-0.1 
 
0.41 
0.89 
Cued reinforcement reaction time 
(CRRT) 
-reward related speeding 
-Total Errors 
 
62.1±331.8 
4.1±5.0 
 
128.0±853.7 
4.5±8.3 
 
0.57 
0.2 
 
0.57 
0.82 
Stop Signal Task (SST) 
-Stop signal reaction time (SSRT) 
 
401.8±213.1 
 
430.6±242.3 
 
0.4 
 
0.81 
Motor Go/NoGo Dprime 3.2±1.3 3.0±1.2 -0.7 0.48 
Saccade Dprime 0.79±1.1 0.62±1.1 -0.4 0.68 
Comparison of imaged versus non-imaged sample using Student’s Independent T-Test 
and Chi-squared for gender comparison between groups. All variables were non-
significant.  
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In contrast to patient ratings, carer ratings of challenging behaviours (component 3) and 
vegetative features (component 2) correlated with frontostriatal and frontotemporal networks 
for motivational and arousal systems145,323,324 and brainstem integrity. Component 3 represents 
a coherent “behaviour” score based on the abnormal behaviour, mood, beliefs, eating habits, 
stereotypical behaviour, memory and motivation sections of the CBI-R, in contrast to everyday 
skills and vegetative functions associated with Component 2. Components 2 and 3 correlated 
with functional/disease severity (FRS) and cognitive decline (ACE-R, MMSE, FAB), 
supporting the hypothesised association between apathy, cognition and functional decline84. 
 
Both semantic and behavioural variants of frontotemporal dementia were strongly weighted to 
component 3 (Figure 16). Although svPPA is primarily diagnosed as a language disorder with 
temporal lobe atrophy, the spread of pathology to orbitofrontal systems and increasing 
behavioural change indicate partial convergence of svPPA and bvFTD phenotypes30. The 
neural correlates of component 3 (Figures 18 & 19) suggest disrupted motivation and reward 
processing circuitry with both apathy and impulsivity, consistent with the regulation of reward, 
motivation and reinforcement by projections from the orbitomedial prefrontal cortex and 
anterior cingulate to ventral striatum101,208,224. Carer ratings closely reflect changes in these 
brain circuits previously implicated in apathetic and impulsive behaviours86,100,111. Analogous 
changes have been observed in many neurological and psychiatric impulsivity 
disorders86,111,208,228. 
 
The white matter correlates of component 2 (everyday skills and vegetative functions) were 
concentrated in the brainstem (Figure 18), with grey matter correlates extending from the 
thalamus to posterior regions of cingulate and parietal cortex (Figure 17). These changes were 
most strongly associated with PSP and CBS, consistent with previous reports50. Degeneration 
of the brainstem is proposed to affect the reticular activating system that regulates wakefulness, 
attention and alertness. Furthermore, sustained attention and oculomotor control require 
functional integration of the brainstem, thalamus and neocortical areas associated with this 
component, and are particularly affected by PSP and CBS.  
 
The stop-signal task was weighted to component 7 and revealed localized changes in focal brain 
regions within the right frontal lobe. Previous studies of health, Parkinson’s disease, ADHD 
and ageing have consistently associated this task with the integrity, activity and connectivity of 
the right inferior frontal gyrus208,211, pre-supplementary area and subthalamic nucleus255, as 
well as noradrenergic130,205 and serotoninergic268 function. Higher scores on component 7 
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(better performance) correlated with increased grey matter volumes in the right inferior frontal 
gyrus and its connections to the striatum, providing further construct validation of this 
dimensional approach.  
 
This imaging study incorporates the methodological and interpretative limitations discussed in 
Chapter 3, in addition to some imaging specific limitations. Despite the substantial literature 
using white matter VBM, there are recognised limitations. Voxel-based methods have used 
either the white matter volume estimates, analogous to grey matter VBM, or voxel based 
comparisons of diffusion metrics like FA and MD. I used the former method in SPM, similar 
to several other studies183,305,307,325. The use of SPM-style VBM (using white matter estimates 
from the T1 image) is of course different from voxel-based analyses of diffusion metrics. There 
are several limitations, including normalisation and mislocalisation errors, as discussed for 
example by326, and while these may motivate DTI based analyses, they qualify but do not 
invalidate VBM of white matter. Agosta for example, has suggested that DTI metrics may serve 
as an early marker of white matter integrity loss that later becomes detectable by VBM327. 
 
VBM changes in white matter should therefore be interpreted with caution326, especially where 
white matter correlates are observed in the absence of grey matter correlates (for example, 
component 1). They may reflect true white matter influences on complex behavioural 
repertoires, but false positive correlations may arise from normalisation and mislocalisation 
errors and the partial-volume effects of smoothing. In contrast, the complementarity of white 
and grey matter correlates of component 2 and 3 strengthens their interpretation. VBM has been 
used extensively in the literature to examine white matter volumes in PSP166,183,305–307,322, 
CBS/D305–307,320 and frontotemporal dementia10. However, alternative methods are increasingly 
common to study white matter changes in FTLD syndromes, including diffusion-weighted 
imaging with voxel-wise, regions-of-interest or tract-based statistics328–330 (Chapter 5).  
 
In disorders of extreme atrophy like svPPA, the risk of mislocalisation in the VBM is acute and 
something which has motivated alternative methods such as TBSS326. However, in head to head 
trials between voxel based and tract based white matter analysis256, the inferences on group-
wise disease-related changes in white matter are remarkably similar. Similar results are seen 
across separate studies by different groups using white matter VBM and DTI based 
measures10,320,329,330. Therefore, despite differences in assumptions, confounds and sensitivity, 
there is generally consensus across methods in the regional effects of FTLD syndromes on 
white matter.  
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4.5 Conclusion  
This dimensional approach provides new insights into the neural basis of apathy and 
impulsivity in FTLD. Structural brain imaging revealed corticospinal tract impairments in 
relation to patient ratings, while carer ratings correlated with frontostriatal, frontotemporal and 
brainstem systems. Objective tests correlated with changes in localised, task-specific brain 
regions. Recognition and quantification of separate neurocognitive systems for behaviour will 
facilitate the development of new symptomatic therapies. The neuroimaging correlates of the 
different “modes” of apathy and impulsivity provide a principled way to clinically assess the 
benefits of symptomatic and disease-modifying drugs on the neural systems that regulate 
different behaviours.  
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Chapter 5 | White Matter Tract Changes Associated with Apathy 
and Impulsivity in Frontotemporal Lobar Degeneration 
Syndromes: A Diffusion Weighted Imaging Analysis. 
 
In the previous chapter, I presented the structural grey and white matter changes associated 
with the components of apathy and impulsivity across frontotemporal lobar degeneration 
syndromes, as measured by voxel based morphometry. In view of the limitations associated 
with white matter analysis using this technique (discussed in Chapter 4), here I employ 
diffusion weighted imaging, specifically tract based spatial statistics, to examine the white 
matter tract changes associated with the components of apathy and impulsivity. 
 
5.1  Introduction 
5.1.1 Diffusion Tensor Imaging 
Diffusion tensor imaging (DTI) is an application of diffusion weighted magnetic resonance 
imaging (DWI) that is sensitive to changes in white matter microstructure and macroscopic 
connectivity in health and disease331, including syndromes associated with FTLD256,322,330,332–
335. DTI measures the diffusion rate (mean diffusivity) and directionality (fractional anisotropy, 
radial and axial diffusivity) of water molecules within a tissue. The tissue type, integrity, and 
architecture all influence molecular diffusion. White matter is considered directionally 
dependent or anisotropic, with preference for diffusion along tracts, while grey matter is less 
anisotropic and cerebral spinal fluid is unrestricted or isotropic331,336. Potential barriers to 
diffusion across white matter tracts include the axon membrane, myelin sheath, microtubules 
and neurofilaments337. 
 
5.1.2 White Matter Change in FTLD Syndromes 
Diffuse structural change in white matter tracts is recognised as a pathological characteristic of 
FTLD syndromes322,332,338. Consistent patterns of grey and white matter pathology are 
reported2,339–342, but white matter disruption often extends beyond regions of grey matter 
atrophy327,332. White matter damage is therefore unlikely to occur simply as a consequence of 
grey matter atrophy, but instead represents a core hallmark of FTLD pathophysiology, 
consistent with autopsy evidence of tau deposition in both grey and white matter343. Changes 
in white matter may even provide greater accuracy for FTLD classification than brain 
atrophy344,345. 
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Across multiple FTLD phenotypes, grey matter atrophy is reported in the dorsolateral and 
medial frontal cortex with white matter abnormalities involving the genu and body of the corpus 
callosum and ventral frontotemporal and dorsal frontoparietal pathways346. However, syndrome 
specific patterns are also observed. Diffusion weighted magnetic resonance imaging has 
revealed widespread reductions of fractional anisotropy (FA) and increased mean diffusivity 
(MD) in frontal, temporal and parietal white matter in bvFTD144,338,347,348. Affected tracts 
include the superior/inferior longitudinal fasciculus, anterior cingulum, genu and body of the 
corpus callosum, anterior commissure, corona radiata, corticospinal tracts, uncinate fasciculus 
and forceps minor327,338,345,348,349. These regions have also been implicated in previous studies 
reporting combined grey and white matter change involving the ventromedial prefrontal cortex, 
insula, temporal and striatal regions and their underlying white matter tracts16,350. Most severe 
changes are reported in the anterior portions of the superior longitudinal fasciculus and inferior 
longitudinal fasciculus, corresponding to high atrophy rates in the anterior frontal and temporal 
lobes341. Despite predominant involvement of the fronto-temporal regions in bvFTD, the lateral 
and medial parietal lobe become increasingly involved with disease progression, reflecting 
associated changes in posterior white matter tracts, including the posterior cingulate and 
posterior aspects of the superior longitudinal fasciculus341.  
 
Language variants also demonstrate structural abnormalities in frontotemporal pathways 
(svPPA) and fronto-parieto-temporal pathways (nvPPA)330, including the anterior corpus 
callosum, uncinate fasciculus, inferior longitudinal fasciculus, inferior fronto-occipital 
fasciculus and corona radiata164. Consistent distributions of grey and white matter change have 
been reported; svPPA show abnormalities (predominantly left-sided) in ventrostriatal temporal 
white matter, in line with previous structural and functional imaging of grey matter atrophy in 
these regions339.  
 
Degeneration of the brainstem and the associational and commissural fibres are hallmarks of 
PSP, with significant white matter change in the superior cerebellar peduncles, body of the 
corpus callosum, inferior longitudinal fasciculus, and superior longitudinal fasciculus334. In 
CBS, changes in frontoparietal connecting fibres, intraparietal associative fibres, sensorimotor 
fibres of the hand cortical representation, and body and splenium of the corpus callosum have 
been reported335.  
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5.1.3 White Matter Changes Associated with Apathy and Impulsivity in FTLD 
Syndromes 
Commonalities in the distribution of grey and white matter change across syndromes likely 
account for the observed overlap in clinical phenotypes342,346, and the development of complex, 
multifaceted behavioural changes including apathy and impulsivity. Disease specificity may 
reflect the pattern and staging of large-scale network breakdown, providing further support for 
a dimensional approach to FTLD research. Studies assessing the white matter correlates of 
apathy and impulsivity in FTLD syndromes are limited and have largely focused on bvFTD, 
for which apathy and impulsivity are clinical criteria. This limits their relevance to other 
syndromes, for which these behaviours are also present. Increased behavioural deficits have 
been associated with atrophy of the frontotemporal lobes and their associated white matter 
connections138,316, with disinhibition linked specifically to FA changes in the uncinate, forceps 
minor, and genu of the corpus callosum144.  
 
The reported white matter neural correlates of apathy are more varied341. Cortico-subcortical 
white matter tracts have been associated with psychological processes linked to apathy, 
including emotion regulation, reward sensitivity and goal-directed behaviour112. Damage to the 
uncinate fasciculus, a large white matter tract which connects the frontal and limbic regions, is 
linked to apathy in in AD165, small vessel disease97, PSP327 and normal ageing351.  
 
The neural mechanisms underlying the clinical coexistence of apathy and impulsivity in 
frontotemporal lobar degeneration syndromes are unclear, but likely reflect disruption to white 
matter tracts connecting frontal-subcortical regions required for selection and initiation of goal 
directed behaviour and motivation352.  
 
In view of this literature reporting white matter changes across the FTLD spectrum, I tested the 
hypothesis that there are distinctive white matter correlates of the major components of apathy 
and impulsivity,  using diffusion tensor imaging with tract based spatial statistics316,322,332,338. 
Based on the volumetric changes discussed in Chapter 4, I predicted that regionally specific 
pathology of white matter tracts leads to different apathetic and impulsive behaviours in 
FTLD50,220. I further hypothesized that separate dimensions of apathy and impulsivity, 
identified from the patients’ perspective, carers’ observation and neuropsychological measures, 
reflect degeneration of distinct white matter tract in the neural systems supporting motivational 
and cognitive control.  
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5.2 Methods  
5.2.1 Cohort 
A subset of 100 participants underwent diffusion weighted magnetic resonance imaging, mostly 
on the same day as cognitive assessment (median and mode=0). After quality control the 
imaging group comprised of 69 patients: 22 PSP, 14 bvFTD, 14 CBS, 11 nvPPA, 4 svPPA, 4 
PPA other and 28 controls from the original 149 PCA subset. The imaged subset did not differ 
significantly from the non-imaged group in terms of demographics, disease features and the 
major outcome variables included in the analysis (Table 15). For the purposes of this analysis, 
the language variants are classified into a single PPA group, providing near equal sample sizes 
for further analysis (22 PSP, 14 bvFTD, 14 CBS, 19 PPA).   
 
5.2.2 Group Comparisons 
Statistical analysis of group differences and correlations used SPSS v23.0. Student’s T-Tests 
comparing the imaged vs non-imaged sample were corrected for multiple comparisons.  
 
5.2.3 Imaging  Acquisition 
MRI used a Siemens Magnetom Tim Trio at 3T (Siemens, Erlangen). Diffusion-weighted 
images (DWI) were acquired using a 63-direction gradient sequence with the following 
parameters: b value 1000s/mm2; TR 7800ms; TE 90ms; axial in-plane acquisition matrix 
96×96; field of view 192×192mm; slice thickness 2mm and a total of 63 contiguous slices with 
in-plane resolution 2 mm isotropic. A single b value of 0 s/mm2 image was acquired.  
 
5.2.4 Diffusion Tensor Imaging 
Diffusion-weighted images were processed using FMRIB Software Library (FSLv5.0; 
www.fmrib.ox.ac.uk/fsl), correcting for eddy currents and subject motion by affine registration 
to the first b0 image using FSL eddy_correct. The bvecs were rotated using fdt_rotate_bvecs. 
The b0 image was extracted and a brain mask created using Brain Extraction Tool (BET).  
Diffusion tensors were fitted using dtifit to create maps of fractional anisotropy (FA) and mean 
diffusivity (MD). FA maps from five representative subjects from each group were non-linearly 
registered to the FMRIB58_FA_1mm target using the tbss_2_reg script, to avoid bias towards 
groups with a larger sample size. The resulting warped FA images were averaged to produce a 
study-specific FA template353. The tbss_2_reg script was then repeated for all subjects using 
the study-specific FA template as target, thereby bringing all subjects into the same anatomical 
space. From this study-specific template, a mean FA skeleton was produced and individual FA 
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skeletons mapped to this using a threshold of 0.2. Finally, the transformations putting the 
individual FA maps into the skeletonised standard space were applied to the L1, RD and MD 
maps.  
 
5.2.5 Tract Based Spatial Statistics 
Tract-based spatial statistics were used to examine the relationships between changes in 
diffusion metrics and behaviour326. Correlations between the skeleton DTI-tracts and principal 
components of apathy and impulsivity were assessed by non-parametric permutation analysis 
using FSL randomise with Threshold-Free Cluster Enhancement (TFCE), 2D optimisation and 
5000 permutations. The design matrix contained a constant-term to model the intercept and 
each of the eight orthogonal principal components of behaviour. Cluster significance was tested 
at p<0.01 and p<0.05, corrected for multiple comparisons. 
 
5.3 Results 
5.3.1 Neuropsychological and Behavioural Results 
Demographic, cognitive, neuropsychological and behavioural results of patients and controls 
who underwent DTI imaging (N=97) are displayed in Table 16. Groups were matched for age 
and sex, while patients were impaired on measures of cognition (ACE-R, MMSE, FAB) and 
disease severity (FRS, PSP-RS), and most measures of apathy and impulsivity.  
 
5.3.2 Diffusion Tensor Imaging 
Tract-based spatial statistics identified significant changes in white matter integrity in relation 
to Component 2 (yellow-red) and Component 3 (green-blue; TFCE corrected p<0.01; see 
Figure 19). Changes in MD and FA were complementary and highlighted concordant patterns 
of white matter change in relation to carer-rated change in everyday skills and self care 
(Component 2) and carer rated change in complex behaviours (Component 3). Component 2 
correlated with global FA (negative) and MD (positive) changes affecting the majority of white 
matter tracts extending from anterior to posterior regions, including the centrum semiovale and 
corticospinal tracts. In contrast, Component 3 reflected disruption in anterior brain regions, 
correlating with FA (negative) and MD (positive) changes in frontotemporal connections 
between the orbital- and ventrolateral-prefrontal cortex, anterior cingulate and temporal pole. 
The anterior-posterior dissociation between component 3 and 2 is most apparent for MD (see 
Figure 19A). Decreased FA and increased MD in the highlighted regions relate to impairments 
in performance (higher scores on components 2 and 3).  
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At the more liberal threshold of p<0.05 corrected, Component 4 correlated with MD changes 
in regions connecting the pre-supplementary motor area to the right dorsolateral prefrontal 
cortex, as well as the occipital lobe (Figure 19B). 
 
Table 15: Comparison of Diffusion Tensor Imaged versus Non Imaged Patients 
 Variable Imaged  
(N=69) 
Non Imaged 
(N=80) 
T Stat 
(2) 
P value 
(unc) 
D
em
o
g
ra
p
h
ic
s 
&
 C
o
g
n
it
io
n
 
 
Age 68.7±8.0 71.1±8.4 1.5 0.14 
Gender M:F 38:31 38:42 (2=0.85) 0.40 
ACE-R Total (max 100) 67.3±22.3 59.3±22.7 -1.6 0.12 
MMSE Total (max 30) 23.0±6.8 20.8±6.7 -1.6 0.14 
FRS % Score (max 100) 40.6±27.3 40.6±27.3 -1.3 0.19 
Q
u
es
ti
o
n
n
a
ir
es
 
Apathy Evaluation Scale (AES, max 72): 
-carer 
-patient 
-clinician 
 
46.9±12.4 
36.7±9.2 
43.4±9.6 
 
50.2±12.3 
34.0±10.0 
44.5±11.3 
 
1.4 
-1.0 
0.5 
 
0.17 
0.29 
0.61 
Barratt Impulsiveness Scale (BIS, max 120) 64.2±7.8 61.0±8.7 -1.4 0.17 
Behavioural Inhibition System/Behavioural 
Activation System (BIS/BAS):  
-BIS subscore 
-BAS drive 
-BAS funseeking 
-BAS Reward Responsivness 
 
 
20.8±4.7 
11.0±3.3 
11.2±2.9 
16.4±2.7 
 
 
19.7±3.4 
10.6±2.8 
11.6±3.7 
17.3±2.7 
 
 
-1.0 
-0.4 
0.4 
1.1 
 
 
0.41 
0.70 
0.70 
0.29 
Motivation and energy inventory (MEI, max 
144) 
80.3±27.4 84.6±21.8 0.5 0.59 
Beck depression inventory (BDI, max 63) 13.3±10.7 12.2±7.6 -0.4 0.70 
Snaith Hamilton pleasure scale (SHAPS, max 
56) 
22.4±5.1 22.9±3.7 0.4 0.70 
Neuropsychiatric inventory (NPI, fraction 
with positive response): 
-Apathy subscore 
-Disinhibition subscore 
 
 
0.60±0.49 
0.36±0.48 
 
 
0.64±0.48 
0.30±0.47 
 
 
0.5 
-0.6 
 
 
0.62 
0.60 
Cambridge behavioural inventory (CBI-R, 
max 180) 
62.8±35.2 72.3±34.9 1.4 0.16 
Kirby (difference) 0.01±0.05 0.03±0.06 1.4 0.17 
B
eh
a
v
io
u
r
a
l 
T
a
sk
s 
  
Information Sampling Task (IST)  
-Probability of being correct Fixed 
-Probability of being correct Decreasing 
 
0.75±0.15 
0.67±0.17 
 
0.74±0.13 
0.67±0.10 
 
-0.3 
0.1 
 
0.80 
0.91 
Cued reinforcement reaction time (CRRT) 
-Total Errors 
 
4.2±5.0 
 
1.9±2.0 
 
-1.5 
 
0.15 
Stop Signal Task (SST) 
-Stop signal reaction time (SSRT) 
 
447.0±244.3 
 
548.5±176.7 
 
1.3 
 
0.20 
Motor Go/NoGo Dprime 3.2±1.3 2.9±1.1 -0.8 0.41 
Saccade Dprime 0.79±1.1 0.62±1.1 -0.4 0.68 
Comparison of imaged versus non-imaged sample using Student’s Independent T-Test 
and Chi-squared for gender comparison between groups. All variables were non-
significant. 
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Table 16: Demographics, Neuropsychiatric and Behavioural Results for Imaged Patients and Controls 
 Variable Imaged 
Controls 
Imaged 
Patients 
T-Test  
P value  
PSP CBS PPA bvFTD 
D
em
o
g
ra
p
h
ic
s 
a
n
d
 
C
o
g
n
it
io
n
/F
u
n
ct
io
n
 N 28 69 NA 22 14 19 14 
Age 68.4±6.0 68.7±8.0 NS 71.4±7.4 66.9±8.0 71.2±7.5 63.9±7.4 
Gender M:F 15:13 38:31 NS 12:10 7:7 11:8 8:6 
ACE-R Total (/100) 96.8±3.2 67.3±22.3 ** 78.6±11.8 66.1±25.3 53.4±21.9 67.2±25.1 
MMSE Total (/30) 29.5±1.0 23.0±6.8 ** 25.9±4.3 21.7±8.2 19.8±7.3 23.5±6.7 
FRS % Score (/100) 95.0±6.8 40.6±27.3 ** 44.4±29.2 34.5±25.7 51.5±29.7 26.0±12.3 
PSP-RS NA 29.9±18.6 ** 40.0±11.4 37.3±19.0 7.3±5.4 16.0±10.5 
FAB 17.2±0.9 10.5±4.2 ** 11.4±3.4 10.8±4.8 8.9±3.8 10.9±5.1 
Q
u
es
ti
o
n
n
a
ir
es
 
Apathy Evaluation Scale (AES /72): 
-carer 
-patient 
-clinician 
 
24.3±5.4 
24.5±5.2 
25.4±7.6 
 
46.9±12.4 
36.7±9.2 
43.4±9.6 
 
** 
** 
** 
 
47.2±11.1 
39.7±10.9 
46.6±10.8 
 
47.4±10.7 
35.2±5.7 
42.4±8.4 
 
41.2±14.9 
37.6±6.3 
38.8±10.0 
 
53.6±9.4 
32.6±10.2 
43.4±6.7 
Barratt Impulsiveness Scale (BIS /120) 57.1±7.8 64.2±7.8 ** 65.4±7.7 61.1±10.5 65.4±7.0 63.7±6.3 
Behavioural Inhibition System Behavioural 
Activation System (BIS/BAS): 
-BIS subscore 
-BAS drive 
-BAS funseeking 
-BAS Reward Responsivness 
 
 
20.3±3.0 
10.5±1.6 
10.9±2.1 
15.7±2.8 
 
 
20.8±4.7 
11.0±3.3 
11.2±2.9 
16.4±2.7 
 
 
NS 
NS 
NS 
NS 
 
 
19.9±3.3 
11.1±3.1 
10.7±2.8 
16.1±2.9 
 
 
21.9±3.0 
9.5±3.2 
9.5±3.1 
16.6±2.2 
 
 
22.4±7.6 
10.6±3.2 
11.8±2.3 
16.4±2.3 
 
 
19.7±3.3 
12.7±3.4 
13.0±2.6 
16.9±3.2 
Motivation and energy inventory (MEI /144) 112.8±15.8 80.3±27.4 ** 67.5±30.4 76.9±25.6 86.7±14.6 97.3±24.9 
Beck depression inventory (BDI /63) 3.6±4.1 13.3±10.7 ** 19.0±12.5 12.6±8.2 9.0±10.0 9.2±6.0 
Snaith Hamilton pleasure scale (SHAPS /56) 18.7±4.8 22.4±5.1 * 22.4±4.7 23.1±5.7 20.6±3.8 23.5±6.3 
Neuropsychiatric inventory (NPI, fraction with 
positive response): 
-Apathy subscore 
-Disinhibition subscore 
 
 
0.00±0.00 
0.04±0.19 
 
 
0.60±0.49 
0.36±0.48 
 
 
** 
** 
 
 
0.60±0.50 
0.29±0.46 
 
 
0.71±0.47 
0.14±0.36 
 
 
0.42±0.51 
0.32±0.51 
 
 
0.71±0.47 
0.77±0.44 
Cambridge behavioural inventory (CBI-R /180) 4.5±4.2 62.8±35.2 ** 50.9±33.9 69.8±36.1 53.3±37.8 85.2±20.4 
Kirby (difference) 0.01±0.02 0.01±0.05 NS 0.03±0.04 0.02±0.05 0.01±0.03 -.001±0.08 
  
 
1
0
0
 
 Variable Imaged Controls Imaged 
Patients 
T-Test  
P value  
PSP CBS PPA bvFTD 
B
eh
a
v
io
u
ra
l 
T
a
sk
s 
Information Sampling Task (IST) 
-Probability of being correct Fixed 
-Probability of being correct Decreasing 
 
0.78±0.10 
0.85±0.12 
 
0.75±0.15 
0.67±0.17 
 
* 
* 
 
0.68±0.15 
0.75±0.15 
 
0.59±0.24 
0.72±0.14 
 
0.64±0.11 
0.68±0.12 
 
0.73±0.19 
0.83±0.14 
Cued reinforcement reaction time (CRRT) 
-Total errors 
 
3.1±2.9 
 
4.2±5.0 
 
NS 
 
3.7±3.3 
 
5.2±5.0 
 
7.0±9.4 
 
2.6±2.1 
Stop Signal Task (SST) 
-Stop signal reaction time (SSRT) 
 
175.8±42.8 
 
447.0±244.3 
 
** 
 
449.4±189.0 
 
544.3±430.7 
 
471.8±242.5 
 
353.0±152.2 
Motor Go/NoGo Dprime 4.5±0.3 3.2±1.3 ** 3.4±1.0 2.9±1.6 3.0±1.4 3.6±1.5 
Saccade Dprime 2.6±0.9 0.8±1.1 ** 0.7±0.9 1.0±0.8 0.5±1.2 1.1±1.4 
 
Stats indicate Student’s T-test results comparing imaged controls (N=28) and patients (N=67) *p<0.05, **p<0.001, **survives Bonferroni correction for 
multiple comparison. 
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Figure 19: White Matter Diffusion Tensor Imaging Correlates of Components 2-4. 
A) Correlates of carer rated change in everyday skills and self care (component 2: yellow-
red) and carer rated change in complex behaviours (component 3: green-blue) in terms 
of (i) mean diffusivity and (ii) fractional anisotropy. Higher scores correlated with 
increased mean diffusivity and decreased fractional anisotropy. B) Mean diffusivity 
correlates of patient performance on objective measures, including the motor and 
saccadic Go/NoGo, IST and CRRT (Component 4). Higher scores correlated with 
increased mean diffusivity. Correlations between the skeletonised DTI-based tracts and 
the components were assessed by non-parametric permutation analysis using FSL 
randomise with Threshold-Free Cluster Enhancement (TFCE) correction, 2D 
optimisation and 5000 permutations. Cluster significance was tested at A) p<0.01 and B) 
p<0.05.  
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5.4 Discussion 
Diffusion tensor imaging confirmed that distinct spatial distributions of white matter tract 
pathology are related to the separate dimensions of apathy and impulsivity, across multiple 
FTLD syndromes. Carers’ ratings of both apathy and impulsivity (Component 3, Figure 19) 
were associated with changes in the white matter tracts connecting ventro-lateral and 
orbitofrontal cortex and temporal poles. In contrast, carers’ ratings of everyday skills, self care 
and apathy (Component 2, Figure 19) correlated with changes in widespread frontal, parietal 
and corticospinal tracts. The objective behavioural tasks of cognitive control (component 4) 
were associated with abnormal white matter connecting the pre-supplementary motor area (pre-
SMA) and lateral prefrontal cortex. The use of tract-based statistics overcomes the limitations 
of voxel-based morphometry used previously to study white matter changes in FTLD326,354, 
especially in populations in which regional atrophy can be severe. There were no significant 
DTI correlates for patient ratings (component 1), in contrast to VBM of white matter which 
revealed correlations with the corticospinal tracts. Potential explanations for these findings are 
discussed below. 
 
The abnormalities of white matter tracts associated with challenging behaviours related to 
apathy and impulsivity (Component 3: AES, NPI disinhibition subscore, and CBI 
abnormal/stereotypic behaviours, eating habits, and motivation subscores), are consistent with 
previous studies of individual disorders relating disinhibition and apathy separately to white 
matter tracts and metabolic activity in these frontotemporal regions100,102,144,164,317100,102. Apathy 
is also reported after anterior cingulate cortex damage due to focal lesions113,355, small vessel 
disease97, neurodegeneration144 and ageing167, while change in the uncinate fasciculus is 
associated with apathy in Alzheimer’s165, small vessel disease97, PSP327, bvFTD164 and normal 
ageing351.  
 
The tract-based statistics were broadly consistent with voxel based volumetry of FTLD354 
suggesting parallel breakdown of frontotemporal circuits for motivation and goal directed 
behaviour13,144,166,342,356. One difference to note is the absence of a tract-based deficit in relation 
to patients’ observations of their own symptomatology, in contrast to the earlier VBM analysis 
of white matter (Chapter 4 and 354). There are a number of possible explanations for this 
discordance. First, patient ratings may reflect heterogeneous, multifocal changes in white 
matter, which prevent the identification of any consistently localized tract correlate. Second, 
VBM and DTI assess fundamentally distinct neural changes (tissue volumetric loss versus the 
diffusional integrity of white matter connections respectively), and may therefore give rise to 
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different results. For example, patient ratings may reflect changes in deep white matter 
structures which are not captured by DTI but are apparent volumetrically. Third, this difference 
may reflect the limitations of white-matter VBM326, including normalisation errors,  
mislocalisation errors and the partial-volume effects of smoothing, which can give rise to false 
positives. The current tract-based method is less vulnerable to these issues, although there are 
potential limitations to tract-based methods and the interpretation of DTI, discussed below. 
 
With the current imaging and statistical modelling methods, the significant white matter 
changes appear to extend beyond significant grey matter atrophy. For example, component 4 
revealed white matter changes extending to the right frontal cortex, while grey matter changes 
were localized to posterior cortical and subcortical regions (Chapter 4)354. This difference may 
be due to differential signal-to-noise of the methods, but may also indicate that white matter 
dysfunction represents a core pathophysiology in FTLD332 . I suggest that disruption to neural 
circuits for selection and initiation of goal directed behaviour and motivation, give rise to apathy 
and disinhibition245,352 and account for their clinical coexistence in FTLD syndromes. 
 
Carer rated change in everyday skills, self-care, motivation and apathy (Component 2: CBI, 
AES and NPI apathy), correlated with widespread white matter changes including the centrum 
semiovale and corticospinal tracts, forceps major, superior and inferior longitudinal fasciculus, 
inferior fronto-occipital fasciculus and corpus callosum. In contrast to component 3, there was 
less in terms of significant frontotemporal involvement (see MD images, Figure 19A). This 
supports previous DTI studies showing (i) degeneration of the brainstem and association and 
commissural fibres in PSP, with significant white matter change in the superior cerebellar 
peduncles, body of the corpus callosum, inferior longitudinal fasciculus, and superior 
longitudinal fasciculus334; (ii) CBS changes in frontoparietal connecting fibres, intraparietal 
associative fibres, sensorimotor fibres of the hand cortical representation, and body and 
splenium of the corpus callosum335 and (iii) widespread changes in FTD345,346.  
 
The widespread white matter correlates support the concept of network based disruption in 
FTLD16,245,271,357, as opposed to focal areas of damage. However, widespread changes 
associated with carer reports may also reflect their inability to discriminate between syndromes 
of goal directed behaviour using these questionnaires.   
 
Although Component 4 showed weaker correlations with FA and MD, its correlates are of 
particular interest. First, all patient groups scored higher on average than controls (see Figure 
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16), confirming the objective neuropsychological deficits as a transdiagnostic deficit, not driven 
by single diagnostic groups. Second, the poor performance on decision making, cued 
reinforcement and response inhibition reflected unilateral FA changes in connections of the 
right pre-SMA, dorsolateral prefrontal cortex and inferior frontal gyrus. These regions are 
strongly associated with cognitive control and goal-directed behaviour in preclinical models 
and human studies358. Effective inhibitory control is mediated by cortical and subcortical 
connections between the pre-SMA, prefrontal cortex, inferior frontal gyrus and subthalamic 
nucleus129,211,255,272,359 and reduced connectivity among these regions impairs response 
inhibition360 and  choices between alternate actions145,361. Component 4 also correlated with 
changes in the occipital lobe, which may reflect shared dependency of the behavioural tasks on 
rapid visual processing.  
 
Components 2-4 correlated with cognitive and functional decline (Table 13). Previous studies 
have reported a link between apathy and poor outcome83,84,95,97, with rapid cognitive and 
functional deterioration in apathetic patients compared to non-apathetic and depressed 
individuals82. Further investigations assessing the prognostic implications of apathy and 
impulsivity in FTLD syndromes are warranted (see Chapter 6). Apathy may represent a marker 
of rapid cognitive decline and a potential target for disease-modifying treatment intervention 
(Chapter 6 and 7). 
 
There are several limitations to this study, including caveats to the imaging and behavioural 
methods. DTI is an indirect measure of the physical properties of white matter connections, 
such as axon density, calibre, and myelination336,362. Despite this limitation, DTI provides in 
vivo, semi quantitative measures that provide important anatomical insights into the human 
brain which can be cross-validated in animal models. For example, preclinical studies link 
fractional anisotropy to myelination, membrane permeability and fibre density in white 
matter337,363,364. However, comparative studies of anatomy across species and in FTLD post 
mortem are required to determine the pathological mechanisms of the observed imaging 
changes. Although different DTI metrics may reflect distinct processes (for example 
demyelination, neurodegeneration, gliosis, calcification, and axonal degeneration), linking 
them to specific leucopathologies remains challenging. One must also consider artefacts from 
motion and registration errors, as multiple directional measurements are obtained at each voxel, 
introducing false-positive differences especially if movement differs by group365. Registration 
also poses significant challenges for analysing disease groups with highly atrophic brains, 
obscuring some tracts. Registration errors may affect the absolute diffusivities or eigenvalues, 
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mimicking the effects of pathology344. White matter change in areas with substantial grey 
matter may lead to changes in estimated FA that reflect differences in the relative amounts of 
tissue types rather than change in white matter326. 
 
5.5 Conclusion 
In conclusion, white matter is markedly abnormal in FTLD syndromes. Diffusion tensor 
imaging is highly sensitive to the white matter changes underlying FTLD-associated 
behaviours, and revealed distinct spatial profiles of FA and MD relating to different 
components of apathy and impulsivity. White matter abnormalities extended beyond grey 
matter change, adding to the growing literature reporting white matter dysfunction as a core 
pathophysiology in FTLD.  
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Chapter 6 | Prognostic Implications of Apathy and Impulsivity in 
Frontotemporal Lobar Degeneration Syndromes. 
 
In this chapter, I employ logistic regression analysis to examine the impact of the apathy and 
impulsivity components (Chapter 3) on prognosis and survival in the PiPPIN cohort.  
 
6.1 Introduction  
Dementia causes functional decline and ultimately leads to early mortality. In FTLD disorders, 
some studies report striking similarities in survival rates across behavioural and language 
variants of frontotemporal dementia366, while others report longer survival rates for svPPA (10-
12 years) than bvFTD (5-8 years)19,200,367. Shorter survival is typical in PSP (typically 5-7 years) 
19,368 and CBS (typically 6-8 years)367, while FTD with motor neurone disease (FTD-MND) is 
associated with the shortest survival rates (2-5 years)200,366,367.  
 
Overall, FTLD syndromes are associated with reduced median survival and faster rate of 
cognitive and functional decline compared to Alzheimer’s disease (AD)366,367,369, which is more 
striking in view of the younger median age of onset. This suggests that degeneration of frontal–
subcortical circuits in FTLD may have greater influence on mortality than AD related atrophy 
of parieto-temporal circuits367. Indeed, predominant frontal atrophy has been liked to fast-
progressing FTLD cases, while patients with predominant temporal lobe atrophy progress at a 
similar rate to those with AD370. 
 
Variations in the estimated survival rates in part reflect the use of clinical versus 
neuropathological cohorts. Clinical cohorts of FTD report 7-13 years median survival from 
diagnosis367,371 while neuropathological series report 6-8 years366,372. Poor clinicopathological 
correlations leading to diagnostic inaccuracy, and the inclusion of non-progressive 
“phenocopy” patients58, who present clinically with superficial bvFTD-like behaviour but have 
normal structural and metabolic imaging, may account for varied and higher survival rates 
among some clinical cohorts. Indeed, the removal of 24 “phenocopy” cases from a cohort of 91 
clinical bvFTD cases caused the median survival to drop from 9.0 years from onset and 5.4 
years from diagnosis to 7.6 and 4.2 years respectively371. Broad convergence of syndromes with 
disease progression further hinders accurate estimation of survival in clinical cohorts. Instead, 
survival should be considered across the unitary continuum of FTLD.  
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Despite improved knowledge of the clinical features and neuropathological hallmarks of FTLD 
syndromes, their influence on survival is unclear. Predicting disease progression and patient 
trajectories therefore remains challenging and the mechanisms underlying variations in survival 
rates remain elusive. Previous studies have reported minor or null-associations between 
survival and patient demographics, a positive family history and dementia severity at the time 
of diagnosis57,366,367,373.  
 
Neuropathological studies have led to increased fractionation of FTLD syndromes, but the 
influence of distinct pathologies on survival remain unclear, with both tau-positive and tau-
negative cases correlating with reduced survival366,367,372,374,375. Although variations in the 
survival rates across clinical phenotypes have been reported, diagnosis alone is not strongly 
predictive of survival in some series373, except for FTD-MND.  
 
Apathy has been associated with worse outcomes across a range of neurological, psychiatric 
and medical conditions including Alzheimer’s Disease91,92, stroke87,94–97, Huntington’s 
Disease93, Parkinson’s Disease83,88,91 FTLD syndromes92,99–103, head injury98 and pre-dementia 
states82–84. Apathy is linked to decreased functioning84,94, caregiver distress104, cognitive 
decline83,105,106, increased dementia conversion rates82,84, poor response to 
treatment/rehabilitation94,107, reduced quality of life97 and poor prognosis108. The direct 
influence of apathy and related behaviours on survival rates has received less attention373,376,377.  
 
The link between apathy and increased morbidity and mortality suggests that apathy may 
represent a clinical biomarker of disease severity and a predictor of poor prognosis. The ability 
to predict survival rates among the FTLD syndromes and subsequently stratify patients into 
rapid and slow progressors would be important for defining disease outcomes, informing 
sample size calculations for future clinical trials and monitoring disease modifying 
therapeutics378. Predicting survival trajectories for newly diagnosed patients will guide clinical 
management, including patient care and caregiver counselling. Furthermore, in view of the 
negative influence of apathy on survival, effective intervention may prove to be “disease 
modifying”.  
 
Here, I use the PiPPIN cohort to test the hypothesis that neurobehavioural components of apathy 
and impulsivity are significant predictors of survival. I employ logistic regression to estimate 
the probability of death occurring within 2.5 years (30 months, 913 days) from PiPPIN 
assessment. Logistic regression estimates the probability of an event occurring; if the modelled 
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probability is greater than or equal to 0.5, then the model classifies the event as occurring while 
probabilities lower than 0.5 are classified as not occurring. By comparing modelled 
classification to real-world data, one can determine whether the model can correctly classify 
patients based on the chosen independent/predictor variables.  
 
For this analysis, predictor variables included age at assessment, gender, cognitive status (ACE-
R), collapsed diagnosis (PSP, CBS, PPA, bvFTD) and the eight principal neuropsychological 
components identified in chapter 3. In view of previous studies highlighting the importance of 
apathy and related behavioural change over demographics, diagnosis and cognitive status, I 
hypothesised that the neurobehavioural components would be most influential on survival. 
Specially, I hypothesised that the major carer-rated components [two and three], which 
reflected widespread neural changes on VBM and DTI would significantly predict death. 
 
6.2 Methods 
6.2.1 Cohort  
Of the 149 PiPPIN patients included in the PCA, 129 patients (PSP 38, CBS 31, PPA 33, bvFTD 
27) were included in a logistic regression analysis to determine survival at 2.5 years post 
PiPPIN assessment. The occurrence and date of death were obtained using the NHS SPINE, an 
electronic register of all NHS patients. Exclusion was due to insufficient complete data for 
logistic regression (eg. limited cognitive/functional, self-rated, carer rated or behavioural 
assessment). Cohort numbers differed slightly depending on the chosen survival cut off and are 
reported in the results. Logistic regression removes cases with missing data “list-wise” by 
default. Therefore, the inclusion of multiple predictor variables (each of which may have a 
small but finite percentage of missing data) results in the additional exclusion of patients.  
 
Kaplan-Meier Survival curves were used to illustrate survival, by diagnostic group. Survival 
rates at 24 and 36 months are also presented, but the principal outcome assessment refers to 30 
months’ survival due to near equal sample sizes across groups (deceased=53 and alive=63). 
Death rates by group were compared by chi-squared test. Logistic regression was used to 
identify predictors of survival.  
 
6.2.2 Logistic Regression  
Logistic regression was carried out using the “Enter” method in SPSS v22. Predictor variables 
included age at assessment, gender, cognitive status (ACE-R), collapsed diagnosis (PSP, CBS, 
PPA, bvFTD) and the eight principal components. In order to predict survival at 30 months, 
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patients were classified as “dead (1)” or “alive (0)” using a cut off of 913 days. Patients who 
were alive but had not yet lived 2.5 years from their PiPPIN assessment were classified as 
“insufficient follow up time (13)” and were excluded from the analysis. 
 
Overall fit of the model was determined by the -2log-likelihood statistic and its associated chi-
square statistic, using a threshold of p<0.05 (indicating significant fit of the data). Cox and 
Snell’s R2 values provided an additional indication of model effect size. The influence of the 
independent variables on predicting outcome (death within 2.5 years) were determined by the 
significance of the Wald statistic (p<0.05). Additional information regarding the directionality 
of effect was provided by the odds ratio [Exp(B)]; values >1 indicate increasing odds of 
outcome occurrence (death) with increased values of the predictor variable while values <1 
indicate decreasing odds of outcome occurrence with increased values of the predictor variable. 
Confidence intervals of the Exp(B) values were used to confirm the direction of the relationship 
in the population. 
 
Classification accuracy of the final model was compared to the baseline model (baseline model 
[constant only] % – new model [all predictor variables] %) to determine whether inclusion of 
the independent variables resulted in significant model improvement.  
 
Sensitivity (the percentage of cases that have the observed characteristic and were correctly 
predicted by the model (true positives)) and specificity (the percentage of cases that did not 
have the observed characteristics and were correctly predicted as not having it (true negatives)) 
of the model were also calculated (Positive predictive value=Number of true positives/[number 
of true positives+number of false positives], Negative predictive value=Number of true 
negatives/[Number of true negatives+number of false negatives]). 
 
Residuals were examined to confirm model fit. Statistics included: standardized residuals to 
measure the model fit to the sample data (<1% of observations ±2.58); Cook’s distance to 
measures the overall influence of an individual case on the model (values <1); and DFBeta 
statistics to measure the influence of a case on the values of b (values <1)379. 
 
6.3 Results 
6.3.1 Cohort 
Of the 129 patients included in the survival analysis, 53 had died at 30 months post assessment, 
including 23 PSP, 16 CBS, 5 PPA and 9 bvFTD. Sixty three patients were classified as “alive” 
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at 30 months after assessment, while thirteen patients were excluded from the analysis due to 
“insufficient follow up time” between assessment date and the current analysis date to 
determine survival within this time frame, leaving 116 patients total for analysis. A further 28 
cases were removed list-wise during the logistic regression due to missing data of interest 
leaving 88 to be included in the logistic regression. The survival subset (N=88) were 
representative of the PCA patient subset (N=149), with no significant differences in terms of 
age, gender, diagnosis and cognitive status (see Table 17).  
 
Table 17: Comparison between Patients Included in the Logistic Regression Cohort and 
those Excluded 
 Excluded (N=61) Included (N=88) T-stat or 2* P Value 
Age 70.48.6 69.78.0 0.46 0.65 
Gender 
Male:37 
Female:26 
Male:39 
Female:47 
2.61* 0.11 
Diagnosis 
PSP:15 
CBS:16 
PPA: 16 
bvFTD 16 
PSP: 26 
CBS: 21 
PPA: 23 
bvFTD: 16 
1.36* 0.71 
Cognitive Status 
(ACE_R) 
72.123.2 63.822.6 0.54 0.59 
 
The number of deaths were also calculated at 24 and 36 months (Figure 20). Of the 129 patients 
included in the survival analysis, 45 had died at 24 months, including 22 PSP, 12 CBS, 3 PPA 
and 8 bvFTD and 1 with insufficient follow up time. At 36 months, 58 patients had died 
including 24 PSP, 19 CBS, 6 PPA and 9 bvFTD and 32 with insufficient follow up time. Of 
those who were alive at 24 months, 16 had subsequently died and of those alive at 36 months, 
3 had since died.  
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Figure 20: Percentage of PiPPIN Patients Deceased at 24, 30 and 36 Months Post 
Assessment. 
 
Death rates were highest at all time points for PSP patients, followed by CBS, bvFTD and 
PPA (Figure 21). At 30 months (the time point used in the logistic regression analysis), 23 
PSP patients, 16 CBS, 9 bvFTD and 5 PPA patients had died. 
 
Figure 21: Mortality by Diagnostic Group  
Death rates by diagnostic group at 24, 30 and 36 months: PSP (58%, 66%, 80%), CBS 
(39%, 55%, 73%), bvFTD (30%, 41%, 53%), and PPA (9%, 17%, 25%). Note that cases 
with insufficient follow up time are excluded from each time point.  
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Survival rates from PiPPIN assessment and from symptom onset were significantly different 
depending on the diagnostic group (see Figures 22 and 23). Kaplan-Meier survival curves 
showed significant differences in survival from PiPPIN assessment (Log Rank [Mantel-Cox] 
χ2=22.960, df=3, p<0.001, pairwise comparisons revealed significant differences for PSP vs 
PPA (χ2=19.0, p<0.001), PSP vs bvFTD (χ2=7.5, p<0.01), CBS vs PPA (χ2=13.8, p<0.001), and 
CBS vs bvFTD (χ2=4.7, p<0.05)). Kaplan-Meier survival curves also showed significant 
differences in survival patterns across diagnostic groups from symptom onset (estimate based 
recall of initial relevant symptoms) (Log Rank [Mantel-Cox] χ2=18.8, df=3, p<0.001, pairwise 
comparisons revealed significant differences for PSP vs PPA (χ2=11.7, p=0.001), PSP vs bvFTD 
(χ2=5.1, p<0.05), CBS vs PPA (χ2=14.0, p<0.001), CBS vs bvFTD (χ2=5.9, p<0.05).  
 
 
 
Figure 22: Kaplan-Meier Survival Curves from PiPPIN Assessment.  
Log Rank [Mantel-Cox] χ2=22.960, df=3, p<0.001, pairwise comparisons revealed 
significant differences for PSP vs PPA (χ2=19.0, p<0.001), PSP vs bvFTD (χ2=7.5, p<0.01), 
CBS vs PPA (χ2=13.8, p<0.001), and CBS vs bvFTD (χ2=4.7, p<0.05). 
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Figure 23: Kaplan-Meier Survival Curves from Onset.  
Log Rank [Mantel-Cox] χ2=18.8, df=3, p<0.001, pairwise comparisons revealed significant 
differences for PSP vs PPA (χ2=11.7, p=0.001), PSP vs bvFTD (χ2=5.1, p<0.05), CBS vs 
PPA (χ2=14.0, p<0.001), CBS vs bvFTD (χ2=5.9, p<0.05). 
 
6.3.2 Logistic Regression 
Including all predictors in the model resulted in a significant fit to the model (-2 log 
likelihood=88.401, χ2=29.9, df=14, p=0.008, Cox & Snell R2=0.288, Nagelkerke R2=0.390). 
Model classification accuracy improved from 60.2% at baseline (including only a constant) to 
73.9% following inclusion of the predictor variables. The model correctly classified 43 as alive 
while incorrectly classifying 13, and correctly classified 22 as dead while incorrectly classifying 
an additional 10, resulting in a positive predictive value of 81% and negative predictive value 
of 63% (PPV = 43/ 43+10 = .811, NPV = 22/22+13 = .629).  
 
Of the predictor variables, Component 2 was the most significant predictor of death within 2.5 
years from PiPPIN assessment (Wald Statistic=8.119, p=0.004, Exp(B)=2.912, C.I.=>1 [1.396-
6.075]; Table 18). An Exp(B) value>1 (and confidence intervals both>1) indicated that 
increases in Component 2 (weighted towards carer rated AES, NPI-apathy and CBI everyday 
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skills, self care, sleep and motivation) significantly increased the odds of death within the 2.5-
year time period. Note that Component 2 was the most significant predictor of death across all 
three time points (subsidiary analyses). Component 8 was also significant at the p<0.05 level. 
Age at assessment had only a trend towards significance. Examination of the residuals 
confirmed model fit: standardised residuals were all within +/-2.58, Cook’s distance and 
DFBeta values were <1. 
 
6.4 Discussion  
This study confirms the deleterious effect of apathy on patient survival in the major syndromes 
associated with FTLD. Component 2, representing carer ratings of apathy (as weighted towards 
the Apathy Evaluation Scale and Neuropsychiatric Inventory Apathy subscores) and functional 
decline in everyday skills, self-care, sleep, and motivation (as measured by the respective CBI 
subscores), was the most significant predictor of death within 30 months from PiPPIN 
assessment (Wald stat=8.119, p=0.004, see Table 18), even after adjusting for diagnostic group 
differences in the model.  Demographics (age, sex) and cognitive performance (ACE-R) did 
not significantly predict survival, in keeping with previous studies367,373. Over two and a half 
years, 53 (41%) of FTLD patients died, with survival ranging from 22 to 910 days post 
assessment (PSP 64-881 days, CBS 22-791 days, PPA 308-910 days, bvFTD 261-761 days). 
Kaplan-Meier curves revealed significant differences in survival across groups (Log Rank 
[Mantel-Cox] χ2=22.960, df=3, p<0.001), with pairwise comparisons highlighting differences 
between CBS versus bvFTD and PPA and PSP versus bvFTD and PPA groups (See Figure 22 
and 23). Death rates were highest for PSP patients (N=23), followed by CBS (N=16), bvFTD 
(N=9) and PPA (N=5), consistent with the full PiPPIN cohort19.  
 
These findings add to the growing literature emphasizing the prognostic importance of 
behavioural change in FTLD syndromes, over and above demographics, cognitive status and 
diagnostic classification373,377,380. Borroni et al (2007) classified FTLD patients into specific 
phenotypes using latent profile analysis; “pseudomanic behaviour”, “cognitive”, and 
“pseudodepressed” on the basis of neuropsychiological, functional and behavioural data381. 
They subsequently showed that prognosis and survival was significantly worse in the 
“pseudomanic” group, who exhibited greater behavioural disturbances, disinhibition and 
abnormal social conduct373. In line with previous studies, “pseudodepressed” patients had the 
best prognosis over time373. Although apathy and depression often co-occur and may even be 
confused by observers, it is apathy, but not depression, that is most associated with poor 
outcomes and increased cognitive and functional decline towards dementia82,382. This likely 
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reflects the distinct underlying neurobiology and neurocircuitry of apathy and depression97,141. 
Clearly the neural correlates of apathy, including disruption to numerous cortico-subcortical 
networks connecting the prefrontal cortex to the basal ganglia (Chapter 4 and 5)111, are more 
closely related to sustained survival. 
 
The influence of dysexecutive syndrome on survival is further emphasised by the observation 
that comorbid FTD-ALS patients survive up to a year less than patients with ‘motor only’ 
symptoms383. Apathy is common in ALS, affecting 40-80% of patients108, and may often 
precede motor symptoms384. Recent studies suggest apathy is an independent, negative 
prognostic factor in ALS, significantly predicting survival even after controlling for clinical 
factors and symptom duration at study entry. Median survival of patients with moderate to 
severe apathy is significantly shorter than those with both mild apathy and no apathy (21.7 vs 
49.9 months vs 51.9 months respectively, p=0.0001)108. 
 
Voxel based morphometry of component 2 (chapter 4) revealed marked white matter atrophy 
of the brainstem, also extending to frontal regions, while widespread grey matter changes were 
observed both subcortically and throughout the middle to posterior cortical areas. Similar neural 
correlates were observed using diffusion tensor imaging, including extensive white matter tract 
abnormalities extending from subcortical to cortical areas, with a predominant middle-posterior 
focus (chapter 5). Patients with PSP and CBS scored highly on component 2, in line with 
previous studies suggesting patients with Pick’s disease survive longer than those with PSP and 
CBD pathology due to differences in the rate of brainstem degeneration12,305,306. Predominant 
bulbar symptoms, reflective of brainstem pathology, are recognised to increase the likelihood 
of death by choking and aspiration12. However, frontal atrophy has also been linked to poor 
outcomes in CBS377, PSP166 and FTD367. Across FTLD, the “pseudomanic” phenotype 
classified by the Borroni cohort and linked to reduced survival, demonstrated greater 
hypoperfusion of the orbitomesial frontal cortex. Greater frontal subcortical dysfunction, which 
often gives rise to behavioural changes such as apathy, may be an important predictor of 
increased mortality. Indeed, frontal lobe symptoms, including apathy, disinhibition or 
irritability, reduced survival in a sample of confirmed CBD cases377. Whether specific 
pathologies underlying dysfunction and atrophy in these brain regions influence survival is 
unclear, with available studies reporting inconsistent results367,372,374.  
  
 
1
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Table 18: Logistic Regression Assessing the Influence of Predictor Variables on Survival 2.5 Years Post PiPPIN Assessment 
Variables  Wald Statistic 
Degrees of 
freedom 
Exp (B) Significance 
95% C.I. for Exp(B) 
Lower Upper 
ACE-R total score 0.095 1 0.995 0.758 0.967 1.025 
Age at assessment 3.601 1 1.077 0.058 0.998 1.162 
Sex 0.027 1 1.096 0.871 0.365 3.293 
Diagnosis Collapsed 1.855 3 - 0.603 - - 
    Diagnosis 1 1.080 1 1.710 0.299 0.622 4.705 
    Diagnosis 2 0.012 1 0.940 0.912 0.312 2.828 
    Diagnosis 3 1.274 1 0.518 0.259 0.165 1.625 
PC1 2.913 1 1.646 0.088 0.929 2.919 
PC2 8.119 1 2.912 0.004** 1.396 6.075 
PC3 1.849 1 1.474 0.174 0.843 2.580 
PC4 0.093 1 0.880 0.760 0.386 2.006 
PC5 1.188 1 1.290 0.276 0.816 2.038 
PC6 1.572 1 1.377 0.210 0.835 2.272 
PC7 2.653 1 .672 0.103 0.416 1.084 
PC8 4.354 1 .509 0.037* 0.270 0.960 
Constant 4.321 1 .002 .038 - - 
Bold figures highlight significant predictors of death 2.5 years (30 months) post PiPPIN assessment (**p<0.01, *p<0.05). Key: C.I. confidence intervals, PC 
principal component. Degrees of freedom is equal to the number of parameters in the model. 
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The non-significant influence of cognitive status on survival is of interest, and complements 
previous studies emphasizing the importance of behavioural features rather than cognitive 
decline as a marker of disease progression and prognosis373,380. The relationship between apathy 
and cognition is complex: does apathy cause cognitive worsening or is apathy a marker of 
cognitive worsening? In pre-dementia states, apathetic patients consistently show rapid 
cognitive and functional decline and increased dementia conversion rates compared to non-
apathetic groups with no neuropsychiatric features82–84. In a small PD sample, eight of twenty 
apathetic patients converted to dementia, compared to one of twenty non-apathetic patients, 
after a median of eighteen months follow up83. Even in those who did not develop dementia, 
apathetic groups showed significantly greater cognitive decline, specifically in terms of 
executive function deficits in response inhibition and action initiation, emphasising the link 
between cognition and apathy. In an MCI/AD sample, patients with apathy, specifically of the 
type causing lack of interest as measured by interview or the Apathy Inventory lack of interest 
dimension, had a greater risk of conversion to dementia over three years, even after controlling 
for potential confounds including age, gender, education and episodic memory performance385. 
Vicini Chilovi et al., (2009) reported dementia conversion rates as high as 60% in apathetic 
MCI patients, compared to 7.9% for depressed MCI and 24% for MCI normal over two years. 
In a study of 131 memory-clinic outpatients with amnestic MCI, patients with apathy had close 
to a seven fold risk of AD progression compared to those without apathy, even following 
adjustment for age, gender, education, baseline global cognitive and functional status and 
depression382. The consistently reported link between apathy and dementia conversion suggests 
successful intervention may alter patient trajectories and delay onset of full blown dementia, 
consequently influencing survival. Addressing this will require development of more effective 
symptomatic treatments targeting the underlying causes of apathy. 
 
In line with previous studies of FTD367,373, diagnostic classification was also not a significant 
predictor of survival, suggesting that the use of predefined clinical criteria for FTLD syndromes 
are unhelpful for prognostic purposes in clinical practice373. Instead, the presence and severity 
of apathy across the spectrum of FTLD disorders largely determines survival, which suggests 
that the remaining features that underlie diagnosis (but are not captured by the components) do 
not influence prognosis. Therefore, I suggest that significant differences in prognosis and 
survival across syndromes (Figure 22 and 23) are driven by the phenotypic features measured 
by component 2, or their neurobiological correlates. Whether the relationship between apathy 
and mortality is causal or correlational is yet to be clarified. Apathy may cause rapid decline to 
death or may represent a marker of other underlying factors that correlate with both apathy and 
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survival, such as brainstem degeneration (neural correlate of component 2). Here, I do not 
present proof of causality, but the relationship between apathy and survival raises the 
hypothesis that treating apathy would improve outcome. To address this, studies are warranted 
to treat apathy either at the behavioural level (symptomatic) or by targeting the underlying 
correlates of apathy, in terms of neural changes (disease modifying). 
 
The observation that diagnosis is not predictive of survival provides additional support for the 
transdiagnostic approach adopted by this study and has direct implications for the design of 
future clinical studies. I propose that emphasis should be placed on recruiting patients who 
present with apathy, or in this case patients who score highly on measures captured by 
component two, rather than focusing on diagnostic labels that require the presence of 
behavioural changes as part of the clinical criteria. Component two was abnormal across 
diagnostic groups, with particularly high scores in PSP and CBS groups, reflecting high 
endorsement of apathetic behaviours and ultimately reduced survival in these patients. 
Profound apathy and associated behavioural changes are increasingly recognised in PSP and 
CBS5,14,201,322, despite being largely overlooked due to predominant motor impairments. In a 
pathological cohort of fourteen CBD patients, frontal lobe symptoms were the initial 
manifestation in 20% of cases377, highlighting the importance of early behavioural changes. 
Apathy has also been associated with executive dysfunction and worse outcomes in PSP319,386. 
 
A number of limitations should be acknowledged. Inherent to all clinical studies estimating 
survival in FTLD syndromes is the variable clinic-pathological correlations, resulting in 
potential misdiagnosis and thereby inaccurate within-syndrome estimates. A recent study 
reported correct clinical diagnosis of PSP in 25% of pathologically proven cases at first visit, 
and 63% at last visit, highlighting that PSP is underdiagnosed15,49, even though PSP-RS has 
very high predictive value for PSP pathology. Reports of syndrome-specific survival rates are 
therefore likely pathologically heterogeneous. Here, I included collapsed diagnostic groups of 
PSP, CBS, bvFTD and PPA in the logistic regression and acknowledge that the clinical 
diagnosis does not confirm the underlying cause of disease.  
 
Logistic regression removes cases list-wise, reducing the power of the analysis. Due to the 
nature of neurodegenerative diseases, some patients are too severely impaired to be assessed 
cognitively. Missing variables resulted in the removal of the 28 patients from the analysis, 
despite recorded behavioural changes, demographics and diagnosis. Although methods such as 
multiple imputation can be employed to estimate scores based on other available measures, they 
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are not without limitations and are uncommon in logistic regression. Importantly, missing data 
are often not missing at random, as those who do not complete an ACE-R are often too impaired 
to do so. Missing data can therefore often be informative in itself.       
 
6.5 Conclusion 
In conclusion, apathy and related behavioural change (component 2) in FTLD syndromes 
significantly predict death within 2.5 years from assessment, while demographics, diagnosis, 
and cognitive status do not. The prognostic importance of high scores on component 2 suggests 
these neurobehavioural components may provide a means to effectively predict survival and 
stratify patients for clinical trials, for example into apathetic (rapid progressor) and non-
apathetic (slow progressor) groups. The irrelevance of diagnosis for predicting survival 
suggests that currently available diagnostic criteria are unhelpful in clinical practice for this 
purpose387. Identification and enrolment of subjects at greater risk of disease progression, such 
as in those with high scores of component 2, or belonging to the “pseudomanic” group 
identified by Borroni et al (2007, 2009), would maximise power to detect a therapeutic effect 
and dramatically decrease the number of patients needed for power calculation. Finally, the 
prognostic importance of apathy highlights the need to develop more effective and targeted 
measurement tools to improve recognition and provide outcome measures for clinical studies. 
Clearly the neural correlates of apathy bear some relationship to prognosis, suggesting the 
implicated neural systems are essential for sustained survival. This raises the possibility that 
effective symptomatic interventions targeting the neurobiology of apathy may also be disease 
modifying, and improve prognosis. 
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Chapter 7 | Thesis Discussion 
 
This thesis provides support for maintaining the clinical and pathological variants of FTD, PSP 
and CBS under a unitary umbrella term based on the pathology within the FTLD spectrum. 
Despite progress in the clinical, pathological, and genetic fractionation of the disorders, the 
PiPPIN data confirm extensive overlap and convergence of syndromes. Their heterogeneity and 
overlap is also recognised for example in the recently developed International Movement 
Disorder Society diagnostic criteria for PSP15, which define multiple clinical syndromes 
associated with a PSP pathology, moving away from a predominantly motor disorder to a 
complex disorder of cognitive, behavioural and motor changes49,59. Critical for this study is the 
recognition of a frontal variant of PSP, which presents with predominant behavioural changes 
such as apathy and impulsivity.  
 
Clinicopathological correlations vary across FTLD syndromes and misdiagnosis is also 
common. This is one reason why several of the newly developed criteria incorporate different 
levels of diagnostic certainty including “possible”, “probable” and “definite”. Advances in 
neuroimaging techniques may facilitate improvements in diagnostic accuracy, but for now 
pathological studies are required for diagnostic confirmation.  
 
Although there are clear differences between the FTLD syndromes in their classical forms, 
there are also similarities, particularly with regard to behavioural changes. This thesis does not 
attempt to undermine the significant advances within each of the conditions, including the 
development of syndrome-specific diagnostic criteria, identification of neuroimaging 
signatures and classification of pathological distinctions. However, the categorical approach to 
diagnosis may be inappropriate for advancing our understanding of symptom commonalities 
and their treatment, which may benefit from the transdiagnostic approaches adopted throughout 
this thesis.  
 
Specifically, this thesis reports the characteristics, components and neural correlates of apathy 
and impulsivity in FTD, CBS and PSP. The data presented are largely concordant with the 
literature and add to the growing body of research highlighting the multifactorial nature of 
apathy and impulsivity.  
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This thesis reports four critical findings specific to FTLD syndromes, in relation to the initial 
hypotheses:  
1) apathy and impulsivity are multifaceted constructs, positively correlated, and 
observed across the spectrum of FTLD syndromes. 
2) patient ratings, carer ratings and objective measures do not correlate, reflecting 
distinct aspects of apathy and impulsivity and dissociable neural systems. 
3) apathy and impulsivity reflect changes in both cerebral grey and white matter. 
4) apathy is a significant predictor of survival.  
 
7.1 Apathy and Impulsivity are Positively Correlated and Observed across FTLD 
Syndromes  
Apathy and impulsivity were positively correlated in the PiPPIN cohort, supporting a growing 
literature recognising their frequent coexistence100,102,224. This contradicts earlier proposals that 
apathy and impulsivity lie at opposite ends of a dopamine-dependent spectrum of motivation86 
and suggests additional non-dopaminergic mechanisms (discussed below in relation to 
treatments).  
 
Apathy and impulsivity were also prevalent across FTD, PSP and CBS, not only in syndromes 
for which they are diagnostic criteria. This has been reported previously. For example, svPPA 
often develop behavioural changes consistent with bvFTD19,30. Furthermore, newly developed 
criteria for PSP15 and CBS5 recognise a “frontal” variant with prominent behavioural change. 
The observation that apathy and impulsivity are present across the spectrum of FTLD 
syndromes has clinical and research implications. First, neurologists should not be overly bound 
by diagnostic criteria, but be aware of behavioural changes that may be masked by predominant 
motor changes in some disorders. Although diagnostic criteria are useful, they attempt to 
classify patients into distinct, clear cut categories which is not always appropriate in the context 
of FTLD. Indeed, some patients may meet criteria for multiple variants. With this in mind, 
clinical studies attempting to treat problematic behavioural changes may benefit from 
stratifying patients based on the presence and severity of symptoms, rather than diagnostic 
labels. By assessing behavioural change only in groups for which apathy and impulsivity are 
diagnostic criteria, for example, bvFTD and PSP, similar changes in language variants and CBS 
may be overlooked.  
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7.2 Patient ratings, Carer ratings and Objective measures do not Correlate, Reflecting 
Distinct Aspects of Apathy and Impulsivity and Dissociable Neural Correlates  
Measuring the multifaceted constructs of apathy and impulsivity poses a significant challenge 
and development of numerous assessment tools have led to variations in their reported 
prevalence across disease groups89,98,231,388. Subjective and objective measures may be 
unrelated196,241,252, consistent with the lack of correlation between questionnaires and 
behavioural tasks in the PiPPIN study (chapter 3). Although there are some studies reporting 
correlations between subjective questionnaires and behavioural tasks389, they likely reflect 
differences between healthy controls and disease groups (for example, self-report measures and 
behavioural tasks may correlate in the healthy population but characteristics such as cognitive 
decline and lack of insight may alter this relationship in disease groups). The observed lack of 
correlation between measures has implications for translation from preclinical to clinical 
populations. Clinical studies (particularly large scale clinical trials) often employ 
questionnaires which are cheap, quick and easy to use, while pre-clinical studies adopt 
behavioural tasks, for which homologous human tasks have been developed (for example, 
SST)233. The PiPPIN data suggests the components of apathy and impulsivity measured by the 
objective tasks may not readily relate to subjectively reported apathy and impulsivity in FTLD. 
Choice of appropriate and sensitive outcome measures are critical for clinical trials and more 
effective, disease-specific assessment tools for FTLD are therefore warranted. 
 
Cross-species translation rests on the concept of homologous tasks in preclinical models and 
clinical populations. This can successfully facilitate translational therapeutics, for example 
atomoxetine improves response inhibition (stop-signal task performance) in rodent, marmoset 
and human studies130,131,205,222,272. Methylphenidate and modafinil also have similar effects in 
humans and animal models233. Although standard research practice relies on animal models to 
provide key insights into the biological basis of various diseases, they may be inappropriate for 
diseases affecting social cognition and other high order cognitive processes, such as FTLD. 
Extrapolating such high order cortical functions across species from rodents to humans is 
difficult and remains controversial208, either because of lack of evidence of the function in 
animals, or major differences in regional cortical functions. For example, action cancellation 
on the SST is associated with the right inferior frontal gyrus in humans, whereas the 
orbitofrontal cortex, but not the infralimbic and prelimbic cortex, is implicated in animal 
studies233. In contrast to the frontal cortex, the subcortical (for example basal ganglia) structures 
appear largely conserved in evolutionary terms, allowing more direct comparisons across 
species233.  
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In this thesis, objective behavioural tasks loaded onto distinct, orthogonal components (Chapter 
3), providing evidence for the multifactorial nature of impulsivity208,216,219,232 and the differing 
sensitivity of the behavioural tasks to distinct components of impulsivity. For example, the SST 
and Go/NoGo are widely recognised to measure distinct aspects of response inhibition and 
reflect dissociable neuropharmacology; action cancellation (SST) is modulated by 
noradrenaline, while action inhibition (Go/NoGo) is influenced by serotonin. Accordingly, the 
SST and Go/NoGo loaded onto different components (Chapter 3) and reflected distinct 
underlying neural correlates (Chapter 4). Concordant with previous studies, the SST reflected 
changes in the right inferior frontal gyrus129,211,255,272, while the Go/NoGo related to other 
measures of disinhibition including reflection impulsivity (information sampling) and reward 
sensitivity (cued reinforcement) and correlated with multiple regions including the thalamus, 
lateral temporal cortex, posterior and dorsal-anterior cingulate cortex and parieto-occipital 
cortex (Chapter 4).   
 
The PiPPIN study data also revealed a discrepancy between patient and carer ratings of 
behavioural change, which has also been observed in PD390 and AD391. Discrepancies may 
reflect loss of patient insight; PD and AD patients demonstrate impaired self-awareness in 
multiple domains, based on discrepancy between patients and their caregivers392. Loss of 
insight is also reported across FTLD syndromes18. Caregiver distress may also contribute to the 
observed discrepancy. Merrilees et al., (2013) reported a correlation between apathy and 
caregiver emotional distress in bvFTD and svPPA103. Carer burden is reported to increase with 
disease progression in FTD, which may also account for higher ratings of apathy/impulsivity 
with increased cognitive decline128, although the exact relationship between apathy and 
cognition remains unclear90.  
 
In contrast, high correlations between patient and carer ratings have been reported for apathy 
in HD393 and ALS394, which may reflect retained patient insight in the early stages of disease 
(while motor features are predominant) or reduced caregiver burden in these groups. Indeed, 
severity of caregiver burden varies across groups and may account for the contrasting 
discrepancy results across dementia types128. While this thesis does not clarify the cause of 
discrepancy between carers and patients, it emphasizes the importance of outcome measure 
selection for clinical trials. 
 
The discrepancy between carer and patient insights raises an important issue; are we to treat the 
patient or the carer? Routine clinical practice and clinical trials largely focus on treating the 
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patient. Where trials aim to reduce carer burden and distress, they may do so by engaging the 
carer directly in the intervention, for example in program of “carer-training”, rather than 
intervening in the patient. Although patient and carer ratings are both important and valid, they 
are distinct. Critically, they can reflect differences in terms of the disease-related features which 
cause the most distress. The observation that patient and carer ratings also reflect distinct neural 
correlates (Chapter 3 and 4) suggests that a treatment for apathy may improve distressing 
behaviours reported by one, while having no influence on behaviours that are of concern to the 
other. For example, by treating features of the disease that are most distressing to the carer, one 
may miss features that are more problematic to the patient – effectively treating the carer and 
not the patient.  
 
7.3 Apathy and Impulsivity reflect Changes in Grey and White Matter  
The components of apathy and impulsivity reflect changes in widespread grey and white matter, 
which have been discussed in the relevant chapters. The neural correlates were broadly 
consistent with the wider literature reporting the neurobiology of apathy and impulsivity (also 
discussed in Chapter 4 and 5), which emphasise the importance of corticostriatal loops, 
including their grey matter targets and white matter connections. Carer ratings reflected 
widespread grey and white matter changes in frontotemporal, frontostriatal and brainstem 
systems, which have been implicated previously in arousal, goal-directed behaviour and 
motivation. Patient ratings reflected changes in the corticospinal tracts, as measured by VBM, 
which I suggest may reflect patients’ retained awareness of their physical impairment while 
their cognitive/behavioural insight is limited. The lack of DTI white matter correlates for patient 
ratings suggests either that the VBM white matter correlates are unreliable due to 
methodological issues (see Chapter 4), or that the multifocal white matter pathology associated 
with FTLD syndromes prevents identification of a single unitary correlate on DTI (see Chapter 
5). The objective tasks correlated with more focal, task-specific brain regions on both VBM 
and DTI. A key validation for the methods adopted by this study was the observation that the 
Stop Signal Task (component 7) correlated with the right inferior frontal gyrus (despite 
accounting for a small proportion of the variance), which is consistently implicated with 
performance on this task in the broader literature209,211,255,272.  
 
7.4 Apathy is a Significant Predictor of Survival 
The link between apathy and rapid cognitive and functional decline is widely recognised, 
particularly in mild cognitive impairment and Alzheimer’s Dementia82–84, but also in FTLD 
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syndromes100,102,103,139. Beyond this, there is accumulating evidence that apathy may be linked 
to reduced survival (Chapter 6 and 367,372–374,377,395).  
 
In PiPPIN, apathy (as measured by Component 2 loadings from the carer rated Apathy 
Evaluation Scale, Neuropsychiatric Inventory Apathy subscore, and Cambridge Behavioural 
Inventory subscores of everyday skills, self-care, sleep and motivation), was a significant 
predictor of death within 2.5 years from assessment. This raises the question of causality; does 
apathy cause a more rapid decline towards death, or is it a biomarker of a more aggressive 
disease? The relationship between the neural changes associated with dementia (including 
pathology (TDP-43, Tau), neurotransmitter systems and neurodegeneration/atrophy), the 
severity of apathy and survival is unclear. This thesis does not attempt to claim causality, but 
discusses the potential mechanisms accounting for the strong correlation between apathy and 
reduced survival in the PiPPIN cohort. Figure 24 suggests four alternate causal relationships of 
the interplay between apathy, neural changes and death, which are explained in more detail 
below. 
 
Clarifying the link between apathy, disease progression and survival is critical for clinical trials 
of novel therapies. The relevance of the four alternative causal relationships (Figure 24) to 
clinical studies are discussed below.  
 
Under model 1, apathy represents a potential biomarker of disease that may identify and stratify 
patients with severe or rapidly progressive disease, but without mediating the effect of 
neurodegeneration on survival. If apathy occurs early in disease, it may also represent a marker 
of early disease changes, or a “pre-diagnosis decline” towards mild cognitive impairment and 
dementia. However, it remains unclear when apathy is first apparent. Advances in our genetic 
understanding of FTLD has enabled studies of presymptomatic mutation carriers, who show 
neural changes 5-10 years prior to the onset of full-blown dementia81. These patients exhibit a 
long prodrome of subtle cognitive, behavioural and neurological changes, occurring years 
before the functional decline that triggers a clinical diagnosis of dementia. Whether increased 
apathy is observed in these genetically predisposed individuals warrants investigation in large 
cohorts targeting the relevant patients (based on the presence and severity of apathy) and using 
the appropriate assessment tools (depending on the type of apathy in question and the target 
population). Previous studies have been hindered by lack of sensitive measurement tools. 
However, recent interest in the biological basis of apathy in the healthy population has led to 
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behavioural paradigms and questionnaires that may capture very subtle changes in apathetic 
states114,117, which may be applicable to presymptomatic groups.  
 
Treatment of apathy under model 1 would be entirely symptomatic, improving quality of life 
but having no influence on survival, while disease modifying treatments must target the 
underlying neurodegenerative process. 
 
 
Figure 24: Causal models for the Impact of Apathy on Survival. 
Four causal models explaining the relationship between apathy (A), neurodegeneration 
(N) and death (D). In brief, 1) apathy and death are incidental but unrelated effects of 
neurodegeneration, 2) neurodegenerative processes affect motivational circuitry 
underlying apathy, which in turn accelerates decline to death, 3) apathy, caused by factors 
such as chemical brain changes in motivational circuitry, mediates death by reducing 
“cognitive reserve” and subsequently increasing vulnerability to neurodegeneration 4) 
apathy and neurodegeneration each cause death, while also exacerbating each other; 
increased neurodegeneration worsens apathy, and reduced motivation accelerates 
neurodegeneration.   
 
Alternatively, under model 2, apathy mediates a more rapid cognitive and functional decline. 
Neurodegenerative processes targeting the neural systems underlying motivation cause apathy, 
which in turn accelerates decline to death. The reverse model 3 is also plausible. Here, apathy 
(caused by non-neurodegenerative factors including chemical/neurotransmitter changes) leads 
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to decreased “cognitive reserve”, increasing vulnerability to neurodegeneration and therefore 
accelerating decline to death. The influence of “cognitive reserve” on dementia risk is widely 
recognised in the literature. This theoretical concept suggests that environmental factors, such 
as education, intelligence and ‘cognitive training’, can influence the brain’s capacity to sustain 
insult and modulate disease onset396,397. Those with greater cognitive reserve are therefore 
thought to have increased neural network flexibility, increasing their ability to sustain greater 
levels of pathology before presenting clinically, and effectively counteracting the disease 
process (for example, those showing substantial AD pathology despite being cognitively 
‘normal’398). I suggest the opposite may be true for apathy, consistent with previous studies 
reporting reduced cognitive reserve in individuals with smaller social networks and increased 
social isolation399 
 
In model 4, apathy and neurodegeneration both cause death via a series of other (physical) 
factors, while also influencing each other; apathy accelerates neurodegeneration and 
neurodegeneration worsens apathy. From the literature (and Chapters 4/5), it seems most likely 
that neurodegenerative processes predominantly drive apathy (NA), although it is possible 
that increased apathy may in turn accelerate the underlying neurodegenerative processes 
(AN) perhaps through reduced “cognitive reserve” (discussed above). Neurodegeneration 
ultimately causes death via a number of physical factors, such as dysphagia in PSP, and 
secondary medical complications, for example pneumonia, while apathy may also reduce 
survival through poor self-care, inactivity and reduced food intake.  
 
In models 2-4, apathy represents a target for both symptomatic and disease-modifying 
treatments; treatments targeting apathy would directly influence survival. Randomised controls 
trials targeting apathy as the primary outcome measure are warranted to clarify causality. 
Potential treatment options are discussed below.  
 
7.5 Treatment of Apathy and Impulsivity 
This thesis has focused largely on understanding the components and neural correlates of apathy 
with the view to informing future treatment studies. However, should one treat apathy? 
Although apathy causes substantial carer distress104,240, apathetic patients may be inherently 
content with their apathetic state (for example, they are happy to sit in front of the TV and do 
nothing all day). This speaks to the question raised earlier: Does one treat the patient or the 
carer? In the event that apathy is correlative (Model 1) rather than causative (Model 2-4) of 
rapid cognitive and functional decline to death, one could argue against the treatment of apathy. 
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Although symptomatic treatment in this context may improve carer burden and distress, 
reducing apathy may improve patient insight and awareness which may have negative 
consequences in the context of a fatal condition. Furthermore, some treatments for apathy may 
have negative side effects; dopaminergic treatment for apathy can cause impulsivity and 
impulse control disorders, which are particularly dangerous and distressing225,262,263. 
 
The widely reported link between apathy, poor outcomes90 and reduced survival373,380(this 
thesis), provides a strong argument in favour of treatment. If apathy is indeed a cause of rapid 
decline, symptomatic intervention to reduce apathy may prove disease-modifying, warranting 
further investigations into potential neural targets. Current treatment options are limited; 
previous studies have been hindered by problems with accurate quantification of apathy. 
Furthermore, the exact underlying causal mechanisms of apathy remain unknown, with 
multiple neural systems implicated199, complicating target identification for 
neuropharmacological treatment trials. The multifaceted nature of apathy and impulsivity and 
their neurobiological dissociations suggests the need for combinational therapy; the cortico-
striatal loops implicated in the proposed framework for apathy and impulsivity111,310,356, and 
also identified in this thesis (Chapters 4 & 5), receive inputs from a number of neurotransmitter 
systems including dopamine, noradrenaline and serotonin. Previous studies have therefore 
focused on manipulating these systems through available dopaminergic, noradrenergic and 
serotonergic drugs.  
 
The dopaminergic system is widely implicated in incentive motivation and reward-related 
behaviours, in both animal and humans studies176–178,400,401. Parkinson’s patients ON dopamine 
medication show greater physical effort expenditure for reward116 and have greater pupillary 
response to rewards relative to OFF patients402, reflecting greater reward sensitivity. Apathy 
and impulsivity are often considered to represent opposite ends of a dopamine-dependent 
spectrum of motivation, with apathy representing a hypodopaminergic state and impulsivity a 
hyperdopaminergic state. Indeed, dopaminergic treatment may improve apathy, while 
dopaminergic overdose of the ventral striatum leads to impulse control disorders86,225,250,262. 
However, apathy and impulsivity are positively correlated and often coexist, suggesting 
involvement of other neurotransmitter systems. Furthermore, dopamine-resistant aspects of 
apathy and impulsivity are increasingly apparent, supporting the proposed pharmacological 
distinction between their components. For example, there is no clear evidence to support role 
for dopamine in action cancellation233. Instead, SST performance appears to be modulated by 
the noradrenergic system, while Go/NoGo is influenced by the serotonergic system131,258,268.  
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The noradrenergic system, which projects from the locus coeruleus (LC) to many regions in the 
cortex, may play a key role in both apathetic and impulsive behaviours and may modulate 
dopaminergic transmission185. The neural pathways mediating pupillary response to reward 
may be regulated by both dopamine and noradrenaline, which have common connections and 
may interact to mediate reward sensitivity and motivation402. There is now substantial evidence 
that noradrenaline improves impulsivity, specifically response inhibition, in PSP, PD, ADHD 
and healthy controls129,245,271,272. Currently, there are few studies providing evidence of the LC-
NA system in apathy due to the difficulty of imaging small brainstem regions. However, the 
ventral striatum, which is often implicated in apathy, receives noradrenergic projections from 
the LC, in addition to its dopaminergic projections78,403. High resolution imaging at 7 Tesla will 
provide the opportunity to investigate the LC and other deep brain structures in more detail, 
which may play a crucial role in apathetic and impulsive behaviours but have not been 
accessible previously through 3T imaging.  
  
There are a number of limitations to previous studies assessing treatments for apathy and 
impulsivity. First, they often focused on a single diagnostic group, despite the prevalence of 
apathy and impulsivity across a number of disorders. This has hindered our understanding of 
the similarities and differences across syndromes. For example, apathy is widely recognised 
across a number of neuropsychiatric illness, but direct comparisons between apathy in 
psychiatric populations and neurological disease groups are lacking. It therefore remains 
unclear whether treatments that improve apathy/impulsivity in one group will do so in another. 
There have been initial reports of improved response inhibition following atomoxetine 
administration in a number of groups including ADHD, PSP, PD and healthy controls214,272, 
providing support for modulating noradrenergic pathways to improve impulsivity across 
syndromes.  
 
Second, cross-species translation may be limited for many available tools, particularly for those 
which measure apathy. Correlations between objective and subjective measures of apathy are 
limited. Most previous studies rely on questionnaire based assessments, which may be 
inappropriate for dementia populations due to cognitive decline and lack of insight. Better 
objective, translational measures that can measure motivation in a preclinical and clinical 
setting, are essential for quantitative assessment of targeted, novel therapeutics. There have 
been promising reports in schizophrenia404,405 and HD (Heath et al., not published) that 
progressive-ratio tasks406, designed to measure the “breakpoint” of effort based behaviour 
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(defined as the point at which an individual is no longer willing to exert the required effort to 
obtain a reward) may facilitate translation of pre-clinical findings into patient populations. 
Consistent findings in clinical cohorts and animal models suggest this task may facilitate 
assessment of the underlying neurobiological mechanisms of apathy and evaluate future 
treatments. Progressive ratio tasks are also reported to correlate with clinical subjective 
measures of apathy such as the AES (Professor Barbara Sahakian, personal communication 
from unpublished data), suggesting they may support the transition from preclinical and small 
detailed clinical studies, to large clinical trials (which often employ questionnaire-based 
measures). 
 
Future studies aiming to understand the components and neural correlates of apathy and 
impulsivity should stratify patients based on the presence and severity of apathy and 
impulsivity, irrespective of their diagnosis, in order to establish similarities and differences 
across groups. Furthermore, choice of assessment tool is dependent on the component of 
apathy/impulsivity in question. Better translational tools are desperately required. Progressive 
ratio tasks demonstrate good face validity, and may provide a better platform for translation 
across species in the context of apathy research. Carefully designed clinical studies targeting 
the relevant patients and using the appropriate outcome measures will clarify whether effective 
intervention is purely symptomatic or also disease modifying. In turn, this may provide some 
clarification regarding causality.  
 
 
7.6 Study Limitations  
Specific limitations are discussed in each chapter, but in this section, a few general limitations 
to the study are highlighted, and possible alternative methods are considered.  
 
7.6.1 Cohort  
The limitations of the PiPPIN cohort have been discussed in detail in Chapter 3. Briefly, the 
PiPPIN study attempted to reach all patients throughout Cambridgeshire and Norfolk with a 
FTLD diagnosis, although it is possible that the cohort is biased and under representative of the 
population. Inherent to studies of apathy, it is likely that individuals taking part in the study 
were more motivated (less apathetic) than those who never present to clinic. However, multiple 
sources of identification were used for patient recruitment and the study team made regular 
home visits in order to reach patients who would otherwise be unable to take part in the study 
for medical or practical reasons. 
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The inclusive approach to this study, considering all FTLD variants together, provides key 
insights into the commonalities observed across the spectrum, but may consequently neglect 
important and well recognised differences between diagnostic groups. By examining the 
component scores by diagnostic group (Chapter 3), distinctions were observed and 
acknowledged. However, the data confirmed the presence of apathy, impulsivity and related 
behaviours (captured by the components) across diagnostic groups, providing support for the 
transdiagnostic approach employed throughout this thesis. 
 
7.6.2 Methods: Limitations and alternative approaches 
The PiPPIN assessment battery attempted to capture all aspects of apathy and impulsivity while 
considering the ability and frailty of FTD, PSP and CBS patients. The battery was necessarily 
selective, attempting to assess the recognised components of apathy and impulsivity through 
available questionnaires and subjective tasks, and results are therefore only applicable to 
measured aspects of motivation. Studies using additional measures may identify distinct or 
additional components.  
 
The selective nature of the assessment battery means that aspects of apathy and impulsivity 
may have been missed. For example, risky decisions and impulsive choice on the Cambridge 
Gambling Task was not assessed, due to difficulty with task engagement in patient groups. 
However, reward sensitivity was quantified using other assessments including the CRRT and 
Kirby.  
 
It is possible that the presence of apathy in severely impaired patients was missed, due to their 
inability to perform on certain questionnaires/tasks. Self-rated questionnaires rely on 
introspection, insight and semantics, while behavioural tasks are heavily dependent on motor 
function, all of which may be limited in FTLD patients. These confounds are inherent to studies 
of dementia populations. By adopting carer reports, some insight was gained regarding 
behavioural changes in these patients, although these are potentially confounded by personal 
distress. Furthermore, the discrepancy between patient and carer ratings suggests they differ in 
their opinion of distressing disease features. Use of large datasets, and examination of 
components rather than individual tests, minimizes the impact of these confounds. 
 
Since the PiPPIN study, there have been a number of new objective measures targeting apathy 
in the healthy population117 and in disease groups116,404,406 which provide useful insights into 
the sub processes underlying motivation. Of particular interest are progressive ratio tasks, 
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which assess the motivational “breakpoint” of an individual or the point at which an individual 
is no longer willing to work for a reward due to effort406. Studies in HD report lower 
“breakpoints” for patients compared to controls, reflecting reduced motivation. Critically, 
progressive ratio tasks show strong translation across species and correlate with subjective 
measures of clinical apathy (AES) (Sahakian et al., unpublished). Whether FTLD patients also 
show lower breakpoints has yet to be investigated. 
 
Pupillometry may also be useful in the assessment of reward sensitivity; reduced pupil dilation 
in response to reward is proposed to reflect insensitivity to reward402, although the associated 
underlying neuropharmacological mechanisms (dopaminergic versus noradrenergic) require 
clarification270,407. Employing eye-related tasks can overcome confounds such as motor 
impairments, which are characteristic of some FTLD groups. In the PiPPIN study, saccade and 
motor Go/NoGo performance loaded onto the same component (Chapter 3, Table 12), 
suggesting the saccadic task is a useful alternative to motor tasks assessing response inhibition 
and cognitive control.   
 
7.6.3 Imaging 
Limitations specific to the imaging methods, including voxel based morphometry (Chapter 4) 
and diffusion weighted imaging (Chapter 5), have been discussed in the relevant chapters. Here, 
I focus on are alternative imaging methods which may be useful in the context of the PiPPIN 
study.  
 
White matter changes were assessed using tract based spatial statistics of diffusion weighted 
imaging, a widely adopted technique developed by Smith et al., (2006). There are of course 
alternative quantitative analysis techniques that could be used, including region of interest 
(ROI) analysis. However, ROI requires manual delineation of a priori specific regions of the 
brain or automated parcellations, which would be inappropriate for the current study, which 
looked at components of behaviours which therefore limited the ability to make a priori 
assumptions.  
 
Resting state MRI is increasingly adopted to measure the brain at rest (‘task-free’), minimizing 
task-related performance confounds which are common to neurodegenerative diseases. This 
imaging method is useful to examine network-related differences between groups (for example 
controls versus patients), providing an ideal platform for future studies assessing the impact of 
candidate treatments on the brain networks that underlie apathy and impulsivity. Borchert et al 
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(2016), reported increased connectivity from the right inferior frontal gyrus to dorsal anterior 
cingulate in PD patients following atomoxetine271, a drug which improves response inhibition 
in multiple disease groups129,214,272, and may represent a potential therapeutic for impulsivity 
(and apathy) in FTLD78.  
 
Positron Emission Tomography (PET) is a useful tool to assess changes in glucose metabolism 
(FDG-PET). Previous studies have reported correlations between brain metabolism and 
behavioural changes in FTLD syndromes; hypometabolism in the dorsolateral and frontal 
medial cortex bilaterally is associated with apathy, while hypometabolism in the orbitofrontal 
cortex, anterior cingulate cortex, hippocampus/amygdala and nucleus accumbens  is reported 
in disinhibited FTD patients168. PET imaging is also increasingly used to target the underlying 
neuropathology of neurodegenerative diseases, using radiotracers (for example for amyloid and 
tau). Neuropathological burden in certain brain regions may cause specific behavioural 
changes; post mortem studies have reported a correlation between NPI apathy and 
neurofibrillary tangles in the anterior cingulate in AD170. There are a number of ongoing PET 
imaging studies in Cambridge assessing the neuropathological changes underlying FTLD 
syndromes408, including their associated behavioural changes. However, these methods are not 
without limitations. Although amyloid imaging has been relatively successful in Alzheimer’s 
research, the reported off-target binding of tau tracers may limit their applicability to FTLD.  
 
Magnetic Resonance Spectroscopy may also have been useful to assess the biochemical 
changes underlying apathy and impulsivity in FTLD syndromes. This is currently being 
investigated in an ongoing study at Cambridge.  
 
7.6.4 Future Directions  
Replication of findings is critical to scientific research. A follow up PiPPIN 2 study is currently 
ongoing, obtaining longitudinal data from PiPPIN 1 participants (who are still alive) while also 
accumulating additional cross-sectional data in a new sample of FTD, PSP and CBS patients. 
The assessment battery is broadly consistent with PiPPIN 1, and will allow replication studies 
for the findings presented throughout this thesis. Additional tests include novel objective 
behavioural tasks such as the progressive-ratio task406. 
 
The PiPPIN 2 study also includes a novel questionnaire called the CamQUAIT (Cambridge 
Questionnaire for Apathy and Impulsivity Traits), which I developed using Rasch Analysis409. 
The scale has yet to be fully validated in a new cohort, and it would therefore be premature to 
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include it in this thesis. The PiPPIN 2 study will provide the ideal platform to validate the 
CamQUAIT, gathering sufficient data in the intended target population (FTLD) to re-analyse 
the questionnaire’s properties through Rasch analysis and determine its face, construct and 
predictive validity. 
 
At the Cambridge Centre for Frontotemporal Dementia and Related Disorders, we are interested 
in pathological validation of these behaviours and their underlying neural systems, including 
neurotransmitter involvement. For example, post-mortem studies are ongoing to clarify the 
noradrenergic hypothesis of apathy and impulsivity, by assessing whether PSP pathology in the 
locus coeruleus, the major source of noradrenaline in the brain, correlates retrospectively with 
impulsivity. Additional noradrenergic studies include 1) 7T imaging of the LC and 2) treatment 
studies of atomoxetine (noradrenaline reuptake inhibitor) in PSP, to determine whether it has a 
similar beneficial effect on network connectivity and clinical impulsivity as reported previously 
in PD205,245,271.  
 
Although genetics analysis was beyond the scope of this thesis, there is some evidence to 
suggest genetic variation influences impulsive behaviours410. Allelic variation in the SLC6A2 
gene, which encodes the noradrenaline transporter, is related to activity in the right inferior 
frontal gyrus and influences response inhibition209. Polymorphisms in the DRD2 gene may also 
influence behavioural inhibition and impulsivity through variations in dopamine 
neurotransmission411,412. Dysregulation of noradrenergic and dopaminergic systems give rise to 
various manifestations of apathy, and may have underlying genetic influences410,413. The extent 
to which genetics can determine clinical expression of FTLD, including the presence and 
severity of apathy and impulsivity, warrants further investigation. 
 
7.7 Conclusion  
This thesis has demonstrated the advantages of transdiagnostic approaches to assess complex 
neurodegenerative disorders and their associated symptom commonalities, including apathy 
and impulsivity. Components of apathy and impulsivity are positively correlated, and observed 
across the FTLD spectrum, not only in syndromes for which they are diagnostic criteria. Novel, 
disease-specific, translational assessment tools are warranted to capture the dissociable 
components or neurocognitive endophenotypes219 of these behaviours. Clinical studies should 
consider the type and severity of apathy and/or impulsivity exhibited, moving away from 
classification based on clinical diagnosis to consider dimensional behavioural constructs. 
 
Chapter 7 
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The prognostic importance of apathy suggests it may represent both a symptomatic and disease-
modifying treatment target. Future studies should clarify the onset of apathy and its associated 
genetic, neurobiological and neuropharmacological influences. Continued advances in our 
understanding of the biological basis of apathy and impulsivity in the healthy population will 
inform studies in disease populations. Recent studies targeting neurotransmitter systems 
underlying apathy and/or impulsivity have reported improvements on clinical and 
neuroimaging measures, although their long term impact on prognosis requires investigation.  
 
Advances in our understanding of these particularly distressing but potentially treatable 
conditions are moving us closer towards effective therapeutic strategies for neurodegenerative 
conditions. The importance of quality, as well as quantity, of life highlights the need to develop 
improved symptomatic therapies in parallel with ongoing studies into disease modifying 
treatments. Studies targeting the disease early, before widespread neuropathology and neuronal 
loss, may provide a breakthrough. The complex multifaceted nature of neurodegenerative 
diseases suggests the need for combinational therapy, targeting both the underlying 
neuropathology and neuropharmacology of disease and its associated disabling symptoms.  
 137 
Reference List 
1. Rohrer, J. D. & Warren, J. D. Phenotypic signatures of genetic frontotemporal 
dementia. Curr. Opin. Neurol. 24, 542–549 (2011). 
2. Piguet, O., Hornberger, M., Mioshi, E. & Hodges, J. R. Behavioural-variant 
frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 
10, 162–172 (2011). 
3. Josephs, K. A. Frontotemporal Dementia and Related Disorders: Deciphering the 
Enigma. Ann. Neurol. 64, 4–14 (2008). 
4. Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural 
variant of frontotemporal dementia. Brain 134, 2456–2477 (2011). 
5. Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. 
Neurology 80, 496–503 (2013). 
6. Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its 
variants. Neurology 76, 1006–1014 (2011). 
7. Pick, A. Ueber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager med 
Wschr 17, 165–167 (1892). 
8. Alzheimer, A. Ueber eigenartige Krankheitsfaelle des spaeteren Alters. Z ges Neurol 
Psychiat 4, 356–385 (1911). 
9. Neary, D. et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic 
criteria. Neurology 51, 1546–1554 (1998). 
10. Rohrer, J. D. et al. Clinical and neuroanatomical signatures of tissue pathology in 
frontotemporal lobar degeneration. Brain 134, 2565–2581 (2011). 
11. Kertesz, A., Martinez-Lage, P., Davidson, W. & Munoz, D. The corticobasal 
degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. 
Neurology 55, 1368–75 (2000). 
12. Josephs, K. A. et al. Clinicopathologic analysis of frontotemporal and corticobasal 
degenerations and PSP. Neurology 66, 41–48 (2006). 
13. Lillo, P. & Hodges, J. R. Frontotemporal dementia and motor neurone disease: 
Overlapping clinic-pathological disorders. J. Clin. Neurosci. 16, 1131–1135 (2009). 
14. Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear 
palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP 
International Workshop. Neurology 47, 1–9 (1996). 
15. Höglinger, G. et al. Clinical diagnosis of progressive supranuclear palsy: the 
Movement Disorder Society Criteria. Mov. Disord. 32, 853–864 (2017). 
16. Seeley, W. W. et al. Frontal Paralimbic Network Atrophy in Very Mild Behavioural 
Variant Frontotemporal Dementia. Arch Neurol 65, 249–255 (2008). 
17. Piguet, O. & Hodges, J. R. Behavioural-variant frontotemporal dementia. Dement. 
Neuropsychol 7, 10–18 (2013). 
18. O’Keeffe, F. M. et al. Loss of insight in frontotemporal dementia , corticobasal 
degeneration and progressive supranuclear palsy. Brain 130, 753–764 (2007). 
19. Coyle-gilchrist, I. T. S. et al. Prevalence, characteristics, and survival of frontotemporal 
lobar degeneration syndromes. Neurology 86, 1–8 (2016). 
20. Snowden, J. S. et al. Distinct clinical and pathological characteristics of frontotemporal 
 138 
dementia associated with C9orf72 mutations. Brain 135, 693–708 (2012). 
21. Serieux, P. Sur un cas de surdite verbale pure. Rev Med 13, 733–750. (1893). 
22. Mesulam, M. Slowly progressive aphasia without gener alized dementia. Ann. Neurol. 
11, 592–598 (1982). 
23. Mesulam, M. & Weintraub, S. Spectrum of primary progressive aphasia. Baillieres 
Clin Neurol 1, 583–609. (1992). 
24. Hodges, J., Patterson, K., Oxbury, S. & Funnell, E. Semantic Dementia: Progressive 
Fluent Aphasia with Temporal Lobe Atrophy. Brain 115, 1783–1806 (1992). 
25. Snowden, J., Goulding, P. & Neary, D. Semantic dementia: a form of circumscribed 
cerebral atrophy. Behav Neurol 2, 167–182. (1989). 
26. Warrington, E. The selective impairment of semantic memory. Q J Exp Psychol 27, 
635–657. (1975). 
27. Grossman, M. et al. Progressive non-fluent aphasia: language, cognitive and PET 
measures contrasted with probable Alzheimer’s disease. J Cogn Neurosci 8, 135–154. 
(1996). 
28. Gorno-Tempini, M. et al. Cognition and anatomy in three variants of primary 
progressive aphasia. Ann. Neurol. 55, 335–346 (2004). 
29. Warren, J. D., Trust, W. & Rohrer, J. D. Frontotemporal dementia. BMJ 347, 1–9 
(2013). 
30. Hodges, J. R. & Patterson, K. Semantic dementia: a unique clinicopathological 
syndrome. Lancet Neurol. 6, 1004–1014 (2007). 
31. Gorno-Tempini, M. et al. Anatomical correlates of early mutism in progressive 
nonfluent aphasia. Neurology. 67, 350–352 (2006). 
32. Josephs, K. A. et al. Clinicopathologic and Imaging Correlates of Progressive Aphasia 
and Apraxia of Speech. Brain. 129, 1385–1398 (2006). 
33. Riley, D. & Lang, A. Clinical Diagnostic Criteria. Adv. Neurol. 29–34 (1999). 
34. Lang, A., Riley, D. & Bergeron, C. Cortico-basal ganglionic degeneration. 
Neurodegener. Dis. (1994). 
35. Rebeiz, J., Kolodny, E. & Richardson, E. J. Corticodentatonigral degeneration with 
neuronal achromasia. Arch Neurol 1, 20–33 (1968). 
36. Soliveri, P. et al. Cognitive and magnetic resonance imaging aspects of corticobasal 
degeneration and progressive supranuclear palsy. Neurology 53, 502–507 (1999). 
37. Litvan, I., Cummings, J. & Mega, M. Neuropsychiatric features of corticobasal 
degeneration. J Neurol Neurosurg Psychiatry 65, 717–721 (1998). 
38. Murray, R. et al. Cognitive and motor assessment in autopsy-proven corticobasal 
degeneration. Neurology 68, 1274–1283 (2007). 
39. Alexander, S. K. et al. Validation of the new consensus criteria for the diagnosis of 
corticobasal degeneration. J. Neurol. Neurosurg. Psychiatry 85, 923–927 (2014). 
40. Josephs, K. A. et al. Neuropathological background of phenotypical variability in 
frontotemporal dementia. Acta Neuropathol. 122, 137–153 (2011). 
41. Grimes, D., Lang, A. & Bergeron, C. Dementia as the most common presentation of 
cortical-basal ganglionic degeneration. Neurology 53, 1969–74 (1999). 
42. Bak, T. & Hodges, J. Corticobasal degenerartion: Clinical aspects. Handb Clin Neurol 
 139 
89, 509–21 (2008). 
43. Boeve, B., Lang, A. & Litvan, I. Corticobasal degeneration and its relationship to 
progressive supranuclear palsy and frontotemporal dementia. Ann. Neurol. 54, 15–19 
(2003). 
44. Litvan, I. et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian 
disorders. Mov. Disord. 18, 467–486 (2003). 
45. Gerstenecker, A., Mast, B., Duff, K., Ferman, T. J. & Litvan, I. Executive dysfunction 
is the primary cognitive impairment in progressive supranuclear palsy. Arch. Clin. 
Neuropsychol. 28, 104–113 (2013). 
46. Ghosh, B. C. P., Carpenter, R. H. S. & Rowe, J. B. A Longitudinal Study of Motor, 
Oculomotor and Cognitive Function in Progressive Supranuclear Palsy. PLoS One 8, 
1–14 (2013). 
47. Pillon, B., Dubois, B., Ploska, A. & Agid, Y. Severity and specificty of cogitive 
impairment in AD, HD and PD and PSP. Neurology 41, 634–643 (1991). 
48. Daniel, S. E., de Bruin, V. M. S. & Lees, A. J. The clinical and pathological spectrum 
of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a 
reappraisal. Brain 118, 759–770 (1995). 
49. Respondek, G. et al. The phenotypic spectrum of progressive supranuclear palsy: A 
retrospective multicenter study of 100 definite cases. Mov. Disord. 29, 1758–1766 
(2014). 
50. Burrell, J. R., Hodges, J. R. & Rowe, J. Cognition in Corticobasal Syndrome and 
Progressive Supranuclear Palsy : A Review. Mov. Disord. 29, 684–693 (2014). 
51. Litvan, I. et al. Validity and Reliability of the Preliminary NINDS Neuropathologic 
Criteria for Progressive Supranuclear Palsy and Related Disorders. J. Neuropathol. 
Exp. Neurol. 55, 97–105 (1996). 
52. Cummings, J. L. & Benson, F. Subcortical Dementia: Review of an Emerging Concept. 
Neurol. Rev. 41, 874–879 (1984). 
53. Aarsland, D., Litvan, I. & Larsen, J. Neuropsychiatric Symptoms of Patients With 
Progressive Supranuclear Palsy and Parkinson’s Disease. J. Neuropsychiatry Clin. 
Neurosci. 13, 42–49 (2001). 
54. Bak, T., Crawford, L., Berrios, G. & Hodges, J. Behavioural symptoms in progressive 
supranuclear palsy and frontotemporal dementia. J Neurol Neurosurg Psychiatry 81, 
1057–1059 (2010). 
55. Brown, R. G. et al. Cognitive impairment in patients with multiple system atrophy and 
progressive supranuclear palsy. Brain 133, 2382–2393 (2010). 
56. Ratnavalli, E., Brayne, C., Dawson, K. & Hodges, J. R. The prevalence of 
frontotemporal dementia. Neurology 58, 184–188 (2002). 
57. Onyike, C. & Diehl-Schmid, J. The Epidemiology of Frontotemporal Dementia. Int 
Rev Psychiatry 25, 130–137 (2013). 
58. Kipps, C. M., Hodges, J. R. & Hornberger, M. Nonprogressive behavioural 
frontotemporal dementia: recent developments and clinical implications of the ‘bvFTD 
phenocopy syndrome’. Curr. Opin. Neurol. 23, 628–632 (2010). 
59. Respondek, G., Kurz, C., Arzberger, T. & et al. Which ante-mortem clinical features 
predict PSP pathology? Mov. Disord. in press, (2017). 
 140 
60. Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J. & Alafuzoff, I. 
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar 
degeneration : an update. Acta Neuropathol. 119, 1–4 (2010). 
61. Neumann, M. et al. A new subtype of frontotemporal lobar degeneration with FUS 
pathology. Brain. 2922–2931 (2009). 
62. Mackenzie, I. R. A. et al. Dementia lacking distinctive histology (DLDH) revisited. 
Acta Neuropathol. 112, 551–559 (2006). 
63. Cairns, N. J. et al. Neuropathologic diagnostic and nosologic criteria for 
frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal 
Lobar Degeneration. Acta Neuropathol. 114, 5–22 (2007). 
64. Sergeant, N., Wattez, A. & Delacourte, A. Neurofibrillary Degeneration in Progressive 
Supranuclear Palsy and Corticobasal Degeneration: Tau Pathologies with Exclusively 
‘Exon 10’ Isoforms. J. Neurochem. 72, 1243–1249 (1999). 
65. de Silva, R. et al. An immunohistochemical study of cases of sporadic and inherited 
frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal 
antibodies. Acta Neuropathol. 111, 329–40 (2006). 
66. Mackenzie, I. R. A. et al. A harmonised classification system for FTD-TDP pathology. 
Acta Neuropathol. 122, 111–113 (2011). 
67. Hattori, M. et al. Distribution of astrocytic plaques in the corticobasal degeneration 
brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy 
brain. Acta Neuropathol. 106, 143–9 (2003). 
68. Litvan, I., Mega, M. S., Cummings, J. L. & Fairbanks, L. Neuropsychiatric aspects of 
progressive supranuclear palsy. Neurology. 47, 1184–1189 (1996). 
69. Rosso, S. M. et al. Frontotemporal dementia in The Netherlands: patient characteristics 
and prevalence estimates from a population-based study. Brain 126, 2016–2022 
(2003). 
70. Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. 
Neurology 73, 1451–1456 (2009). 
71. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding 
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256 
(2011). 
72. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of 
chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268 (2011). 
73. Pottier, C. et al. Whole‑genome sequencing reveals important role for TBK1 and 
OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. 
Acta Neuropathol. 130, 77–92 (2015). 
74. Broustal, O. et al. FUS mutations in frontotemporal lobar degeneration with 
amyotrophic lateral sclerosis. J Alzheimers Dis 22, 765–9 (2010). 
75. Kertesz, A., Mcmonagle, P., Blair, M., Davidson, W. & Munoz, D. G. The evolution 
and pathology of frontotemporal dementia. Brain 128, 1996–2005 (2005). 
76. Rowe, J. Editorial. Brain 138, 2461–2462 (2015). 
77. Huey, E. D., Putnam, K. T. & Grafman, J. A systematic review of neurotransmitter 
deficits and treatments in frontotemporal dementia. Neurology. 66, 17–22 (2006). 
78. Loued-khenissi, L. & Preuschoff, K. Apathy and noradrenaline: silent partners to mild 
 141 
cognitive impairment in Parkinson’s disease? Curr. Opin. Neurol. 28, 344–350 (2015). 
79. Boxer, A. & Boeve, B. Frontotemporal Dementia Treatment : Current Symptomatic 
Therapies and Implications of Recent Genetic, Biochemical and Neuroimaging Studies. 
Alzheimer Dis Assoc Disord 21, 79–87 (2007). 
80. Vossel, K. A. & Miller, B. L. New Approaches to the Treatment of Frontotemporal 
Lobar Degeneration. Curr Opin Neurol. 21, 708–716 (2009). 
81. Rohrer, J. D. et al. Presymptomatic cognitive and neuroanatomical changes in genetic 
frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) 
study: a cross-sectional analysis. Lancet Neurol 14, 253–262 (2015). 
82. Vicini Chilovi, B. et al. Differential impact of apathy and depression in the 
development of dementia in mild cognitive impairment patients. Dement. Geriatr. 
Cogn. Disord. 27, 390–398 (2009). 
83. Dujardin, K., Sockeel, P., Delliaux, M., Defebvre, L. & Deste, A. Apathy May Herald 
Cognitive Decline and Dementia in Parkinson’s Disease. Mov. Disord. 24, 2391–2397 
(2009). 
84. Starkstein, S. E., Jorge, R., Mizrahi, R. & Robinson, R. G. A prospective longitudinal 
study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 77, 8–11 
(2006). 
85. Landes, A. M., Sperry, S. D. & Strauss, M. E. Apathy in Alzheimer’s Disease. J Am 
Geriatr Soc 49, 1700–1707 (2001). 
86. Sinha, N., Manohar, S. & Husain, M. Impulsivity and apathy in Parkinson’s disease. J 
Neuropsychol 7, 255–283 (2013). 
87. Caeiro, L., Ferro, J. & Figueira, M. Apathy in acute stroke patients. Eur. J. Neurol. 19, 
291–297 (2012). 
88. Pluck, G. C. & Brown, R. G. Apathy in Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 73, 636–642 (2002). 
89. Ishii, S., Weintraub, N. & Mervis, J. R. Apathy: a common psychiatric syndrome in the 
elderly. J Am Med Dir Assoc 10, 381–393 (2009). 
90. van Reekum, R., Stuss, D. T. & Ostrander, L. Apathy: Why Care? J. Neuropsychiatry 
Clin. Neurosci. 17, 7–19 (2005). 
91. Starkstein, S. E., Mayberg, H. S., Andrezejewski, P., Leiguarda, R. & Robinson, G. 
Reliability, Validity and Clinical Correlates of Apathy in Parkinson’s Disease. J. 
Neuropsychiatry Clin. Neurosci. 4, 134–139 (1992). 
92. Benoit, M., Andrieu, S. & Lechowski, L. Apathy and depression in Alzheimer’s 
disease are associated with functional deficit and psychotropic prescription. Int. J. 
Geriatr. Psychiatry. 23, 409–414 (2008). 
93. Paulsen, J. S., Ready, R. E., Hamilton, J. M., Mega, M. S. & Cummings, J. L. 
Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 5, 
310–314 (2001). 
94. Hama, S., Yamashita, H., Yamawaki, S. & Kurisu, K. Post-stroke depression and 
apathy: Interactions between functional recovery, lesion location, and emotional 
response. Psychogeriatrics. 11, 68–76 (2011). 
95. Harris, A., Elder, J., Schiff, N., Victor, J. & Goldfine, A. Post-stroke apathy and 
hypersomnia lead to worse outcomes from acute rehabilitation. Transl Stroke Res. 5, 
292–300 (2014). 
 142 
96. Hackett, M., Kohler, S., O’Brien, J. & Mead, G. Neuropsychiatric outcomes of stroke. 
Lancet Neurol. 13, 525–534 (2014). 
97. Hollocks, M. J. et al. Differential relationships between apathy and depression with 
white matter microstructural changes and functional outcomes. Brain 138, 3803–3815 
(2015). 
98. Kant, R., Duffy, J. & Pivovarnik, A. Prevalence of apathy following head injury. Brain 
Inj. 12, 87–93 (1998). 
99. Kertesz, A., McMonagle, P. & Jesso, S. Extrapyramidal syndromes in frontotemporal 
degeneration. J. Mol. Neurosci. 45, 336–342 (2011). 
100. Zamboni, G., Huey, E. D., Krueger, F., Nichelli, P. F. & Grafman, J. Apathy and 
disinhibition in frontotemporal dementia: Insights into their neural correlates. 
Neurology 71, 736–742 (2008). 
101. Eslinger, P., Moore, P., Antani, S., Anderson, C. & Grossman, M. Apathy in 
frontotemporal dementia: Behavioural and neuroimaging correlates. 25, 127–136 
(2013). 
102. Massimo, L. et al. Neuroanatomy of Apathy and Disinhibition in Frontotemporal 
Lobar Degeneration. Dement. Geriatr. Cogn. Disord. 27, 96–104 (2009). 
103. Merrilees, J. et al. Characterization of Apathy in Persons with Frontotemporal 
Dementia and The Impact on Family Caregivers. Alzheimer Dis Assoc Disord 27, 62–
67 (2013). 
104. Leroi, I. et al. Carer burden in apathy and impulse control disorders in Parkinson’s 
disease. Int. J. Geriatr. Psychiatry. 27, 160–166 (2012). 
105. Landes, A. M., Sperry, S. D. & Strauss, M. E. Depression in Relation to Dementia 
Severity in Alzheimer’s Disease. J. Neuropsychiatry Clin. Neurosci. 17, 342–349 
(2005). 
106. Baudic, S. et al. Cognitive Impairment Related to Apathy in Early Huntington’s 
Disease. Dement. Geriatr. Cogn. Disord. 21, 316–321 (2006). 
107. Starkstein, S. E., Ingram, L., Garau, M. L. & Mizrahi, R. On the overlap between 
apathy and depression in dementia. J Neurol Neurosurg Psychiatry 76, 1070–1074 
(2005). 
108. Caga, J. et al. Apathy is associated with poor prognosis in amyotrophic lateral 
sclerosis. Eur. J. Neurol. 23, 891–897 (2016). 
109. Marin, R. S. & Biedrzycki, R. C. Reliability and Validity of the Apathy Evaluation 
Scale. Psychiat 38, 143–162 (1991). 
110. Brown, R. G. & Pluck, G. Negative symptoms: the ‘pathology’ of motivation and goal-
directed behaviour Phenomenology of negative symptoms and apathy. Trends 
Neurosci. 23, 412–417 (2000). 
111. Levy, R. & Dubois, B. Apathy and the Functional Anatomy of the Prefrontal Cortex-
Basal Ganglia Circuits. Cereb. Cortex 16, 916–928 (2006). 
112. Alexander, G., DeLong, M. & Strick, P. Parallel Organisation of Functionally 
Segregated Circuits Linking Basal Ganglia and Cortex. Ann Rev Neurosci 9, 357–81 
(1986). 
113. Grunsfeld, A. A. & Login, I. S. Abulia following penetrating brain injury during 
endoscopic sinus surgery with disruption of the anterior cingulate circuit: case report. 
BMC Neurol. 6, 4 (2006). 
 143 
114. Ang, Y., Lockwood, P., Apps, M. A. J., Muhammed, K. & Husain, M. Distinct 
Subtypes of Apathy Revealed by the Apathy Motivation Index. PLoS One 12, 1–15 
(2017). 
115. Le Bouc, R. et al. Computational Dissection of Dopamine Motor and Motivational 
Functions in Humans. J. Neurosci. 36, 6623–6633 (2016). 
116. Chong, T. T. et al. Dopamine enhances willingness to exert effort for reward in 
Parkinson’s disease. CORTEX 69, 40–46 (2015). 
117. Bonnelle, V., Manohar, S., Behrens, T. & Husain, M. Individual Differences in 
Premotor Brain Systems Underlie Behavioral Apathy. Cereb. Cortex 807–819 (2016). 
118. Clarke, D. E. et al. Apathy in Dementia : An Examination of the Psychometric 
Properties of the Apathy Evaluation Scale. J Neuropsychiatry Clin Neurosci 19, 57–64 
(2007). 
119. Robert, P. et al. The apathy inventory: assessment of apathy and awareness in 
Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr 
Psychiatry 12, 1099–105 (2002). 
120. Stockeel, P. et al. The Lille apathy rating scale (LARS), a new instrument for detecting 
and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 77, 579–584 (2006). 
121. Cummings, J. et al. The Neuropsychiatric Inventory : Comprehensive assessment of 
psychopathology in dementia. Neurology 44, 2308–2314 (1994). 
122. Leuken, U. et al. Development of a short version of the Apathy Evaluation Scale 
specifically adapted for demented nursing home residents. Am J Geriatr. Psychiatry 15, 
376–85 (2007). 
123. Strauss, M. & Sperry, S. An informant-based assessment of apathy in Alzheimer 
disease. Neuropsychiatry Neuropsychol Behav Neurol. 15, 176–83 (2002). 
124. Gorno-tempini, M. L., Murray, R. C., Rankin, K. P., Michael, W. & Miller, B. L. 
Clinical, Cognitive and Anatomical Evolution from Nonfluent Progressive Aphasia to 
Corticobasal Syndrome: A Case Report. Neurocase 10, 426–436 (2008). 
125. Mioshi, E., Dawson, K., Mitchell, J., Arnold, R. & Hodges, J. R. The Addenbrooke’s 
Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia 
screening. Int. J. Geriatr. Psychiatry. 21, 1078–1085 (2006). 
126. Sands, L., Ferreira, P., Stewart, A., Brod, M. & Yaffe, K. What explains differences 
between dementia patients’ and their caregivers’ ratings of patients’ quality of life? Am 
J Geriatr Psychiatry. 12, 272–80 (2004). 
127. Mioshi, E., Bristow, M., Cook, R. & Hodges, J. R. Factors underlying caregiver stress 
in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord 27, 
76–81 (2009). 
128. Mioshi, E. et al. The Impact of Dementia Severity on Caregiver Burden in 
Frontotemporal Dementia and Alzheimer Disease Article. Alzheimer Dis Assoc Disord 
27, 68–73 (2013). 
129. Ye, Z. et al. Improving response inhibition in Parkinson’s disease with atomoxetine. 
Biol Psychiatry 77, 740–748 (2015). 
130. Kehagia, A. A. et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. 
Brain 137, 1986–1997 (2014). 
131. Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W. & Rowe, J. B. Improving 
 144 
response inhibition systems in frontotemporal dementia with citalopram. Brain 138, 
1961–1975 (2015). 
132. Chong, T. T.-J. & Husain, M. The role of dopamine in the pathophysiology and 
treatment of apathy. 229, (2016). 
133. Bonnelle, V. et al. Characterization of reward and effort mechanisms in apathy. J. 
Physiol. - Paris 109, 16–26 (2015). 
134. Clarke, D. et al. Are the available apathy measures reliable and valid? A review of the 
psychometric evidence. J Psychosom Res 70, 73–97 (2011). 
135. Radakovic, R., Harley, C., Abrahams, S. & Starr, J. M. A systematic review of the 
validity and reliability of apathy scales in neurodegenerative conditions. Int. 
Psychogeriatrics 27, 903–923 (2015). 
136. Bozeat, S., Gregory, C. A., Ralph, M. A. L. & Hodges, J. R. Which neuropsychiatric 
and behavioural features distinguish frontal and temporal variants of frontotemporal 
dementia from Alzheimer’s disease ? J Neurol Neurosurg Psychiatry 69, 178–186 
(2000). 
137. Liu, W. et al. Behavioral disorders in the frontal and temporal variants of 
frontotemporal dementia. Neurology 62, 742–748 (2004). 
138. Rosen, H. J. et al. Neuroanatomical correlates of behavioural disorders in dementia. 
Brain 128, 2612–2625 (2005). 
139. Diehl-Schmid, J., Pohl, C., Perneczky, R., Forstl, H. & Kurz, A. Behavioral 
Disturbances in the Course of Frontotemporal Dementia. Dement Geriatr Cogn Disord 
22, 352–357 (2006). 
140. Muhammed, K. & Husain, M. Clinical significance of apathy in Parkinson’s disease. 
EMJ 4, 56–63 (2016). 
141. Levy, M. L. et al. Apathy Is Not Depression. J. Neuropsychiatry Clin. Neurosci. 10, 
314–319 (1998). 
142. Skorvanek, M. et al. The associations between fatigue, apathy, and depression in 
Parkinson’s disease. Acta Neurol Scand 131, 80–7 (2014). 
143. Cochrane, G. D. et al. Parkinsonism and Related Disorders The association between 
fatigue and apathy in patients with either Parkinson’s disease or multiple sclerosis. 
Park. Relat. Disord. 21, 1093–1095 (2015). 
144. Hornberger, M., Geng, J. & Hodges, J. R. Convergent grey and white matter evidence 
of orbitofrontal cortex changes related to disinhibition in behavioural variant 
frontotemporal dementia. Brain 134, 2502–2512 (2011). 
145. Rushworth, M. F. Intention, Choice, and the Medial Frontal Cortex. Ann. N. Y. Acad. 
Sci. 207, 181–207 (2008). 
146. Jahanshahi, M., Obeso, I., Rothwell, J. C. & Obeso, J. A. A fronto–striato–
subthalamic–pallidal network for goaldirected and habitual inhibition. Nat. Rev. 16, 
719–732 (2015). 
147. Cools, R. et al. Tryptophan Depletion Disrupts the Motivational Guidance of Goal-
Directed Behavior as a Function of Trait Impulsivity. Neuropsychopharmacology 30, 
1362–1373 (2005). 
148. Eslinger, P. & Damasio, A. Severe disturbance of higher cognition after bilateral 
frontal lobe ablation. Neurology 35, 1731–1741 (1985). 
 145 
149. Luria, A. Higher cortical functions in Man. (1980). 
150. Chow, T. W. et al. Apathy Symptom Profile and Behavioral Associations in 
Frontotemporal Dementia vs. Alzheimer’s Disease. Arch Neurol. 66, 888–893 (2009). 
151. Rosen, H. J., Gorno-Tempini, M. L. & Goldman, W. P. Patterns of brain atrophy in 
frontotemporal dementia and semantic dementia. Neurology 58, 198–208 (2002). 
152. Mendez, M. F., Adams, N. L. & Lewandowski, K. S. Neurobehavioral changes 
associated with caudate lesions. Neurology 39, 349–354 (1989). 
153. Bhatia, K. P. & Marsden, C. D. The behavioural and motor consequences of focal 
lesions of the basal ganglia in man. Brain 117, 859–876 (1994). 
154. Laplane, D. et al. Obsessive-Compulsive and Other Behavioural Changes with 
Bilateral Basal Ganglia Lesions. Brain 112, 699–725 (1989). 
155. Middleton, F. A. & Strick, P. L. Basal-ganglia ‘ Projections’ to the Prefrontal Cortex of 
the Primate. Cereb. Cortex 12, 926–935 (2002). 
156. Kemp, J. M. & Powell, T. P. S. The Cortico-Striate Projection in the Monkey. Brain 
93, 525–546 (1970). 
157. Lehericy, S. et al. Diffusion Tensor Fiber Tracking Shows Distinct Corticostriatal 
Circuits in Humans. Ann. Neurol. 55, 522–529 (2004). 
158. Alexander, G., Crutcher, M. & DeLong, M. Basal ganglia-thalamocortical circuits: 
parallel substrates for motor, oculomotor, ‘prefrontal’ and ‘limbic’ functions. Prog 
Brain Res 85, 119–46 (1990). 
159. Alexander, G. & Crutcher, M. Functional architecture of basal ganglia circuite: neural 
substrates of parallel processing. TIMS 13, 226–271 (1990). 
160. Haber, S. N. et al. Reward-Related Cortical Inputs Define a Large Striatal Region in 
Primates That Interface with Associative Cortical Connections , Providing a Substrate 
for Incentive-Based Learning. J Neurosci 26, 8368–8376 (2006). 
161. Haber, S. N. Corticostriatal Circuitry. Dialogues Clin. Neurosci. 18, 7–21 (2016). 
162. Haber, S. N. & Knutson, B. The Reward Circuit : Linking Primate Anatomy and 
Human Imaging. Neuropsychopharmacology 35, 4–26 (2010). 
163. Draganski, B. et al. Evidence for Segregated and Integrative Connectivity Patterns in 
the Human Basal Ganglia. J. Neurosci. 28, 7143–7152 (2008). 
164. Powers, J. et al. White Matter Disease Contributes to Apathy and Disinhibition in 
Behavioural Variant Frontotemporal Dementia. Cogn Behav Neurol 27, 206–214 
(2014). 
165. Hahn, C. et al. Apathy and White Matter Integrity in Alzheimer’s Disease : A Whole 
Brain Analysis with Tract-Based Spatial Statistics. PLoS One 8, 4–9 (2013). 
166. Brenneis, C. et al. Voxel based morphometry reveals a distinct pattern of frontal 
atrophy in progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 75, 246–9 
(2004). 
167. Spalletta, G., Fagioli, S., Caltagirone, C. & Piras, F. Brain microstructure of subclinical 
apathy phenomenology in healthy individuals. Hum. Brain Mapp. 34, 3193–3203 
(2013). 
168. Franceschi, M. et al. Glucose Metabolism and Serotonin Receptors in the 
Frontotemporal Lobe Degeneration. Ann. Neurol. 57, 216–225 (2005). 
169. Salmon, E. et al. Predominant ventromedial frontopolar metabolic impairment in 
 146 
frontotemporal dementia. Neuroimage 20, 435–440 (2003). 
170. Cummings, J. L. et al. Neuropathologic Correlates of Apathy in Alzheimer’s Disease. 
Dement. Geriatr. Cogn. Disord. 21, 144–147 (2006). 
171. Gray, T. Functional and Anatomical Relationships among the Amygdala, Basal 
Forebrain, Ventral Striatum, and Cortex. Ann. N. Y. Acad. Sci. 877, 439–444 (1999). 
172. Salamone, J. D., Correa, M., Farrar, A. M., Nunes, E. J. & Pardo, M. Dopamine, 
behavioral economics, and effort. Front. Behav. Neurosci. 3, 1–12 (2009). 
173. Salamone, J. D., Correa, M., Farrar, A. & Mingote, S. M. Effort-related functions of 
nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology. 
191, 461–482 (2007). 
174. Levy, R. Apathy: A pathology of goal-directed behaviour . A new concept of the clinic 
and pathophysiology of apathy. Rev. Neurol. (Paris). 168, 585–597 (2012). 
175. Robbins, T. & Everitt, B. J. Neurobehavioural mechanisms of reward and motivation. 
Curr Opin Neurol. 6, 228–236 (1996). 
176. Schultz, W. Behavioral dopamine signals. TRENDS Cogn. Neurosci. 30, 203–210 
(2007). 
177. Schultz, W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 80, 1–27 
(1998). 
178. Berridge, K. C. & Robinson, T. E. What is the role of dopamine in reward: hedonic 
impact, reward learning, or incentive salience? Brain Res. Rev. 28, 309–369 (1998). 
179. Czernecki, V. et al. Motivation, reward, and Parkinson’s disease: influence of 
dopatherapy. Neuropsychologia 40, 2257–2267 (2002). 
180. Adam, R. et al. Dopamine reverses reward insensitivity in apathy following globus 
pallidus lesions. CORTEX 49, 1292–1303 (2013). 
181. Gil-Navarro, S. et al. Decreased striatal dopamine transporter uptake in the non-fluent / 
agrammatic variant of primary progressive aphasia. Eur. J. Neurol. 20, 1459–1466 
(2013). 
182. Warren, N. M. et al. Basal Ganglia Cholinergic and Dopaminergic Function in 
Progressive Supranuclear Palsy. Mov. Disord 22, 1594–1600 (2007). 
183. Cordato, N. J. et al. Clinical deficits correlate with regional cerebral atrophy in 
progressive supranuclear palsy. Brain 128, 1259–1266 (2005). 
184. Frisoni, G. B. et al. Single photon emission computed tomography with [99Tc]‐HM‐
PAO and [123I]‐IBZM in Alzheimer’s disease and dementia of frontal type: 
preliminary results. Acta Neurol. Scand. 89, 199–203 (1994). 
185. Ventura, R., Alcaro, A., Puglisi-allegra, S. & Psicologia, D. Prefrontal Cortical 
Norepinephrine Release is Critical for Morphine-induced Reward, Reinstatement and 
Dopamine Release in the Nucleus Accumbens. Cereb. Cortex 15, 1877–1886 (2005). 
186. Sara, S. J. The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. 
10, 211–223 (2009). 
187. Berridge, C. W. & Waterhouse, B. D. The locus coeruleus – noradrenergic system : 
modulation of behavioral state and state-dependent cognitive processes. Brain Res. 
Rev. 42, 33–84 (2003). 
188. Aston-Jones, G. & Cohen, J. D. An Integrative Theory of Locus Function : Adaptive 
Gain and Optimal Performance. Ann Rev Neurosci 28, 403–50 (2005). 
 147 
189. Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson’s 
disease : loss of dopamine and noradrenaline innervation in the limbic system. Brain 
128, 1314–1322 (2005). 
190. Hauw, J., Daniel, S. E., Dickson, D. & Horoupian, D. S. Preliminary NINDS 
neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive 
supranuclear palsy). Neurology. 44, 2015–2019 (1994). 
191. Drijgers, R. L. & Verhey, F. R. J. Pharmacological Treatment of Apathy in 
Neurodegenerative Diseases : A systematic review. Dement Geriatr Cogn Disord 28, 
13–22 (2009). 
192. Newburn, G. & Newburn, D. Selegiline in the management of apathy following 
traumatic brain injury. Brain Inj. 19, 149–154 (2005). 
193. Van Reekum, R., Bayley, M. & Garner, S. N of 1 study: amantadine for the 
amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 9, 49–53 
(1995). 
194. Kohno, N. et al. Successful treatment of post-stroke apathy by the dopamine receptor 
agonist ropinirole. J. Clin. Neurosci. 17, 804–806 (2010). 
195. Czernecki, V., Schu, M., Yaici, S. & Le, R. Apathy Following Subthalamic 
Stimulation in Parkinson Disease : A Dopamine Responsive Symptom. Mov. Disord. 
23, 964–969 (2008). 
196. Dalley, J. W. & Roiser, J. P. Dopamine, Serotonin and Impulsivity. Neuroscience 215, 
42–58 (2012). 
197. Marin, R. S. & Wilkosz, P. A. Disorders of Diminished Motivation. J Head Trauma 
Rehabil 20, 377–388 (2005). 
198. Corcoran, C., Wong, M. L. & O’Keane, V. Bupropion in the management of apathy. 
Psychopharmacology. 18, 300–302 (2014). 
199. Pagonabarraga, J., Kulisevsky, J., Strafella, A. P. & Krack, P. Apathy in Parkinson’s 
disease : clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 
14, 518–531 (2015). 
200. Rabinovici, G. D. & Miller, B. L. Frontotemporal Lobar Degeneration: Epidemiology, 
Pathophysiology, Diagnosis and Management. CNS Drugs 24, 375–398 (2010). 
201. Rittman, T., Coyle-gilchrist, I. T. S. & Rowe, J. B. Managing cognition in progressive 
supranuclear palsy. Neurodegen Dis Manag 6, 499–508 (2016). 
202. Trinh, N.-H., Hoblyn, J., Mohanty, S. & Yaffe, K. Efficacy of Cholinesterase Inhibitors 
in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in 
Alzheimer’s Disease. JAMA 289, 210–216 (2003). 
203. Devos, D., Moreau, C., Maltete, D., Lefaucheur, R. & et al. Rivastigmine in apathetic 
but dementia and depression-free patients with Parkinson’s disease: a double-blind, 
placebo-controlled, randomised clinical trial. J. Neurol. Neurosurg. Psychiatry 85, 
668–74 (2014). 
204. Bayley, M., Masanic, C. A. & Bayley, M. T. Open-label study of donepezil in 
traumatic brain injury Open-Label Study of Donepezil in Traumatic Brain Injury. Arch. 
Phys. Med. Rehabil. 82, 896–901 (2001). 
205. Ye, Z. et al. Improving Response Inhibition in Parkinson’s Disease with Atomoxetine. 
Biol. Psychiatry 77, 740–748 (2015). 
206. Rosenberg, P. B. et al. Safety and Efficacy of Methylphenidate for Apathy in 
 148 
Alzheimer’s Disease: A Randomized, Placebo-Controlled Trial. J Clin Psychiatry 74, 
810–816 (2014). 
207. Frakey, L. L., Salloway, S., Buelow, M. & Malloy, P. A Randomized, Double-Blind, 
Placebo-Controlled Trial of Modafinil for the Treatment of Apathy in Individuals With 
Mild-to-Moderate Alzheimer’s Disease. J Clin Psychiatry 73, 796–801 (2012). 
208. Dalley, J. W., Everitt, B. J. & Robbins, T. W. Impulsivity, Compulsivity and Top-
Down Cognitive Control. Neuron 69, 680–694 (2011). 
209. Whelan, R. et al. Adolescent impulsivity phenotypes characterized by distinct brain 
networks. Nat. Neurosci. 15, 920–927 (2012). 
210. Bunge, S. A., Dudukovic, N. M., Thomason, M. E., Vaidya, C. J. & Gabrieli, J. D. E. 
Immature Frontal Lobe Contributions to Cognitive Control in Children : Evidence from 
fMRI. Neuron 33, 301–311 (2015). 
211. Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J. & Robbins, T. W. Stop-
signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat. 
Neurosci. 6, 115–116 (2003). 
212. Heery, E. et al. Delay Discounting in Schizophrenia. Cogn Neuropsychiatry 12, 213–
221 (2007). 
213. Winstanley, C. A., Eagle, D. M. & Robbins, T. W. Behavioral models of impulsivity in 
relation to ADHD : Translation between clinical and preclinical studies. Clin. Psychol. 
Rev. 26, 379–395 (2006). 
214. Chamberlain, S. R. et al. Atomoxetine Improved Response Inhibition in Adults with 
Attention Deficit / Hyperactivity Disorder. Biol Psychiatry 62, 977–984 (2007). 
215. Frank, M. J., Samanta, J., Moustafa, A. A. & Sherman, S. J. Hold Your Horses: 
Impulsivity, Deep Brain Stimulation and Medication in Parkinsonism. Science (80-. ). 
318, 1309–1312 (2007). 
216. Nombela, C., Rittman, T., Robbins, T. W. & Rowe, J. B. Multiple Modes of 
Impulsivity in Parkinson’s Disease. PLoS One 9, 18–21 (2014). 
217. O’Callaghan, C., Hodges, J. & Hornberger, M. Inhibitory Dysfunction in 
Frontotemporal Dementia A Review. Alzheimer Dis Assoc Disord 27, 102–108 (2013). 
218. Napier, T. C., Corvol, J., Grace, A. A. & Roitman, J. D. Linking neuroscience with 
modern concepts of impulse control disorders in Parkinson’s disease. Mov. Disord. 30, 
141–149 (2015). 
219. Robbins, T. W., Gillan, C. M., Smith, D. G., Wit, S. De & Ersche, K. D. 
Neurocognitive endophenotypes of impulsivity and compulsivity : towards dimensional 
psychiatry. Cell Press 16, 81–91 (2012). 
220. Zhang, J. et al. Different decision deficits impair response inhibition in progressive 
supranuclear palsy and Parkinson’s disease. Brain 139, 1–13 (2016). 
221. O’Callaghan, C., Naismith, S. L., Hodges, J. R., Lewis, S. J. G. & Hornberger, M. 
Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson ’ s disease 
versus behavioural variant frontotemporal dementia. CORTEX 49, 1833–1843 (2012). 
222. Robinson, E. S. J. et al. Similar effects of the selective noradrenaline reuptake inhibitor 
atomoxetine on three distinct forms of impulsivity in the rat. 
Neuropsychopharmacology 33, 1028–37 (2008). 
223. Ersche, K. D. et al. Response Perseveration in Stimulant Dependence Is Associated 
with Striatal Dysfunction and Can Be Ameliorated by a D 2 / 3 Receptor Agonist. BPS 
 149 
70, 754–762 (2011). 
224. Ahearn, D. J. et al. An Exploration of Apathy and Impulsivity in Parkinson Disease. 
Curr. Gerontol. Geriatr. Res. 2012, (2012). 
225. Weintraub, D. Dopamine and Impulse Control Disorders in Parkinson’s Disease. Ann 
Neurol 64, 93–100 (2012). 
226. O’Sullivan, S. et al. Impulsive-compulsive Spectrum Behaviours in Pathologically 
Confirmed PSP. Mov. Disord. 25, 623–646 (2010). 
227. Kirby, K. N., Petry, N. M. & Kirby, K. Heroin and cocaine abusers have higher 
discount rates for delayed rewards than alcoholics or non-drug-using controls. 
Addiction 99, 461–471 (2004). 
228. Ersche, K. D. et al. Abnormal structure of frontostriatal brain systems is associated 
with aspects of impulsivity and compulsivity in cocaine dependence. Brain 134, 2013–
2024 (2011). 
229. Mitchell, J. M., Fields, H. L., Esposito, M. D. & Boettiger, C. A. Impulsive 
Responding in Alcoholics. Alcohol. Clin. Exp. Res. 29, 2158–2169 (2005). 
230. Lawrence, A. J., Luty, J., Bogdan, N. A., Sahakian, B. J. & Clark, L. Problem gamblers 
share deficits in impulsive decision-making with alcohol-dependent individuals. 
Addiction 104, 1006–1015 (2009). 
231. Chamorro, J. et al. Impulsivity in the general population: A national study. J Psychiatr 
Res. 46, 994–1001 (2012). 
232. Evenden, J. L. Varieties of impulsivity. Psychopharmacology. 146, 348–361 (1999). 
233. Eagle, D. M., Bari, A. & Robbins, T. W. The neuropsychopharmacology of action 
inhibition : cross-species translation of the stop-signal and go / no-go tasks. 
Psychopharmacology. 199, 439–456 (2008). 
234. Patton, J. H., Stanford, M. & Barratt, E. Factor structure of the Barratt Impulsiveness 
Scale. J Clin Psychol. 51, 768–774 (1995). 
235. Carver, C. S. & White, T. L. Behavioural Inhibition, Behavioural Activation, and 
Affect Responses to Impending Reward and Punishment: The BIS/BAS Scales. J. 
Pers. Soc. Psychol. 67, 319–333 (1994). 
236. Cummings, J. L. The Neuropsychiatric Inventory : Assessing psychopathology in 
dementia patients. Neurology 48, 10–16 (1997). 
237. Wear, H. J. et al. The Cambridge Behavioural Inventory revised. Dement. 
Neuropsychol. 2, 102–107 (2008). 
238. Wedderburn, C., Wear, H., Brown, J. & Mason, S. The utility of the Cambridge 
Behavioural Inventory in neurodegenerative diseases. J. Neurol. 79, 500–503 (2008). 
239. Grace, J. & Malloy, P. Frontal Systems Behavior Scale (FrSBe): Professional Manual. 
Lutz, FL: Psychological Assessment Resources Inc. (2001). 
240. Nicolaou, P., Egan, S., Gasson, N. & Kane, R. Identifying the needs, burden and 
distress of carers of people with Frontotemporal dementia compared to Alzheimer’s 
disease. Dementia. 9, 215–235 (2010). 
241. Clark, L., Robbins, T. W., Ersche, K. D. & Sahakian, B. J. Reflection Impulsivity in 
Current and Former Substance Users. Biol Psychiatry 60, 515–522 (2006). 
242. Kirby, K. & Marakovic, N. Delay-discounting probabilistic rewards : Rates decrease as 
amounts increase. Psychon. Bull. Rev. 3, 100–104 (1996). 
 150 
243. Odum, A. Delay Discounting: I’m a K, You’re a K. J. Exp. Anal. Behav. 96, 427–439 
(2011). 
244. Zois, E. et al. Decision-making deficits in patients diagnosed with disordered gambling 
using the Cambridge Gambling task: the effects of substance use disorder comorbidity. 
Brain Behav. 4, 484–494 (2014). 
245. Rae, C. L. et al. Atomoxetine restores the response inhibition network in Parkinson’s 
disease. Brain 139, 2235–2248 (2016). 
246. Ainslie, G. Specious Reward: A behavioural theory of impulsiveness and impulse 
control. Psychol. Bull. 82, 463–496 (1975). 
247. Bechara, A., Damasio, A., Damasio, H. & Anderson, W. Insensitivity to future 
consequences following damage to human prefrontal cortex. Cognition 50, 7–15 
(1994). 
248. Manes, F. et al. Decision-making processes following damage to the prefrontal cortex. 
Brain 125, 624–639 (2002). 
249. Manes, F. F. et al. Frontotemporal dementia presenting as pathological gambling. Nat. 
Rev. Neurol. 6, 347–352 (2010). 
250. Weintraub, D. et al. Impulse Control Disorders in Parkinson Disease. Arch Neurol 67, 
589–595 (2010). 
251. Zamarian, L., Benke, T., Brand, M., Djamshidian, A. & Delazer, M. Impaired 
Information Sampling in Mild Dementia of Alzheimer’s Type but Not in Healthy 
Aging. Neuropsychology 29, 353–367 (2015). 
252. Reynolds, B., Richards, J. B. & de Wit, H. Dimensions of impulsive behavior : 
Personality and behavioral measures. Personal. Individ. Differ. 40, 305–315 (2006). 
253. Cardinal, R. N., Pennicott, D. R., Sugathapala, C. L., Robbins, T. W. & Everitt, B. J. 
Impulsive Choice Induced in Rats by Lesions of the Nucleus Accumbens Core. Science 
(80-. ). 292, 2499–2501 (2001). 
254. Hariri, A. R. et al. Preference for Immediate over Delayed Rewards Is Associated with 
Magnitude of Ventral Striatal Activity. J. Neurosci. 26, 13213–13217 (2006). 
255. Aron, A. R., Robbins, T. W. & Poldrack, R. A. Inhibition and the right inferior frontal 
cortex. TRENDS Cogn. Neurosci. 8, 170–177 (2004). 
256. Rae, C. L. et al. White matter pathology in Parkinson’s disease: The effect of imaging 
protocol differences and relevance to executive function. Neuroimage 62, 1675–1684 
(2012). 
257. Cordato, N. J. et al. Frontal atrophy correlates with behavioural changes in progressive 
supranuclear palsy. Brain 125, 789–800 (2002). 
258. Bari, A., Eagle, D. M., Mar, A. C., Robinson, E. S. J. & Robbins, T. W. Dissociable 
effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task 
performance in rats. Psychopharmacology. 205, 273–283 (2009). 
259. Chamberlain, S. R. et al. Neurochemical Modulation of Response Inhibition and 
Probabilistic Learning in Humans. Science (80-. ). 311, 861–863 (2006). 
260. Linnet, J., Møller, A., Peterson, E., Gjedde, A. & Doudet, D. Inverse association 
between dopaminergic neurotransmission and Iowa Gambling Task performance in 
pathological gamblers and healthy controls. Scand. J. Psychol. 52, 28–34 (2011). 
261. Cools, R., Barker, R. A., Sahakian, B. J. & Robbins, T. W. l -Dopa medication 
 151 
remediates cognitive inflexibility, but increases impulsivity in patients with 
Parkinson’s disease. Neuropsychologia 41, 1431–1441 (2003). 
262. Potenza, M., Voon, V. & Weintraub, D. Drug Insight: impulse control disorders and 
dopamine therapies in Parkinson’s disease. Nat. Clin. Pract. Neurol. 12, 664–72 
(2007). 
263. Rowe, J. B. et al. Parkinson’s disease and dopaminergic therapy differential effects on 
movement, reward and cognition. Brain. 131, 2094–2105 (2008). 
264. Cools, R. & Robbins, T. W. Chemistry of the adaptive mind. Philos Trans A Math 
Phys Eng Sci 362, 2871–2888 (2004). 
265. Bari, A. et al. Prefrontal and monoaminergic contributions to stop-signal task 
performance in rats. J Neurosci 31, 9254–9263 (2011). 
266. Dong, J. & Blier, P. Modification of norepinephrine and serotonin, but not dopamine, 
neuron firing by sustained bupropion treatment. Psychopharmacol. 155, 52–57 (2001). 
267. Evenden, J. Impulsivity: a discussion of clinical and experimental findings. J. 
Psychopharmacol. 13, 180–92. (1999). 
268. Ye, Z. et al. Selective serotonin reuptake inhibition modulates response inhibition in 
Parkinson’s disease. Brain 137, 1145–1155 (2014). 
269. Rogers, R. et al. Tryptophan Depletion Alters the Decision- Making of Healthy 
Volunteers through Altered Processing of Reward Cues. Neuropsychopharmacology 
28, 153–162 (2003). 
270. Varazzani, X. C., San-galli, A., Gilardeau, S. & Bouret, X. Noradrenaline and 
Dopamine Neurons in the Reward / Effort Trade-Off : A Direct Electrophysiological 
Comparison in Behaving Monkeys. Jounrnal Neurosci. 35, 7866–7877 (2015). 
271. Borchert, R. J. et al. Atomoxetine Enhances Connectivity of Prefrontal Networks in 
Parkinson’s Disease. Neuropsychopharmacology 41, 2171–2177 (2016). 
272. Chamberlain, S. R. et al. Atomoxetine Modulates Right Inferior Frontal Activation 
During Inhibitory Control: A Pharmacological Functional Magnetic Resonance 
Imaging Study. Biol. Psychiatry 65, 550–555 (2009). 
273. Goldstein, D. S. et al. Catechols in post-mortem brain of patients with Parkinson 
disease. Eur J Neurol 18, 703–710 (2011). 
274. Vazey, E. M. & Aston-jones, G. The emerging role of norepinephrine in cognitive 
dysfunctions of Parkinson’s disease. Front. Behav. Neurosci. 6, 1–6 (2012). 
275. Ye, Z. et al. Predicting Beneficial Effects of Atomoxetine and Citalopram on Response 
Inhibition in Parkinson’s Disease with Clinical and Neuroimaging Measures. Hum. 
Brain Mapp. 37, 1026–1037 (2016). 
276. Mendez, M. F., Lauterbach, E. C. & Sampson, S. M. An Evidence-Based Review of 
the Psychopathology of Frontotemporal Dementia : A Report of the ANPA Committee 
on Research. J Neuropsychiatry Clin Neurosci 20, 130–149 (2008). 
277. Everitt, B. J. & Robbins, T. W. Neural systems of reinforcement for drug addiction : 
from actions to habits to compulsion. Nat. Neurosci. 8, 1481–1490 (2005). 
278. Adam, R., Bays, P. M. & Husain, M. Rapid decision-making under risk. Cogn. 
Neurosci. 3, 52–61 (2012). 
279. Cuthbert, B. N. Research Domain Criteria: toward future psychiatric nosologies. 
Dialogues Clin. Neurosci. 17, 89–97 (2015). 
 152 
280. Kozak, M. J. & Cuthbert, B. N. The NIMH Research Domain Criteria Initiative: 
Background, Issues and Pragmatics. Psychophysiology 53, 286–297 (2016). 
281. Fehnel, S. E., Bann, C. M., Hogue, S. L., Kwong, W. J. & Mahajan, S. S. The 
development and psychometric evaluation of the Motivation and Energy Inventory 
(MEI). Qual. Life Res. 12, 1321–1336 (2004). 
282. Beck, A. ., Ward, C. H., Medndelson, M., Mock, J. & Erbaugh, J. An Inventory for 
Measuring Depression. JAMA Psychiatry 4, 561–571 (1961). 
283. Snaith, R. P., Hamilton, M., Morley, S., Humayan, A. & Trigwell, P. A Scale for the 
Assessment of Hedonic Tone The Snaith Hamilton Pleasure Scale. Br. J. Psychiatry 
167, 99–103 (1995). 
284. Chaudhuri, K. R. et al. The Parkinson’s disease sleep scale: a new instrument for 
assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 73, 629–635 (2002). 
285. Ware, J. E., Sherbourne, C. D., Care, S. M. & Jun, N. The MOS 36-Item Short-Form 
Health Survey (SF-36). Med. Care 30, 473–483 (1992). 
286. Dubois, B., Slachevsky, A., Litvan, I. & Pillon, B. The FAB : Frontal Assessment 
Battery at bedside. Neurology 55, 1621–1621 (2000). 
287. Mioshi, E. & Hornberger, M. Clinical staging and disease progression in 
frontotemporal dementia. Neurology 74, 1591–1597 (2010). 
288. Kirby, K. N. Heroin addicts have higher discount rates for delayed rewards than non-
drug-using controls. J. Exp. Psychol. Gen. 128, 78–87 (1999). 
289. Housden, C. R., Sullivan, S. S. O., Joyce, E. M., Lees, A. J. & Roiser, J. P. Intact 
Reward Learning but Elevated Delay Discounting in Parkinson’s Disease Patients With 
Impulsive-Compulsive Spectrum Behaviors. Neuropsychopharmacology 35, 2155–
2164 (2010). 
290. Murray, G. K. et al. Incentive motivation in first-episode psychosis : A behavioural 
study. BMC Psychiatry 8, 1–7 (2008). 
291. Williams, D. R. & Lees, A. J. Progressive supranuclear palsy: clinicopathological 
concepts and diagnostic challenges. Lancet Neurol. 8, 270–279 (2009). 
292. Amodio, D. M., Master, S. L., Yee, C. M. & Taylor, S. E. Neurocognitive components 
of the behavioral inhibition and activation systems : Implications for theories of self-
regulation. Psychophysiology 45, 11–19 (2008). 
293. Perneczky, R. et al. Saccadic latency in Parkinson’s disease correlates with executive 
function and brain atrophy, but not motor severity. Neurobiol. Dis. 43, 79–85 (2011). 
294. Shallice, T. From Neuropsychology to Mental Structure. (Cambridge University Press, 
1988). 
295. Wright, I. et al. A voxel based method for the statistical analysis of gray and white 
matter density applied to schizophrenia. Neuroimage 2, 244–252 (1995). 
296. Friston, K. J., Worsley, K. J., Frackowiak, R. S. J., Mazziotta, J. C. & Evans, A. C. 
Assessing the Significance of Focal Activations Using Their Spatial Extent. Hum. 
Brain Mapp. 1, 210–220 (1994). 
297. Whitwell, J. et al. Magnetic Resonance Imaging Signatures of Tissue Pathology in 
Frontotemporal Dementia. Arch Neurol 62, 1402–1408 (2005). 
298. Good, C. D. et al. Automatic Differentiation of Anatomical Patterns in the Human 
 153 
Brain : Validation with Studies of Degenerative Dementias. Neuroimage 46, 29–46 
(2002). 
299. Frings, L., Mader, I., Landwehrmeyer, B. G., Weiller, C. & Hu, M. Quantifying 
Change in Individual Subjects Affected by Frontotemporal Lobar Degeneration Using 
Automated Longitudinal MRI Volumetry. Hum. Brain Mapp. 33, 1526–1535 (2012). 
300. Krueger, C. E. et al. Logitudinal Rates of Lobar Atrophy in Frontotemporal Dementia, 
Semantic Dementia and Alzheimer’s Disease. Alzheimer Dis Assoc Disord 24, 43–48 
(2010). 
301. Rohrer, J. D. et al. Rates of hemispheric and lobar atrophy in the language variants of 
frontotemporal lobar degeneration. J Alzheimers Dis 30, 407–411 (2015). 
302. Chan, D. et al. Patterns of Temporal Lobe Atrophy in Semantic Dementia and 
Alzheimer’s Disease. Ann Neurol 49, 433–442 (2001). 
303. Galton, C. et al. Differing patterns of temporal atrophy in Alzheimer’s disease. 
Neurology 57, 216–225 (2008). 
304. Mummery, C. J. et al. A Voxel-Based Morphometry Study of Semantic Dementia : 
Relationship between Temporal Lobe Atrophy and Semantic Memory. Ann Neurol 47, 
36–45 (2000). 
305. Boxer, A. et al. Patterns of Brain Atrophy That Differentiate Corticobasal 
Degeneration Syndrome From Progressive Supranuclear Palsy. Arch Neurol 63, 81–86 
(2006). 
306. Josephs, K. A. et al. Voxel-based morphometry in autopsy proven PSP and CBD. 
Neurobiol. Aging 29, 280–289 (2009). 
307. Dutt, S. et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. 
Neurology 87, 2016–2025 (2016). 
308. Cordato, N., Halliday, G., Harding, A., Hely, M. & Morris, J. G. . Regional Brain 
Atrophy in Progressive Supranuclear Palsy and Lewy Body Disease. Ann. Neurol. 47, 
718–728 (2000). 
309. Revesz, T., Sangha, H. & Daniel, S. E. The nucleus raphe interpositus in the Steele- 
Richardson-Olszewski syndrome ( progressive supranuclear palsy ). Brain 119, 1137–
1143 (1996). 
310. Cummings, J. L. Frontal-Subcortical Circuits and Human Behavior. Arch Neurol 50, 
873–880 (1993). 
311. Groschel, K. et al. Magnetic resonance imaging-based volumetry differentiates 
progressive supranuclear palsy from corticobasal degeneration. NeuroImage. 21, 714–
724 (2004). 
312. Johnson, K. A. et al. Cerebral Perfusion in Progressive Supranuclear Palsy. J. Nucl. 
Med. 33, 704–709 (1992). 
313. Rosano, C. et al. Pursuit and Saccadic Eye Movement Subregions in Human Frontal 
Eye Field : A High-resolution fMRI Investigation. Cereb. Cortex 12, 107–115 (2002). 
314. Schofield, E. C., Caine, D., Kril, J. J., Cordato, N. J. & Halliday, G. M. Staging 
Disease Severity in Movement Disorder Tauopathies : Brain Atrophy Separates 
Progressive Supranuclear Palsy From Corticobasal Degeneration. Mov. Disord. 20, 34–
39 (2005). 
315. Ishizawa, K. & Dickson, D. Microglial Activation Parallels System Degeneration in 
Progressive Supranuclear Palsy and Corticobasal Degeneration. J. Neuropathol. Exp. 
 154 
Neurol. 60, 647–657 (2001). 
316. Whitwell, J. L. et al. Frontal asymmetry in behavioural variant FTD: clinicoimaging 
and pathogenic correlates. Neurobiol. Aging 34, 636–639 (2013). 
317. Peters, F. et al. Orbitofrontal Dysfunction Related to Both Apathy and Disinhibition in 
Frontotemporal Dementia. Dement Geriatr Cogn Disord 21, 373–379 (2006). 
318. Barnes, J. et al. Head size, age and gender adjustment in MRI studies : a necessary 
nuisance? Neuroimage 53, 1244–1255 (2010). 
319. Paviour, D. C., Price, S. L., Jahanshahi, M., Lees, A. J. & Fox, N. C. Longitudinal MRI 
in progressive supranuclear palsy and multiple system atrophy : rates and regions of 
atrophy. Brain 129, 1040–1049 (2006). 
320. Whitwell, J. L. & Jack, C. R. Imaging correlates of pathology in corticobasal 
syndrome. Neurology 75, 1879–1887 (2010). 
321. Wolpe, N. et al. The medial frontal-prefrontal network for altered awareness and 
control of action in corticobasal syndrome. Brain 137, 208–220 (2014). 
322. Ghosh, B. C. P. et al. Social cognitive deficits and their neural correlates in progressive 
supranuclear palsy. Brain 135, 2089–2102 (2012). 
323. Chudasama, Y. & Robbins, T. W. Functions of frontostriatal systems in cognition: 
Comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol. 
Psychiatry 73, 19–38 (2006). 
324. Berridge, K. C., Robinson, T. E. & Aldridge, J. W. Dissecting components of reward: 
‘liking’, ‘wanting’, and learning. Curr. Opin. Pharmacol. 9, 65–73 (2009). 
325. Butler, R. A., Ralph, M. A. L. & Woollams, A. M. Capturing multidimensionality in 
stroke aphasia: mapping principal behavioural components to neural structures. Brain 
137, 3248–3266 (2014). 
326. Smith, S. M. et al. Tract-based spatial statistics: Voxelwise analysis of multi-subject 
diffusion data. Neuroimage 31, 1487–1505 (2006). 
327. Agosta, F. et al. White Matter Damage in Frontotemporal Lobar Degeneration 
Spectrum. Cereb. Cortex 22, 2705–2714 (2012). 
328. Josephs, K. A. et al. Characterizing a neurodegenerative syndrome: Primary 
progressive apraxia of speech. Brain 135, 1522–1536 (2012). 
329. Mahoney, C. J. et al. Longitudinal Diffusion Tensor Imaging in Frontotemporal 
Dementia. Ann. Neurol. 77, (2014). 
330. Mandelli, M. L. et al. Frontal white matter tracts sustaining speech production in 
primary progressive aphasia. J Neurosci 34, 9754–9767 (2014). 
331. Johansen-Berg, H. & Rushworth, M. F. S. Using Diffusion Imaging to Study Human 
Connectional Anatomy. Annu. Rev. Neurosci. 32, 75–94 (2009). 
332. Mahoney, C. J. et al. Profiles of White Matter Tract Pathology in Frontotemporal 
Dementia. Hum. Brain Mapp. 35, 4163–4179 (2014). 
333. Filippini, N. et al. Corpus callosum involvement is a consistent feature of amyotrophic 
lateral sclerosis. Neurology 75, 1645–1652 (2010). 
334. Whitwell, J. L. et al. Clinical correlates of white matter tract degeneration in PSP. Arch 
Neurol 68, 753–760 (2011). 
335. Borroni, B. et al. White matter changes in corticobasal degeneration syndrome and 
correlation with limb apraxia. Arch. Neurol. 65, 796–801 (2008). 
 155 
336. Jbabdi, S., Sotiropoulos, S. N., Haber, S. N., Essen, D. C. Van & Behrens, T. E. 
Measuring macroscopic brain connections in vivo. Nat. Neurosci. 18, 1546–1555 
(2015). 
337. Beaulieu, C. The basis of anisotropic water diffusion in the nervous system - a 
technical review. NMR Biomed. 15, 435–455 (2002). 
338. Zhang, Y. et al. White matter damage in frontotemporal dementia and Alzheimer’s 
disease measured by diffusion MRI. Brain 132, 2579–2592 (2009). 
339. Acosta-Cabronero, J. et al. Atrophy, hypometabolism and white matter abnormalities 
in semantic dementia tell a coherent story. Brain 134, 2025–2035 (2011). 
340. Padovani, A. et al. Diffusion tensor imaging and voxel based morphometry study in 
early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 77, 457–463 
(2006). 
341. Whitwell, J. & Josephs, K. Recent Advances in the Imaging of Frontotemporal 
Dementia. Curr Neurol Neurosci Rep 12, 715–723 (2013). 
342. Nguyen, T. et al. Grey and white matter brain network changes in frontotemporal 
dementia subtypes. Transl. Neurosci. 4, 410–418 (2013). 
343. Schofield, E., Kersaitis, C., Shepherd, C. E., Kril, J. J. & Halliday, G. M. Severity of 
gliosis in Pick’s disease and frontotemporal lobar degeneration: tau-positive glia 
differentiate these disorders. Brain 126, 827–840 (2003). 
344. Zhang, Y., Carmela, M., Schuff, N. & Chiang, G. C. MRI Signatures of Brain 
Macrostructural Atrophy and Microstructural Degradation in Frontotemporal Lobar 
Degeneration Subtypes. J. Alzheimer’s Dis. 33, 431–444 (2013). 
345. Tovar-moll, F. et al. White Matter Tract Damage in the Behavioral Variant of 
Frontotemporal and Corticobasal Dementia Syndromes. PLoS One 9, (2014). 
346. Agosta, F. et al. MRI Signatures of the Frontotemporal Lobar Degeneration 
Continuum. Hum. Brain Mapp. 36, 2602–14 (2015). 
347. Pievani, M. et al. Brain connectivity in neurodegenerative diseases — from phenotype 
to proteinopathy. Nat. Rev. Neurol. 10, 620–633 (2014). 
348. Whitwell, J. L., Avula, R. & Vemuri, P. Gray and white matter water diffusion in the 
syndromic variants of frontotemporal dementia. 1279–1287 (2010). 
349. Lillo, P. et al. Grey and White Matter Changes across the Amyotrophic Lateral 
Sclerosis-Frontotemporal Dementia Continuum. PLoS One 7, 1–10 (2012). 
350. Rabinovici, G. et al. Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer’s 
Disease and Frontotemporal Lobar Degeneration G. Am J Alzheimers Dis Other 
Demen. 22, 474–488 (2007). 
351. Grool, A. M. et al. Structural MRI correlates of apathy symptoms in older persons 
without dementia. Neurology 82, 1628–1635 (2014). 
352. Holroyd, C. B. & Yeung, N. Motivation of extended behaviors by anterior cingulate 
cortex. Trends Cogn. Sci. 16, 122–128 (2012). 
353. Douaud, G. et al. DTI measures in crossing-fibre areas: Increased diffusion anisotropy 
reveals early white matter alteration in MCI and mild Alzheimer’s disease. Neuroimage 
55, 880–890 (2011). 
354. Lansdall, C. J. et al. Apathy and Impulsivity in Frontotemporal Lobar Degeneration 
Syndromes. Brain 140, 1792–1807 (2017). 
 156 
355. Cohen, R. A. et al. Alteration of Intention and Self-Initiated Action Associated With 
Bilateral Anterior Cingulotomy. J Neuropsychiatry Clin Neurosci 114, 444–453 
(1999). 
356. Bonelli, R. M. & Cummings, J. L. Frontal-subcortical circuitry and behaviour. Transl. 
Res. 9, 141–151 (2007). 
357. Hughes, L. E., Ghosh, B. C. P. & Rowe, J. B. Reorganisation of brain networks in 
frontotemporal dementia and progressive supranuclear palsy. NeuroImage Clin. 2, 
459–468 (2013). 
358. Miller, E. K. & Cohen, J. D. An integrative theory of prefrontal cotex function. Annu. 
Rev. Neurosci. 24, 167–202 (2001). 
359. Aron, A. R., Behrens, T. E., Smith, S., Frank, M. J. & Poldrack, R. A. Triangulating a 
Cognitive Control Network Using Diffusion-Weighted Magnetic Resonance Imaging 
(MRI) and Functional MRI. J. Neurosci. 27, 3743–3752 (2007). 
360. Forstmann, B. U. et al. Cortico-striatal connections predict control over speed and 
accuracy in perceptual decision making. PNAS 107, 15916–15920 (2010). 
361. Rowe, J. B., Hughes, L. & Nimmo-smith, I. Action selection: A race model for selected 
and non-selected actions distinguishes the contribution of premotor and prefrontal 
areas. Neuroimage 51, 888–896 (2010). 
362. Douaud, G. et al. In vivo evidence for the selective subcortical degeneration in 
Huntington’s disease. Neuroimage 46, 958–966 (2009). 
363. Song, S. et al. Dysmyelination Revealed through MRI as Increased Radial (but 
Unchanged Axial) Diffusion of Water. Neuroimage 17, 1429–1436 (2002). 
364. Song, S. et al. Diffusion tensor imaging detects and differentiates axon and myelin 
degeneration in mouse optic nerve after retinal ischemia. Neuroimage 20, 1714–1722 
(2003). 
365. Pardoe, H. R., Hiess, R. K. & Kuzniecky, R. Motion and morphometry in clinical and 
nonclinical populations. Neuroimage 135, 177–185 (2016). 
366. Hodges, J. R., Davies, R., Xuereb, J., Kril, J. & Halliday, G. Survival in frontotemporal 
dementia. Neurology 349–354 (2003). 
367. Roberson, E. D. et al. Frontotemporal dementia progresses to death faster than 
Alzheimer disease. Neurology 65, 719–725 (2005). 
368. Chiu, W. Z. et al. Survival in progressive supranuclear palsy and frontotemporal 
dementia. J. Neurol. Neurosurg. Psychiatry 81, 441–5 (2010). 
369. Rascovsky, K. et al. Rate of progression differs in frontotemporal dementia and 
Alzheimer disease. Neurology 65, 397–403 (2005). 
370. Chan, D. et al. Rates of global and regional cerebral atrophy in AD and frontotemporal 
dementia. Neurology 57, 1756–1763 (2001). 
371. Garcin, B., Piguet, O. & Nestor, P. J. Determinants of survival in behavioral variant 
frontotemporal dementia. Neurology 73, 1656–1661 (2009). 
372. Xie, S. X. et al. Factors associated with survival probability in autopsy-proven 
frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 79, 126–129 
(2008). 
373. Borroni, B. et al. Survival in Frontotemporal Lobar Degeneration and Related 
Disorders : Latent Class Predictors and Brain Functional Correlates. Rejuvenation Res. 
 157 
12, 33–44 (2009). 
374. Josephs, K. et al. Survival in two variants of tau-negative frontotemporal lobar 
degeneration : FTLD-U vs FTLD-MND. Neurology 65, 645–647 (2005). 
375. Kertesz, A., Hillis, A. & Munoz, D. Frontotemporal Degeneration, Pick’s Disease, Pick 
Complex, and Ravel. Ann. Neurol. 54, 1–2 (2003). 
376. Tun, S., Daniel, L., Heidi, L., Christopher, C. & Eye, A. Von. Predictive Validity of 
Neuropsychiatric Subgroups on Nursing Home placement and survival in patients with 
Alzheimer disease. Am. J. Geriatr. Psychiatry 15, 314–327 (2007). 
377. Wenning, G. K. et al. Natural history and survival of 14 patients with corticobasal 
degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 
64, 184–189 (1998). 
378. Kipps, C. M., Nestor, P. J., Dawson, C. E., Mitchell, J. & Hodges, J. R. Measuring 
progression in frontotemporal dementia Implications for therapeutic interventions. 
Neurology 70, 2046–2051 (2008). 
379. Field, A. Discovering Statistics using SPSS. (SAGE Publications, 2009). 
380. Hu, W. T. et al. Behavior Matters — Cognitive Predictors of Survival in Amyotrophic 
Lateral Sclerosis. PLoS One 8, (2013). 
381. Borroni, B. et al. Latent profile analysis in frontotemporal lobar degeneration and 
related disorders : clinical presentation and SPECT functional correlates. BMC Neurol. 
12, 1–12 (2007). 
382. Palmer, K., Di, F., Erika, A., Gianni, W. & Sancesario, G. Neuropsychiatric Predictors 
of Progression from Amnestic-Mild Cognitive Impairment to Alzheimer’s Disease : 
The Role of Depression and Apathy. J. Alzheimer’s Dis. 20, 175–183 (2010). 
383. Olney, R. K. et al. The effects of executive and behavioral dysfunction on the course of 
ALS. Neurology 65, 1774–1777 (2005). 
384. Mioshi, E. et al. Neuropsychiatric changes precede classic motor symptoms in ALS 
and do not affect survival. Neurology. 82, 1–7 (2013). 
385. Robert, P. H., Berr, C., Volteau, M. & Bertogliati-file, C. Importance of Lack of 
Interest in Patients With Mild Cognitive Impairment. Am. J. Geriatr. Psychiatry 16, 
770–776 (2008). 
386. Litvan, I. et al. Natural history of progressive supranuclear palsy (Steele-Richardson-
Olszewski syndrome) and clinical predictors of survival : a clinicopathological study. J. 
Neurol. Neurosurg. Psychiatry 61, 615–620 (1996). 
387. Borroni, B. et al. Evidence of White Matter Changes on Diffusion Tensor Imaging in 
Frontotemporal Dementia. Arch Neurol. 64, 246–251 (2007). 
388. Voon, V. et al. Prevalence and reward-seeking behaviors in Parkinson’s disease. 
Neurology 67, 1254–1257 (2006). 
389. Logan, G. D., Schachar, R. J. & Tannock, R. Impulsivity and Inhibitory Control. 
Psychol. Sci. 8, 60–65 (1997). 
390. Schiehser, D. M. et al. Predictors of Discrepancies in Parkinson’s Disease Patient and 
Caregiver Ratings of Apathy , Disinhibition , and Executive Dysfunction before and 
after Diagnosis. J. Int. Neuropsychol. Soc. 19, 295–304 (2013). 
391. Guercio, B. et al. The Apathy Evaluation Scale: A Comparison of Subject, Informant, 
and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J 
 158 
Alzheimers Dis 47, 421–432 (2015). 
392. Seltzer, B., Vasterling, J., Mathias, C. & Brennan, A. Clinical and neuropsychological 
correlates of impaired awareness of deficits in Alzheimer disease and Parkinson 
disease: a comparative study. Neuropsychiatry Neuropsychol Behav Neurol. 12, 122–9 
(2001). 
393. Mason, S. & Barker, R. Rating apathy in Huntington’s Disease: Patients and 
Companions Agree. J. Huntingtons Dis. 4, 49–59 (2015). 
394. Radakovic, R. et al. Multidimensional apathy in ALS : validation of the Dimensional 
Apathy Scale. Neuropsychiatry (London). 87, 663–669 (2016). 
395. Hu, W. T. et al. Survival profiles of patients with frontotemporal dementia and motor 
neuron disease. Arch Neurol 66, 1359–1364 (2009). 
396. Premi, E. et al. Cognitive reserve and TMEM106B genotype modulate brain damage in 
presymptomatic frontotemporal dementia : a GENFI study. BRAIN 140, 1784–1791 
(2017). 
397. Wilson, R. S. et al. Participation in Cognitively Stimulating Activities and Risk of 
Incident Alzheimer Disease. JAMA 287, 742–748 (2002). 
398. Katzman, R. et al. Clinical, pathological, and neurochemical changes in dementia: A 
subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 
23, 138–44 (1988). 
399. Bennett, D. A., Schneider, J. A., Tang, Y., Arnold, S. E. & Wilson, R. S. The effect of 
social networks on the relation between Alzheimer’s disease pathology and level of 
cognitive function in old people : a longitudinal cohort study. Lancet Neurol 5, 406–12 
(2006). 
400. Berridge, K. C. The debate over dopamine’s role in reward : the case for incentive 
salience. Psychopharmacology. 191, 391–431 (2007). 
401. Norbury, A., Manohar, S., Rogers, R. D. & Husain, M. Dopamine Modulates Risk-
Taking as a Function of Baseline Sensation-Seeking Trait. J. Neurosci. 33, 12982–
12986 (2013). 
402. Muhammed, K. et al. Reward sensitivity deficits modulated by dopamine are 
associated with apathy in Parkinson’s disease. BRAIN 139, 2706–2721 (2016). 
403. Martínez-horta, S. et al. Apathy in Parkinson’s Disease: Neurophysiological Evidence 
of Impaired Incentive Processing. J. Neurosci. 37, 5918–5926 (2014). 
404. Wolf, D. H. et al. Amotivation in Schizophrenia : Integrated Assessment With 
Behavioral, Clinical, and Imaging Measures. Schizophr. Bull. 40, 1328–1337 (2014). 
405. Strauss, G. P. et al. Avolition in Schizophrenia is Associated with Reduced 
Willingness to Expend Effort for Reward on a Progressive Ratio Task. Schizophr Res. 
170, 198–204 (2017). 
406. Bland, A. R. et al. EMOTICOM: A Neuropsychological Test Battery to Evaluate 
Emotion, Motivation, Impulsivity, and Social Cognition. Front. Behav. Neurosci. 10, 
1–17 (2016). 
407. Murphy, P. R., Robertson, I. H., Balsters, J. H. & O’Connell, R. Pupillometry and P3 
index the locus coeruleus – noradrenergic arousal function in humans. 
Psychophysiology 48, 1531–1542 (2011). 
408. Passamonti, L. et al. 18F-AV-1451 positron emission tomography in Alzheimer’s 
disease and progressive supranuclear palsy. Brain 140, 781–791 (2017). 
 159 
409. Bond, T. & Fox, C. M. Applying the Rasch model: Fundamental measurement in the 
human sciences. (Routledge, 2015). 
410. Borroni, B. et al. Genetic correlates of behavioral endophenotypes in Alzheimer 
disease : Role of COMT , 5-HTTLPR and APOE polymorphisms. Neurobiol. Aging 27, 
1595–1603 (2006). 
411. Blum, K. et al. Dopamine D2 receptor gene variants: association and linkage studies in 
impulsive-addictive-compulsive behaviour. Pharmacogenet. Genomics 5, 121–141 
(1995). 
412. Hamidovic, A., Dlugos, A., Skol, A., Palmer, A. A. & Wit, H. De. Evaluation of 
Genetic Variability in the Dopamine Receptor D2 in Realtion to Behavioural Inhibition 
and Impulsivity/Sensation Seeking: An Exploratory Study with d-Amphetamine in 
Healthy Participants. Exp. Clin Psychophamracol 17, 374–383 (2009). 
413. Proitsi, P. et al. Association of serotonin and dopamine gene pathways with behavioral 
subphenotypes in dementia. Neurobiol. Aging 33, 791–803 (2012). 
 
 
  
 
1
6
0
 
Appendix A: Grey Matter Voxel-based Morphometry Coordinates 
Component Brain Regions Cluster Extent Peak (x, y, z) Peak Z score 
2 Precentral/postcentral gyrus and putamen  
  
 
44087 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3739 
1080 
54 
2 
26 
-26 
40 
-12 
8 
58 
0 
-12 
-38 
-25 
0 
20 
36 
30 
-30 
-16 
60 
16 
-6 
24 
66 
-38 
-42 
-42 
-4 
-22 
8 
4 
-60 
-88 
-78 
-12 
-30 
-60 
-62 
18 
20 
-52 
32 
-22 
46 
-40 
-44 
-56 
-72 
-16 
-46 
-14 
-46 
-62 
42 
54 
4 
8 
-26 
18 
-14 
10 
-12 
44 
-30 
64 
38 
-54 
44 
70 
26 
-48 
48 
16 
-44 
-32 
12 
52 
46 
12 
6.00 
4.79 
4.59 
4.58 
4.20 
4.14 
4.09 
4.02 
3.97 
3.96 
3.93 
3.88 
3.84 
3.69 
3.64 
3.56 
3.50 
3.49 
3.26 
3.20 
3.19 
3.04 
2.90 
4.86 
4.04 
3.59 
3 Temporal pole, orbitofrontal cortex and anterior insula 68792 -32 
26 
36 
-2 
-56 
60 
8 
-22 
-8 
52 
-38 
16 
10 
-20 
26 
-18 
-12 
40 
-26 
20 
38 
-8 
-28 
-32 
-10 
-8 
-24 
-32 
24 
-26 
44 
-14 
8 
6.24 
6.24 
5.74 
5.69 
5.34 
5.33 
5.06 
4.92 
4.50 
4.32 
4.31 
  
 
1
6
1
 
Component Brain Regions Cluster Extent Peak (x, y, z) Peak Z score 
3 
(continued) 
Temporal pole, orbitofrontal cortex and anterior insula 68792 -2 
-12 
-24 
-4 
-28 
64 
60 
-44 
50 
0 
-68 
-26 
-46 
48 
62 
46 
-54 
-10 
-4 
26 
-16 
-40 
52 
8 
-18 
4 
28 
-8 
10 
54 
20 
4 
4 
4.12 
4.09 
3.88 
3.79 
3.75 
3.73 
3.49 
3.49 
2.96 
2.89 
2.86 
4 Thalamus 16149 
 
 
 
 
 
 
 
 
 
 
 
 
 
6213 
-12 
-38 
-54 
-52 
10 
-36 
18 
18 
36 
-10 
-50 
20 
6 
-4 
18 
58 
56 
58 
58 
36 
46 
-30 
-58 
-36 
-26 
-14 
-56 
-22 
-80 
-60 
-84 
-70 
-24 
-76 
-42 
4 
-12 
-8 
-40 
8 
12 
-22 
0 
54 
22 
-20 
58 
-10 
18 
28 
-4 
44 
22 
-32 
-10 
38 
-14 
38 
6 
12 
-22 
54 
-30 
4.40 
4.03 
4.03 
3.95 
3.95 
3.86 
3.45 
3.44 
3.43 
3.42 
3.41 
3.39 
3.18 
3.13 
4.05 
3.65 
3.47 
3.44 
3.25 
2.86 
2.83 
7 Middle frontal gyrus, supplementary motor cortex 3618 44 
4 
32 
50 
4 
12 
24 
42 
20 
-6 
48 
46 
30 
4 
66 
4.52 
3.56 
3.31 
3.21 
3.16 
Cluster FWE p<0.05 corrected, peak-level p<0.001 uncorrected. Brain regions identified using Neuromorphometrics atlas in SPM12. 
  
 
1
6
2
 
 
Appendix B: White Matter Voxel-based Morphometry Coordinates 
Cluster FWE p<0.05 corrected, peak-level p<0.001 uncorrected. Brain regions identified using Neuromorphometrics atlas in SPM12. 
Component Brain Regions Cluster Extent Peak (x, y, z) Peak Z score 
1 Middle frontal gyrus, cerebral white matter 20478 -38 
36 
-16 
-8 
10 
24 
22 
-46 
-16 
-44 
62 
20 
-20 
20 
10 
-14 
-26 
18 
-44 
16 
18 
-36 
-18 
2 
-14 
-32 
-32 
-38 
50 
2 
14 
34 
58 
54 
-18 
22 
54 
8 
26 
-26 
-28 
28 
4.72 
4.32 
4.13 
3.86 
3.71 
3.66 
3.59 
3.45 
3.32 
3.18 
3.01 
3.01 
3.01 
2.60 
2 Brain stem  7360 
 
 
 
2064 
-6 
8 
-16 
32 
-28 
-12 
-18 
-38 
-36 
-14 
-56 
20 
10 
60 
-58 
-26 
-16 
-12 
14 
48 
18 
5.02 
4.18 
3.40 
2.85 
3.95 
3.35 
2.85 
3 Right cerebral white matter (including amygdala, hippocampus), 
temporal pole 
23273 32 
-36 
34 
18 
38 
-32 
-16 
-10 
-40 
-2 
0 
-30 
30 
26 
-38 
46 
14 
8 
-28 
-18 
-12 
-14 
18 
-10 
18 
44 
18 
6.64 
5.71 
5.44 
4.69 
4.56 
4.56 
4.40 
4.29 
3.50 
7 Left Cerebral white matter (including anterior cingulate, frontal 
gyrus and supplementary motor cortex) 
1818 -14 
-48 
24 
16 
26 
4 
3.93 
2.93 
